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Background: Imatinib dose escalation is advocated for gastrointestinal stromal tumour 
(GIST) treatment, but its effectiveness compared with sunitinib and best supportive care 
(BSC) after failure at the 400 mg/day dose is unknown.
Objectives: To assess the effectiveness and cost-effectiveness of imatinib at escalated 
doses of 600 or 800 mg/day for patients with unresectable and/or metastatic GISTs whose 
disease had progressed on 400 mg/day.
Data sources: Electronic databases, including MEDLlNE, MEDLINE In-Process, EMBASE, 
BIOSIS, Science Citation Index, Health Management Information Consortium and the 
Cochrane Controlled Trials Register, were searched until September 2009.
Review methods: A systematic review of the literature was carried out according 
to standard methods. An economic model was constructed to assess the cost-
effectiveness of seven alternative pathways for treating patients with unresectable and/or 
metastatic GISTs.
Results: Five primary studies involving 669 people were included for clinical effectiveness; 
four reported imatinib and one reported sunitinib. The data were essentially observational 
as none of the studies was designed to specifically assess treatment of patients whose 
disease had progressed on 400 mg/day imatinib. For 600 mg/day imatinib, between 26% 
and 42% of patients showed either a partial response (PR) or stable disease (SD). Median 
time to progression was 1.7 months (range 0.7–24.9 months). For 800 mg/day imatinib, 
between 29% and 33% of patients showed either a PR or SD. Median overall survival 
(OS) was 19 months [95% confidence interval (CI) 13 to 23 months]. Progression-free 
survival ranged from 81 days to 5 months (95% CI 2 to 10 months). Median duration 
of response was 153 days (range 37–574 days). Treatment progression led to 88% 
discontinuations but between 16% and 31% of patients required a dose reduction, and iv Abstract
23% required a dose delay. There was a statistically significant increase in the severity of 
fatigue (p < 0.001) and anaemia (p = 0.015) following dose escalation. For sunitinib, median 
OS was 90 weeks (95% CI 73 to 106 weeks). For the cost-effectiveness review, only one 
full-text study and one abstract were identified, comparing imatinib at an escalated dose, 
sunitinib and BSC, although neither was based on a UK context. The definition of BSC 
was not consistent across the studies, and the pattern of resources (including drugs for 
treatment) and measures of effectiveness also varied. Within the model, BSC (assumed 
to include continuing medication to prevent tumour flare) was the least costly and least 
effective. It would be the care pathway most likely to be cost-effective when the cost per 
quality-adjusted life-year threshold was < £25,000. Imatinib at 600 mg/day was most likely 
to be cost-effective at a threshold between £25,000 and £45,000. Imatinib at 600 mg/day 
followed by further escalation followed by sunitinib was most likely to be cost-effective at a 
threshold > £45,000.
Limitations: The evidence base was sparse, data were non-randomised and potentially 
biased. The economic model results are surrounded by a considerable degree of 
uncertainty and open to biases of unknown magnitude and direction.
Conclusions: Around one-third of patients with unresectable and/or metastatic GIST, who 
fail on 400 mg/day of imatinib, may show response or SD with escalated doses. Between 
a threshold of £25,000 and £45,000, provision of an escalated dose of imatinib would be 
most likely to be cost-effective. However, these results should be interpreted with caution 
owing to the limited evidence available on outcomes following imatinib dose escalation or 
sunitinib for this group of patients.
Funding: The National Institute for Health Research Health Technology 
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Executive summary
Background
Fewer than 1% of all cancers in the gastrointestinal (GI) tract are gastrointestinal stromal 
tumours (GISTs). The median age of patients at diagnosis is between 50 and 60 years, and 
diagnosis typically depends upon morphological and clinical features being consistent with 
positive KIT/CD117 protein expression. Surgical resection is potentially curative but some 
patients will have unresectable and/or metastatic disease. Conventional chemotherapy and 
radiotherapy are ineffective in the management of unresectable and/or metastatic GIST and 
symptom control through best supportive care (BSC) was the main treatment available until 
imatinib (Glivec, Novartis Pharmaceuticals UK) at a dose of 400 mg/day was recommended 
in the 2004 guidance of the National Institute for Health and Clinical Excellence (NICE), as 
first-line management for those with KIT (CD117)-positive unresectable and/or metastatic GIST. 
Dose escalation upon disease progression after initially responding at the 400 mg/day dose was 
not recommended, although other recent guidelines have recommended dose escalation to a 
maximum dose of 800 mg/day, particularly for those patients with unresectable and/or metastatic 
GIST who also have specific exon mutations in the KIT gene. Since the 2004 guidance, sunitinib 
malate (Sutent, Pfizer UK), another tyrosine kinase inhibitor, has been licensed for the treatment 
of people with unresectable and/or metastatic GIST. NICE guidance recommends sunitinib as 
a treatment option for people with unresectable and/or metastatic malignant GISTs if imatinib 
treatment has failed because of resistance or intolerance, and the drug cost of sunitinib for the 
first treatment cycle is met by the manufacturer.
Objectives
The aim was to assess the effectiveness and cost-effectiveness of imatinib at escalated doses of 
600 and 800 mg/day following progression of disease at a dose of 400 mg/day, compared with 
sunitinib, or the provision of BSC only for patients with unresectable and/or metastatic GISTs. 
Particular subgroups of interest were patients with specific KIT mutations.
Methods
Electronic searches were undertaken to identify published and ongoing randomised controlled 
trials (RCTs), non-randomised comparative studies and case series. Participants were adult 
patients with unresectable and/or metastatic GISTs whose disease had progressed on an imatinib 
dose of 400 mg/day. The interventions considered were imatinib at doses of 600 and 800 mg/day, 
sunitinib, or BSC only. Outcomes considered included overall response, overall survival (OS), 
disease-free survival, progression-free survival (PFS), time to treatment failure, health-related 
quality of life (HRQoL) and adverse effects.
The titles and abstracts of all identified reports were screened and full-text reports of potentially 
relevant studies assessed. Data were extracted from included studies, including details of study 
design, participants, interventions, comparators and outcomes. These studies were quality 
assessed using a checklist developed for non-randomised studies and case series, adapted 
from several sources, including the Centre for Reviews and Dissemination’s guidance for those 
carrying out or commissioning reviews, Verhagen et al., Downs and Black, and the Generic x Executive summary
Appraisal Tool for Epidemiology (GATE) (Verhagen AP, de Vet HC, de Bie RA, Kessels AG, 
Boers M, Bouter LM, et al. The Delphi List: a criteria list for quality assessment of randomized 
clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 
1998;51:1235–41; Downs SH, Black N. The feasibility of creating a checklist for the assessment 
of the methodological quality both of randomised and non-randomised studies of health care 
intervention. J Epidemiol Community Health 1998;52:377–84). The Cochrane Collaboration’s 
risk of bias tool was also used to evaluate the quality of sequence generation and allocation 
concealment of RCTs. Data analysis was confined to a comparison of data extracted from 
published Kaplan–Meier curves, and a narrative synthesis of results was presented.
For the review of economic evaluations, electronic searches were undertaken to identify cost 
or cost-effectiveness analyses relevant to the study question. Selection of relevant papers used 
similar methods to the review of clinical effectiveness. For included studies, data were extracted 
and critically appraised according to the guidelines produced by the Centre of Reviews and 
Dissemination for the critical appraisal of economic evaluations, and guidelines relevant to 
modelling studies. A Markov model was developed to compare the cost-effectiveness of seven 
clinically plausible alternative care pathways. The data used to populate the model were derived 
from the review of clinical effectiveness as well as the review of economic studies. Within the 
model people were assumed to move to the next therapy specified for a care pathway unless they 
had responded to treatment. All pathways ended with BSC, which patients would enter if they 
had exhausted all other treatments in a pathway. Both deterministic and probabilistic sensitivity 
analyses were conducted. The latter was restricted to considering distributions for the probability 
of death and non-response to focus attention on uncertainty in these data.
Results
Clinical effectiveness
Five studies (containing 669 patients in relevant treatment arms) met the inclusion criteria, with 
four (n = 318) reporting outcomes for patients who received escalated doses of imatinib and 
one (n = 351) reporting outcomes for patients who received sunitinib. No studies meeting our 
inclusion criteria were identified for BSC. The included studies were essentially observational 
in nature and subject to the biases associated with such data, consisting mostly of reporting 
of subgroups of patients who had been enrolled in RCTs that were not designed to assess the 
effects of dose escalation on patients with advanced and/or metastatic GIST whose disease had 
progressed on the 400 mg/day dose. Therefore, the selection of patients was neither randomised 
nor consecutive.
At an escalated dose of 600 mg/day, between 26% and 42% of patients showed either a partial 
response (PR) or stable disease (SD). Median time to progression was 1.7 months (range 
0.7–24.9 months). No data on other outcomes were available.
At an escalated dose of 800 mg/day between 29% and 33% of patients showed either a PR or SD. 
The median OS was 19 months [95% confidence interval (CI) 13 to 23 months]. PFS ranged from 
81 days to 5 months (95% CI 2 to 10 months). The median duration of response was 153 days 
(range 37–574 days). Treatment progression led to 88% discontinuations but between 16% and 
31% of patients required a dose reduction, and 23% required a dose delay. There was a statistically 
significant increase in the severity of fatigue (p < 0.001) and anaemia (p = 0.015) following 
dose escalation.
For sunitinib, median OS was 90 weeks (95% CI 73 to 106 weeks). No data were available for 
other outcomes.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Insufficient data were available on the subgroup population of interest with KIT mutations, and 
these were not considered in the economic analysis.
Cost-effectiveness
Although seven economic studies were identified, only one full-text study and one abstract, 
comparing imatinib at an escalated dose, sunitinib and BSC, were identified. Neither was based 
on a UK context. The definition of BSC was not consistent across the studies, and the pattern of 
resources (including drugs for treatment) and measures of effectiveness also varied.
For economic evaluation, a Markov model was developed to compare the alternative treatment 
strategies for people with KIT (CD117)-positive unresectable and/or metastatic GISTs, whose 
disease has progressed on treatment with imatinib at a dose of 400 mg/day.
The assumed pathway of the model
The model was based on seven clinically plausible care pathways. The states considered in the 
model were those thought to reflect care pathways for people with GIST. Patients entering the 
pathways were those who failed on imatinib 400 mg/day. The alternative treatments considered 
were imatinib 600 mg/day, imatinib 800 mg/day, sunitinib (within its licensed dose regimen), and 
BSC. The patient pathways considered in the model were:
  ■ start with imatinib 600 mg then imatinib 800 mg if the patient fails on 600 mg, or
  ■ start with imatinib 600 mg then imatinib 800 mg if the patient fails on 600 mg, and then 
sunitinib if the patient progresses or fails on 800 mg, or
  ■ start with imatinib 600 mg then move to treatment with sunitinib if the patient fails to 
respond to 600 mg.
Within the model, Path-1, BSC (which was assumed to include continuing medication to prevent 
tumour flare), was the least costly and least effective pathway. It would be the care pathway most 
likely to be cost-effective when the cost per quality-adjusted life-year (QALY) threshold was less 
than £25,000. Path-4, imatinib at 600 mg/day, was most likely to be cost-effective at a threshold of 
between £25,000 and £45,000. Imatinib at 600 mg/day followed by further escalation followed by 
sunitinib was most likely to be cost-effective at a threshold > £45,000.
Sensitivity analysis
The results did not greatly alter under the majority of the sensitivity analyses conducted. 
However, all of the economic data were based upon point estimates for mortality and response 
rates that were, in turn, based upon sparse and potentially biased data.
It was also not possible, owing to lack of data, to make alternative assumptions about probabilities 
of death and response change over time, or reductions in utility associated with adverse effects 
of treatment. Further assumptions that were required to be made in the model were that patients 
who move on to BSC would remain on treatment with imatinib at 400 mg/day to prevent tumour 
flare (but that this would have no impact on effectiveness).
Discussion
Relatively few relevant data were identified for this review and what data were available are 
essentially observational and non-comparative. Such data are potentially biased, with both the 
magnitude and direction of the bias being uncertain. Therefore, all results should be interpreted 
with caution.xii Executive summary
Approximately one-third of unresectable and/or metastatic patients with GIST who receive dose-
escalated imatinib show either response or SD, which can be maintained over several months. 
However, few data were available for imatinib at 600 mg/day and median OS for imatinib at 
800 mg/day and sunitinib was < 24 months. Few data were available on adverse events but up to 
one-third of patients may need a dose reduction or a dose delay. Patients may see a significant 
worsening of anaemia and/or fatigue upon dose escalation.
The results of the economic model showed that pathways involving dose escalation would be 
cost-effective should the cost per QALY threshold be ≥ £30,000. Treatment with sunitinib after 
progressing on imatinib at 400 mg/day was not likely to be cost-effective. However, this result was 
based on limited non-comparative data for this treatment and is probably unreliable.
There are a number of remaining uncertainties, including:
  ■ The results are suggestive of a benefit from dose escalation but the non-randomised, non-
comparative data available for review are potentially biased. This limits the usefulness of both 
the review of effectiveness and the economic model.
  ■ There was a lack of evidence on quality-of-life (QoL) outcomes, which would have informed 
the economic model, and would also be of importance to patients.
  ■ There was little evidence on response and survival on escalated doses of imatinib, specifically 
for those with different mutations in the KIT gene.
  ■ There is uncertainty surrounding the effects of dose modifications and potential differential 
effects of sunitinib for both the population being given this drug because of intolerance to 
imatinib and those receiving sunitinib after failure on imatinib.
  ■ There is also uncertainty surrounding the nature and severity of adverse events and their 
impact on quality and quantity of life and costs.
Conclusions
Implications for service provision
There was very limited evidence available from very few studies on the effects of escalated doses 
of imatinib or treatment with sunitinib for the target population. The evidence that was available 
was essentially observational in nature and subject to the biases associated with such data, 
consisting mostly of reporting of subgroups of patients in RCTs that were not designed to assess 
the effects of dose escalation.
The limited evidence base suggests that around one-third of patients with unresectable and/
or metastatic GIST who have failed on a dose of 400 mg/day may show response or SD with 
escalated doses of imatinib, and those who do respond may have a reasonable chance of 
maintaining this response over a longer period of time than would otherwise have been the case.
For all patients receiving either dose-escalated imatinib, or sunitinib, median OS, where reported, 
was < 2 years.
The results of the economic model are surrounded by a considerable degree of uncertainty due to 
the limited nature of the available evidence base, and the direction and magnitude of biases in the 
results is unclear, so these results need to be interpreted with caution. They indicate that should 
society’s threshold for willingness to pay be less than £25,000 per QALY a pathway of BSC only 
has the highest probability of being cost-effective. Between a threshold of £25,000 and £45,000 
provision of an escalated dose of imatinib would be most likely to be cost-effective. Above a © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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threshold of £45,000 a pathway of escalated doses of imatinib followed by sunitinib, if necessary, 
would be most likely to be cost-effective.
In terms of policy-making, the degree of uncertainty itself, in the authors’ opinion, clearly 
illustrates that at present there is insufficient available evidence to show that dose escalation 
of imatinib upon progression at the 400 mg/day dose (for patients with unresectable and/or 
metastatic GISTs) would be a cost-effective strategy for the NHS.
Recommendations for research
Suggested priorities for further research are made:
  ■ Ideally, an RCT involving patients who progress on 400 mg/day imatinib in which patients 
are randomised to pathways describing alternative combinations of dose escalation with 
imatinib and the use of sunitinib should be performed. Such a study may be difficult to 
organise as neither patients nor practitioners may be in equipoise. Therefore, alternative 
quasi-experimental or observational designs should be considered but with sufficient focus 
on understanding and controlling for selection biases.
  ■ The pathways most likely to be cost-effective at thresholds society might be willing to pay 
and hence, potentially, the most useful to assess in any further primary study are dose 
escalation with imatinib and dose escalation with imatinib followed by sunitinib if necessary. 
A trial should include an economic evaluation and measurement of health-state utilities and 
have sufficiently long enough follow-up to capture all outcomes of interest.
  ■ Where possible further studies should also report outcomes for subgroups of patients with 
specific KIT mutations.
  ■ In any prospective comparative study a wider perspective on the consideration of costs might 
also be informative (e.g. costs that fall on Personal Social Services, which would be relevant 
for NICE to consider, and costs for patients and their families, which goes beyond NICE’s 
reference case).
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Chapter 1  
Background
Description of health problem
Introduction
Gastrointestinal stromal tumours (GISTs) are tumours of mesenchymal origin that arise in 
the gastrointestinal tract (GI tract). Historically, and based upon morphological appearance 
alone, GISTs were considered to be of smooth muscle origin and regarded as leiomyomas or 
leiomyosarcomas. Subsequently, electron microscopic and molecular analysis has demonstrated 
that GISTs are a distinct tumour type arising from the interstitial cells of Cajal, and 
characterised by the expression of receptor tyrosine kinase KIT (CD117) protein demonstrated 
by immunohistochemistry.1 CD117/KIT immunoreactivity now provides the diagnostic 
criteria for GISTs, although there is recognition that a small proportion of GISTs (4%) are KIT 
immunoreactive negative.2,3
Aetiology, pathology and prognosis
Recent investigation has provided clinically significant insights into the molecular pathogenesis 
of GISTs. This has allowed the rational development of systemic therapies (including imatinib 
and sunitinib), provided robust diagnostic criteria for GISTs, and demonstrated the ability of 
certain pathogenic gene mutations to predict clinical behaviour and response to therapy in GISTs, 
therefore having potential application as predictive biomarkers.
Activating mutations in the KIT proto-oncogene are an early and key event in the pathogenesis 
of GISTs, and present in up to 95% of cases.4–10 The protein product is a member of the receptor 
tyrosine kinase family and a transmembrane receptor for stem cell factor (SCF).11 Extracellular 
binding of SCF to the receptor results in dimerisation of KIT and subsequent activation of 
the intracellular KIT kinase domain,9 leading to activation of intracellular signalling cascades 
controlling cell proliferation, adhesion and differentiation. KIT mutation is necessary but 
not sufficient for the pathogenesis of GISTs; other mutations are essential, and KIT mutation 
is absent in a minority of cases (< 5%).12,13 In the majority of KIT mutation-negative cases, 
mutational activation of the closely related tyrosine kinase platelet-derived growth factor 
receptor alpha (PDGFRA) is the pathogenic event, and KIT and PDGFRA activation have similar 
biological effects.12,13
It has been demonstrated that KIT and PDGFRA gene mutations are mutually exclusive7,8,10,14 and 
GISTs with no KIT mutations have either PDGFRA-activating mutations or no identified kinase 
mutations.13 GISTs that lack KIT mutations may still have high KIT kinase activity and so may 
have KIT mutations that are not detected by conventional screening methods. Alternatively, KIT 
kinase activation may be due to non-mutational mechanisms.6
Diagnosis of GIST is made when morphological and clinical features of the tumour are 
consistent and the tumour has positive KIT/CD117 protein expression.15 However, as noted 
above, approximately 4% of GISTs have clinical and morphological features of GIST but 
have negative KIT immunoreactivity.2 These KIT-negative GISTs are more likely to contain 
PDGFRA mutations.2 It is important in these cases, when KIT/CD117 staining is negative, 2 Background
that other markers are investigated to confirm GIST diagnosis. Recent studies have shown 
that a novel protein DOG1 is highly expressed in both KIT and PDGFRA mutant GISTs,16,17 
and immunostaining for DOG1 can be used in conjunction with CD117 staining, and 
diagnosis of GIST made on the basis of KIT and/or DOG1 immunoreactivity.15 PDGRFA 
immunohistochemistry should also be performed and positivity can assist with diagnosis. 
Mutational analysis also plays a role in the diagnosis of KIT/CD117-negative suspected GISTs, as 
with consistent morphological and clinical features, positive mutation analysis for either KIT or 
PDGFRA is diagnostic.15
Without treatment GISTs are progressive and will eventually metastasise to distant organs and 
so are invariably fatal without any intervention. GISTs are resistant to ‘conventional’ oncology 
treatments of cytotoxic chemotherapy and radiotherapy. Prognosis is highly dependent on the 
resectability of the tumour; however, only 50% of GIST patients have resectable disease at first 
presentation.18,19 Ten-year survival for resectable/non-metastatic tumours is 30–50%, and at least 
50% will relapse within 5 years of surgery, but for unresectable tumours prognosis is very poor, 
with survival generally < 2 years without further treatment.18,19
Epidemiology and incidence
While GISTs are the most common mesenchymal tumour of the GI tract, overall they are a rare 
cancer, accounting for less than 1% of all cancers of the GI tract.20 GISTs can occur anywhere 
in the GI tract from the oesophagus to the rectum, but most arise in the stomach or small 
intestine.21 They are rare before the age of 40 years and very rare in children, with a median age 
at diagnosis of 50–60 years.22,23 Some data show a slight male predominance but this is not a 
consistent finding.22,24,25
Retrospective studies carried out using KIT immunoreactivity as a diagnostic criterion have 
shown that GISTs have been underdiagnosed in the past.26,27 These retrospective population-
based reclassification studies provide the most reliable and accurate current estimate of an annual 
incidence of 15 cases per million, which would equate to 900 cases in the UK.15
Impact of health problem
The symptoms of GISTs depend on the size and location of the primary tumour and any 
metastatic deposits. While one-third of cases are asymptomatic and discovered incidentally 
during investigations or surgical procedures for unrelated disease, severe and debilitating 
symptoms occur in many patients and are invariable in those patients who have (or develop) 
metastatic disease.28
Gastrointestinal stromal tumours of < 2 cm in size with no metastatic disease are usually 
asymptomatic. Larger primary tumours and those of patients with metastatic disease are usually 
symptomatic and the most common symptom is GI tract bleeding, which occurs in 50% of 
patients, 25% of these patients presenting as emergencies with acute GI haemorrhage, either 
into the intestine or peritoneum.29 Abdominal discomfort is a feature of larger tumours.30 
Oesophageal GISTs typically present with dysphagia, which represents the main symptomatic 
problem in these cases, and colorectal GISTs may cause bowel obstruction. In metastatic disease, 
debilitating systemic symptoms, such as fever, night sweats and weight loss, are common.
Current service provision
Management of disease
There is wide consensus that the management of GISTs should be undertaken in the context of 
discussion of individual cases by a multidisciplinary team.15,31© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Management of resectable disease
Surgical resection is the primary treatment for GISTs and offers the only possibility of cure. 
Surgical resection is undertaken with the aim of achieving a complete microscopic resection 
(R0 resection). Evaluation of the suitability and possibility of a complete microscopic resection 
of a GIST is made after appropriate preoperative assessment to determine stage and also the 
fitness of the patient for the procedure required. Preoperative assessment for staging includes (as 
a minimum) a computerised tomography (CT) scan of the chest, abdomen and pelvis, and, in 
specific circumstances, there is a role for endoscopic ultrasound, laparoscopy and angiography.
After resection patients are followed up with protocols involving clinical examination and/or 
surveillance imaging, based upon relapse risk stratification by means of histopathological criteria 
of the resected tumour.15,32 Preliminary results from one randomised, placebo-controlled Phase 
III trial suggest that adjuvant therapy with imatinib (400 mg/day for 1 year) increases recurrence-
free survival following resection, and it is therefore suggested that adjuvant imatinib may have 
an important role to play in the prevention of recurrence of GISTs after resection.33 The results of 
other similar adjuvant trials are awaited.15 At present imatinib is licensed for adjuvant treatment 
of patients who are at a significant risk of relapse,34 but although Scottish guidelines recommend 
adjuvant imatinib (400 mg/day) in patients considered to be of moderate or high risk of relapse, 
according to histopathological criteria,15 a National Institute for Health and Clinical Excellence 
(NICE) Technology Appraisal for this indication is still ongoing,35 and it is acknowledged that, 
until more data are available from ongoing adjuvant studies, there is still uncertainty regarding 
the optimal duration of treatment, and also the subgroups of patients who may or may not 
benefit from adjuvant therapy. The use of imatinib as an adjuvant therapy may have implications, 
for example with regard to the development of drug resistance, for the subsequent systemic 
treatment of GISTs upon recurrence.36
Studies are ongoing to determine the role of imatinib as preoperative therapy in resectable 
tumours.37 Nevertheless, the use of imatinib preoperatively to downstage tumours from 
unresectable to resectable is considered safe and clinically worthwhile.15 Similarly, preoperative 
imatinib has also been recommended to limit the extent and (accordingly) morbidity of resection 
in specific circumstances, for example to facilitate sphincter-sparing resection in rectal GISTs.
Management of unresectable and metastatic disease
Conventional cytotoxic chemotherapy and radiotherapy are ineffective in the treatment of 
advanced GISTs. Similarly, initial debulking surgery is not recommended unless there is an 
immediate clinical need, such as to remove an obstructing tumour.
Imatinib (Glivec, Novartis Pharmaceuticals UK) is a rationally designed small molecule 
inhibitor of several tyrosine kinases, including KIT and PDGFRA, and has provided the first 
clinically effective systemic therapy for GISTs. The European licence for imatinib was based 
on a Phase II study of 147 patients who were randomised to receive imatinib at either 400 or 
600 mg orally taken once daily.38 The treatment was well tolerated, objective response rate was 
the primary efficacy outcome and an overall partial response (PR) rate of 67% was demonstrated 
with no difference between treatment arms. Long-term results revealed median survival of 
57 months for all patients.39 A concurrent study investigated dose escalation and established 
800 mg daily as the maximum tolerated dose.40 Phase III trials performed both in Europe and 
Australasia [European Organisation for Research and Treatment of Cancer (EORTC) 62005 
study], and in North America (S0033 Intergroup study), confirmed the efficacy of imatinib in a 
larger patient population, and established the starting dose of 400 mg orally per day.41,42
Primary resistance to imatinib is uncommon, but acquired resistance is highly likely, and 
manifest clinically by the observation of disease progression.41–45 Guidelines suggest that 4 Background
patients should have a CT scan every 3 months while on therapy.15 Measurement of response by 
conventional criteria, such as Response Evaluation Criteria in Solid Tumors (RECIST), based 
on objectively measured changes in tumour size, may not occur, or may happen only after many 
months of treatment. This means that definitive evidence of patient response, and therefore 
clinical benefit, can be difficult to ascertain (at least initially). This has been addressed by the 
development of alternate methods of GIST response assessment, such as the ‘Choi criteria’ based 
upon tumour density as well as tumour size.46,47 Similarly, fluorodeoxyglucose-positron emission 
tomography (FDG-PET) has demonstrated some efficacy in predicting early response to imatinib 
therapy,48 although it should be noted that PET scanning is not widely available in the UK as very 
few NHS centres have access to this technology.
In addition, the assessment of progression of GISTs may be problematic if based on RECIST-
based tumour size criteria, as tumour liquefaction (cystic degeneration) can occur, which may 
give the appearance of progressive disease (PD) although the tumour is actually responding.47 
Accordingly, it is recognised that experienced radiologists should assess CT scans before 
confirming progression.
It has been demonstrated that interruption of treatment results in rapid disease progression in 
many patients with advanced GISTs.45 This includes patients with disease progression in whom 
a symptomatic worsening or ‘flare’ has been described.49 Therefore, continuation of imatinib in 
these patients has been common practice despite progression, as part of best supportive care 
(BSC).
Several studies have reported further disease control after progression on an initial imatinib dose 
of 400 mg orally per day with dose escalation of imatinib to 800 mg orally per day, and this has 
also become common practice.39,44 However, it should be noted that current NICE guidelines 
for imatinib do not actually recommend dose escalation for patients with unresectable and/or 
metastatic GISTs who progress on an initial dose of 400 mg/day.50
Recently, sunitinib (Sutent, Pfizer UK), another molecular-based treatment for GIST, became 
available, and has been approved by NICE for patients with unresectable and/or metastatic GIST 
who have progressed on treatment with imatinib.51 The NICE advice follows a randomised, 
double-blind, placebo-controlled, multicentre Phase II trial in which 312 patients, who were 
resistant or intolerant to imatinib, received either sunitinib (50-mg starting dose in 6-week cycles; 
4 weeks on and 2 weeks off treatment) or placebo;52 the trial was unblinded early when interim 
analysis showed a significantly longer time to tumour progression (the primary end point) 
with sunitinib.
To date, no randomised trial has been conducted comparing imatinib and sunitinib. One had 
been planned but was stopped owing to poor recruitment.53 As new options for management 
of patients with unresectable and/or metastatic GIST have developed since the initial 2004 
publication of NICE guidance for GIST treatment with imatinib, a review of the evidence 
available on treatments currently used in clinical practice is required.
Current service cost and anticipated costs associated with the intervention
As GIST affects mostly the middle-aged and older age population, the loss of productivity 
from the middle-aged population suffering from GIST is of concern. The median age of the 
GIST patients was found to be between 50 and 60 years,22,23 and incidence of GIST was found 
to increase with increase in age.54 The cost of different treatment strategies needs thorough 
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Treatment with imatinib per patient within an NHS setting has been estimated at £18,896 and 
£24,368 annually for patients on 400 and 600 mg/day, respectively.55 Other associated annual 
costs of treatment (including the treatment of adverse events) were estimated at £2730 (price 
year not stated). Estimates from previous disease models suggest that in 2 years it would cost the 
NHS approximately £31,160 to treat a patient with imatinib, and for 10 years this figure would be 
£56,146 (2002 price year).54,55 Costs would differ when patients who fail to respond to imatinib 
are provided with higher doses or alternative treatments (e.g. sunitinib).50
The costs of treating patients with unresectable and/or metastatic GIST using imatinib were 
estimated at between £1557 and £3115 per month per patient, resulting in a cost to the NHS 
(England and Wales) of between approximately £5.6M and £11.2M per year (2002 price year).55 
Another study estimates that the total costs over 10 years for managing GIST patients with 
molecularly targeted treatment would be between £47,521 and £56,146 per patient compared 
with a cost of between £4047 and £4230 per patient when managed with BSC (price year 
not stated).54
Variation in service and uncertainty about best practice
The treatment of GISTs after progression on imatinib is generally decided on a case-by-case 
basis by multidisciplinary teams, and the alternatives are dose escalation of imatinib, sunitinib at 
50 mg/day (4 weeks out of 6 weeks) or, alternatively, BSC only (although due to the ‘symptomatic 
flare’ already mentioned this may include continuation of imatinib at 400 mg/day). Many 
clinicians advocate initial dose escalation of imatinib and then consider sunitinib on subsequent 
progression, but there will be variation in clinical practice depending on the specific needs of 
individual patients.
Relevant national guidelines
UK guidelines recommend the dose escalation of imatinib, and/or sunitinib following imatinib 
failure,15,56 but also suggest that clinical decisions are made on an individual case-by-case basis, 
reflecting uncertainty regarding optimal practice.
Description of technology under assessment
Summary of intervention
Imatinib
Imatinib (Glivec) is a rationally designed small molecule inhibitor of several oncogenic tyrosine 
kinases: c-Abl, PDGFRA and the KIT tyrosine kinases. Its therapeutic activity in GISTs relates 
to inhibition of KIT, although in cases with no KIT mutation the inhibition of PDGFRA is 
likely to be of therapeutic importance.2 Imatinib is a derivative of 2-phenylaminopyrimidine, 
and a competitive antagonist of adenosine triphospate (ATP) binding, which blocks the ability 
of KIT to transfer phosphate groups from ATP to tyrosine residues on substrate proteins. This 
interrupts KIT-mediated signal transduction, which is the key pathogenic driver for many GISTs. 
The inhibitory activity of imatinib on KIT is highly selective, and minimal inhibition of other 
kinases that are important in normal cell function occurs, thereby affording a good toxicity and 
safety profile.
Imatinib is licensed and approved for use in the UK NHS in KIT-immunoreactive positive 
advanced/unresectable GISTs.50,57
Sunitinib
Sunitinib malate (Sutent), is a tyrosine kinase inhibitor targeting KIT, PDGFRA, all three 
isoforms of vascular endothelial growth factor receptor (VEGFR), FMS-like tyrosine kinase 3 6 Background
(FLT3) colony-stimulating factor 1 receptor (CSF-1R) and glial cell line-derived neurotrophic 
factor receptor.58 Sunitinib activity in GISTs may predominantly relate to inhibition of KIT and/
or PDGFRA, and ex vivo investigation has shown that sunitinib can inhibit the kinase activity of 
KIT molecules harbouring secondary mutations conferring imatinib resistance.59 However, the 
potent antiangiogenic activity of sunitinib as a consequence of strong VEGFR inhibition may also 
be important for clinical activity in GISTs.
Best supportive care
Best supportive care is not well defined or standardised, and can also be referred to as ‘supportive 
care’ or ‘active symptom control’.55 It usually involves interventions to manage pain and treat 
fever, anaemia (due to GI haemorrhage) and GI obstruction,50 and can include palliative 
measures.60 A Cochrane review of supportive care for patients with GI cancer defined supportive 
care as ‘the multi-professional attention to the individual’s overall physical, psychosocial, spiritual 
and cultural needs’.61 It was argued that this type of care should ethically be made available to 
all treatment groups, meaning that treatment with imatinib or sunitinib could not be provided 
without concomitant supportive care as well in clinical practice for patients with GIST, although 
it is possible that treatment with BSC could be provided without additional drug treatment with 
either imatinib or sunitinib. It should be noted that the amount of care required as part of BSC is 
likely to increase as the disease progresses and symptoms become worse.
Identification of important subgroups
The differential benefit from imatinib and sunitinib in subgroups of patients with GIST, whose 
tumours have different primary and secondary KIT mutations, has suggested possible benefits in 
personalising first- and second-line therapy.
Primary KIT mutations are those that are pathogenic and present before any systemic treatment, 
while secondary mutations are those that have been identified after imatinib treatment and 
confer resistance to imatinib. Identification of secondary mutations requires rebiopsy of tumours, 
and studies have suggested that the emergence of secondary (or acquired) imatinib resistance is 
polyclonal, so patients with GIST may acquire more than one secondary KIT mutation.62
A meta-analysis of 1640 patients revealed that patients with KIT exon 9 primary mutations have a 
better outcome if treated at the escalated dose of 800 mg daily.63 Similarly, objective response rates 
to imatinib 400 mg/day are higher in patients with exon 11 primary mutations than in those with 
exon 9 mutations, or those with no detectable KIT or PDGFR mutation.14,41 Therefore, advanced 
GIST patients with exon 9 mutations may benefit from immediate dose escalation of imatinib, 
and the benefit of dose escalation on progression may be more significant in this subgroup of 
patients and thereby have implications for therapeutic alternatives and choices on progression in 
different groups of patients defined by KIT mutations. Recent studies have indicated that plasma 
monitoring in GIST patients could assist clinicians’ decision-making with regard to whether or 
not dose escalation of imatinib is required for particular patients, including those with mutations 
in KIT.64–66
Secondary mutations in KIT exons 13, 14, 17 and 18 are associated with acquired resistance 
to imatinib.43 Sunitinib activity after progression on imatinib has been demonstrated in GIST 
patients with imatinib resistance conferring secondary KIT mutations.62 However, both the 
primary KIT mutation genotype and secondary KIT mutations may influence the clinical benefit 
effect of sunitinib in GIST patients who have progressed on imatinib.62 Interestingly, in contrast 
to imatinib, greater benefit from sunitinib (after imatinib failure) is seen in patients with primary 
exon 9 mutations or wild-type KIT as opposed to primary exon 11 mutations.62 However, it is 
not clear how dose-escalated imatinib (800 mg/day) compares with sunitinib in patients with 
primary exon 9 KIT mutations. While the polyclonal emergence of resistance is an investigational © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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and clinical challenge, it appears that GIST patients with secondary KIT mutations associated 
with acquired imatinib resistance in exons 13 or 14 (which involve the KIT–ATP binding 
pocket) appear to gain greater clinical benefit from sunitinib after imatinib failure than those 
patients with exon 17 or 18 imatinib resistance secondary mutations (which involve the KIT 
activation loop).62
Changes in FDG (fluorodeoxyglucose) avidity of GISTs measured by FDG-PET occur earlier 
than anatomical changes in GISTs and so may also have a role as a predictive biomarker 
for imatinib response, and also for detecting early disease progression49 in the future as the 
technology becomes more widely available in NHS settings.
Current usage in the NHS
Current practice is to commence patients on imatinib 400 mg/day, and on confirmed disease 
progression the options are dose escalation of imatinib up to 800 mg/day or sunitinib, or BSC 
only. Practice is variable, and decided on a case-by-case basis. Some clinicians proceed with dose 
escalation of imatinib initially and then, on further progression, use sunitinib. Some guidelines 
and clinicians advocate returning to imatinib for symptomatic benefit, when there are no other 
therapeutic options, and the cessation of imatinib in the absence of alternative treatment options 
is not recommended owing to the tumour flare phenomenon, with rapid deterioration in 
symptoms observed in some patients.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
9   Health Technology Assessment 2011; Vol. 15: No. 25 DOI: 10.3310/hta15250
Chapter 2  
Definition of the decision problem
Decision problem
Specific information on the population, interventions, comparators and relevant outcomes 
considered for this review are discussed in detail in Chapter 4 (see Identification of studies).
Until the licensing of imatinib, the prognosis for people with unresectable and/or metastatic 
GISTs was poor.19 Since 2002, the clinical effectiveness of treatment for GIST with imatinib at a 
dose of 400 mg/day has been well documented.50,55 There is also clinical trial evidence showing 
that patients with unresectable and/or metastatic GIST can also respond to higher doses of 
imatinib, up to a maximum tolerated dose of 800 mg/day,40 and that patients with different 
exon mutations in the KIT gene may differ in their response to imatinib at both standard and 
escalated doses.14
Guidance from NICE does not currently recommend the prescription of escalated doses of 
imatinib upon progression on the standard 400 mg/day dose,50 although it is common in clinical 
practice.15,32 Most of the evidence relating to dose-escalated imatinib comes from randomised 
trials where participants were randomised to doses greater that 400 mg/day, as opposed to 
receiving these higher doses upon disease progression on the 400 mg/day dose. However, 
evidence suggests that tolerability of higher doses may depend on the extent of prior exposure to 
the drug,66 and if in clinical practice escalated doses are prescribed only upon progression, these 
trial data may not provide reliable estimates of response, progression-free survival (PFS) and 
overall survival (OS), quality-of-life effects or the extent of adverse event occurrence. In addition, 
if patients with unresectable and/or metastatic GIST are likely to attain different levels of clinical 
benefit from different imatinib doses then clinicians’ decision-making on appropriate dosages for 
individual patients should be informed by the best available evidence.
The development of imatinib has represented a paradigm shift in the treatment of unresectable 
and/or metastatic GIST, as, prior to its introduction onto the market, the only available treatment 
remaining for this population group was BSC, which, given the severity of this disease, represents 
essentially palliative intervention. Since the introduction of imatinib, other new treatments for 
unresectable and/or metastatic GIST have become available, including sunitinib, which has been 
recommended by NICE as the second-line treatment for the population of interest, after failure 
on treatment with imatinib.51 As there are now various options available for treating unresectable 
and/or metastatic GIST, it is therefore necessary to review the available evidence on imatinib at 
escalated doses, when compared with sunitinib, for patients with unresectable and/or metastatic 
GIST, whose disease has progressed on the standard imatinib dose of 400 mg/day.
Overall aims and objectives
The aim of this review was to assess the clinical effectiveness and cost-effectiveness of imatinib 
at escalated doses (i.e. 600 or 800 mg/day) within its licensed indication,67 for the treatment of 
patients with unresectable and/or metastatic GISTs, who have progressed on imatinib at a dose of 
400 mg/day.10 Definition of the decision problem
The objectives of this review will help facilitate decision-making on the most appropriate 
treatment(s) for patients with unresectable and/or metastatic GIST who have progressed on 
imatinib at a dose of 400 mg/day, by:
  ■ conducting a systematic review of the evidence available on the clinical effectiveness of 
imatinib at dosages of 600 or 800 mg/day compared with sunitinib and/or BSC
  ■ conducting a systematic review of the cost-effectiveness of imatinib at dosages of 600 or 
800 mg/day compared with sunitinib and/or BSC
  ■ analysing available outcome data for particular subgroups of interest (e.g. patients with 
different KIT mutations) in order to establish any differences in clinical effectiveness for 
specific groups
  ■ developing an economic model to compare the cost-effectiveness and cost–utility of imatinib 
at a dose of 600 or 800 mg/day with those of sunitinib (within its recommended dose range) 
or BSC only.
This report contains reference to confidential information provided as part of the NICE appraisal 
process. This information has been removed from the report and the results, discussions and 
conclusions of the report do not include the confidential information. These sections are clearly 
marked in the report.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Chapter 3  
Critique of the manufacturer 
submission
T
he manufacturer of imatinib (Novartis) did not provide an economic analysis in their 
submission, stating that, owing to the limited amount of data available from the key clinical 
studies and the dearth of data comparing imatinib dose escalation with sunitinib and BSC, they 
were unable to submit a sufficiently robust economic analysis that met the scope for the appraisal. 
However, they did provide a summary of clinical evidence and implications for the economic 
analysis. With the exception of the Executive Summary section, and most of the References 
section, a large proportion of the submission document was highlighted as commercial in 
confidence (CiC). Electronic copies of all the papers cited in the References section, including 
two labelled as CiC by the manufacturer, were provided. Apart from both of the CiC documents, 
these studies had already been retrieved by our searching process and are discussed in Chapter 4.
Of the two CiC reports provided, one (CiC information has been removed) was a report on the 
randomised, Phase II, B2222 trial comparing imatinib at doses of 400 and 600 mg/day. Patient 
data from this trial that are relevant to this review have since been published by Blanke et 
al.39 in the Journal of Clinical Oncology. The remaining CiC report (CiC information has been 
removed) provided a meta-analysis of data from the randomised, Phase III, intergroup S0033 
trial comparing imatinib at doses of 400 and 800 mg/day, and the randomised, Phase III, EORTC-
ISG (Italian Sarcoma Group)-AGITG (Australasian Gastro-Intestinal Trials Group) trial, also 
comparing imatinib at these doses. Crossover data from the S0033 trial have been published 
separately,41,68 as have crossover data from the EORTC-ISG-AGITG trial.44 (CiC information has 
been removed.)
(CiC information has been removed.) All relevant results pertaining to the population of interest 
for this review have been provided in Chapter 4 (Assessment of clinical effectiveness). (CiC 
information has been removed) but as more recent results for the study population of interest 
have been published, only study characteristics information was used in Chapter 4 of this review.
The key points made in the manufacturer submission were as follows:
  ■ The limited number of data available from the key clinical studies and the paucity of data 
comparing imatinib dose escalation with sunitinib and BSC prevent, in the opinion of the 
manufacturer, the submission of a sufficiently robust economic analysis which meets the 
scope of the appraisal.
  ■ There are currently no head-to-head trial data comparing imatinib with sunitinib.
  ■ Sunitinib represents a third-line treatment, rather than second line as per the scope of 
the evaluation, making it difficult, if not impossible, to conduct a robust and plausible 
indirect comparison of the two technologies. UK National GIST Guidelines56 recommend 
that changing treatment to sunitinib should be considered only after patients have shown 
progression on imatinib dose escalation.
  ■ Since the publication of TA86 clinical practice has evolved to consider dose escalation to a 
daily dose of 600 or 800 mg, when patients progress on the standard daily dose of 400 mg, 
and this change in clinical practice is reflected within UK National GIST Guidelines.5612 Critique of the manufacturer submission
  ■ (CiC information has been removed.)
  ■ (CiC information has been removed.)
  ■ (CiC information has been removed.)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
13   Health Technology Assessment 2011; Vol. 15: No. 25 DOI: 10.3310/hta15250
Chapter 4  
Assessment of clinical effectiveness
Methods for reviewing effectiveness
Identification of studies
Extensive sensitive electronic searches were conducted to identify reports of published and 
ongoing studies on the clinical effectiveness of imatinib. The searches were also designed to 
retrieve clinical effectiveness studies of the comparator treatments (sunitinib and BSC). In 
addition, reference lists of retrieved papers and submissions from industry and other consultees 
were scrutinised to identify additional potentially relevant studies.
The databases searched were MEDLINE (1966 – September, week 3, 2009), MEDLINE In-Process 
(25 September 2009), EMBASE (1980 – week 39, 2009), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL) (September 2009), Science Citation Index (SCI) (2000 – 
26 September 2009), BIOSIS (2000 – 24 September 2009), Health Management Information 
Consortium (September 2009), and the Cochrane Controlled Trials Register for primary research 
and the Database of Abstracts of Reviews of Effects (DARE) (October 2009), the Cochrane 
Database of Systematic Reviews (CDSR) (Issue 3, 2009) and the Health Technology Assessment 
(HTA) database (October 2009).
Ongoing and recently completed trials were searched in the following databases: current research 
registers, including Clinical Trials, Current Controlled Trials (CCT), National Institute of Health 
Research (NIHR) Portfolio, World Health Organization (WHO) International Clinical Trials 
Registry Platform, International Federation of Pharmaceutical Manufacturers & Associations 
(IFPMA) Clinical Trials and the Association of the British Pharmaceutical Industry (ABPI) 
database. Recent conference proceedings of key oncology and GI organisations, including the 
American Society for Clinical Oncology (ASCO), European Society for Medical Oncology 
(ESMO) and the European Cancer Organisation, were screened. Websites of the GIST Support 
International, and the drug manufacturers Pfizer and Novartis were also scrutinised.
Full details of the search strategies used are reproduced in Appendix 1.
Inclusion and exclusion criteria
Types of studies
An initial scoping search suggested that there would be few studies looking specifically at either 
of the named interventions (imatinib 600 or 800 mg/day). Therefore, we considered all of the 
following types of studies for the assessment of clinical effectiveness:
1.  randomised controlled trials (RCTs)
2.  non-randomised comparative studies, and
3.  case series.
If the number of studies meeting our inclusion criteria was sufficiently large, consideration was 
to be given to limiting them by type of study design, and also possibly other factors (e.g. sample 
size). Additionally, we planned to exclude non-English language papers, and/or reports published 14 Assessment of clinical effectiveness
as meeting abstracts, if the evidence base of English language and/or full-text reports was 
sufficiently large.
Types of participants
Participants considered were people with KIT (CD117)-positive unresectable and/or metastatic 
malignant GISTs, whose disease had progressed on treatment with imatinib at a dose of 
400 mg/day. If sufficient evidence was available, subgroup analysis was to be undertaken for 
those patients with different mutations of CD117, as there is some evidence to suggest this 
may affect their response to escalated doses of imatinib14,41,63 (see Chapter 1, Identification of 
important subgroups). In addition, subgroup analysis was also to be undertaken on methods used 
to identify response or resistance (e.g. FDG-PET or CT scanning) and the use of imatinib in a 
neoadjuvant or adjuvant setting for patients with previously resectable GIST, where sufficient data 
were available.
Types of intervention and comparators
The interventions considered were imatinib at escalated doses of 600 and 800 mg/day, 
respectively, being prescribed with BSC. The comparators considered were sunitinib, prescribed 
within its recommended dose range of 27–75 mg and provided with BSC, and BSC only. As 
previously stated, BSC is defined as ‘the multi-professional attention to the individual’s overall 
physical, psychosocial, spiritual and cultural needs’.61
Types of outcomes
For the assessment of clinical effectiveness, the following outcomes were considered:
  ■ overall response
  ■ overall survival
  ■ disease-free survival
  ■ progression-free survival
  ■ time to treatment failure
  ■ health-related quality of life (HRQoL) [e.g. European Quality of Life-5 Dimensions (EQ-5D) 
scores]
  ■ adverse effects of treatment (e.g. number of discontinuations due to adverse events).
Exclusion criteria
We excluded studies of animal models, preclinical and biological studies, reviews, editorials, 
opinions, case reports and reports investigating technical aspects of the interventions.
Data extraction strategy
The titles and abstracts (where available) of all records identified by the search strategy were 
screened by two reviewers independently. Full-text copies of all potentially relevant reports 
were retrieved. The full-text reports were assessed against the inclusion and exclusion criteria 
by two reviewers independently. Full-text papers and conference abstracts were assessed using 
a screening form that was developed and piloted for this purpose. Any disagreements were 
resolved by consensus or arbitration by a third party. A copy of the screening form used can be 
found in Appendix 2.
A data extraction form was developed and piloted (Appendix 3). One reviewer extracted details 
of the study design, participants, intervention, comparator and outcomes, and a second reviewer 
checked the data extraction for accuracy. Any disagreements were resolved by consensus or 
arbitration by a third party.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Quality assessment strategy
Two reviewers independently assessed the methodological quality of the included full-text 
studies. Non-randomised comparative studies were assessed using an 18-question checklist, 
with the same checklist minus four questions used to assess the methodological quality of case 
series. This checklist for non-randomised studies and case series was adapted from several 
sources, including the Centre for Reviews and Dissemination’s guidance for those carrying out or 
commissioning reviews,69 Verhagen et al.,70 Downs and Black,71 and the Generic Appraisal Tool 
for Epidemiology (GATE). It assesses bias and generalisability, sample definition and selection, 
description of the intervention, outcome assessment, adequacy of follow-up, and performance of 
the analysis. The checklist was developed through the Review Body for Interventional Procedures 
(ReBIP). ReBIP is a joint venture between Health Services Research at Sheffield University and 
the Health Services Research Unit at the University of Aberdeen, and works under the auspices of 
the NICE Interventional Procedures Programme.
We planned to assess the quality of RCTs using the Cochrane Collaboration’s tool for assessing 
risk of bias.72 The tool addresses six specific domains: sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective outcome reporting and other issues. 
Each quality assessment item had three possible responses: ‘yes’, ‘no’ or ‘unclear’, with space for 
additional comments. Disagreements between reviewers over study quality were to be resolved 
by consensus and, if necessary, arbitration by a third party. Abstracts were not quality assessed 
because they were considered unlikely to provide sufficient methodological information to enable 
an accurate assessment of study quality. Methodological quality did not form part of the criteria 
for the inclusion or exclusion of studies. A copy of the quality assessment tool can be found in 
Appendix 4.
Data analysis
The type of data analysis considered was dependent on the number of studies meeting the 
specified inclusion criteria, and study design. Where a quantitative synthesis was considered 
inappropriate or not feasible, it was planned that a narrative synthesis of results would be 
provided instead.
For relevant outcomes from randomised comparisons, it was decided that meta-analysis (where 
appropriate) would be used to estimate a summary measure of effect. Dichotomous outcome data 
for the overall response outcome would be combined using the Mantel–Haenszel relative risk 
(RR) method, and continuous outcomes by using the inverse variance weighted mean difference 
(WMD) method. For both of these estimates, 95% confidence intervals (CIs) and p-values 
would also be calculated. Chi-squared tests and I2-statistics were to be used to explore statistical 
heterogeneity across studies, with possible reasons for heterogeneity explored using sensitivity 
analysis. Where no obvious reason for heterogeneity was found, the implications would be 
explored using random effects methods.
The pooled weighted ratio of median survival would be derived for OS, disease-free survival 
and PFS. The hazard ratio (HR) is the most appropriate statistic for time-to-event outcomes 
(i.e. for time to treatment failure). If available, the HR would be extracted directly from the trial 
publications, but if not reported it would be extracted if possible from other available summary 
statistics or from data extracted from published Kaplan–Meier curves using methods described 
by Parmar et al.73 A pooled HR from available RCTs could then be obtained by combining 
the observed (O) minus expected (E) number of events and the variance obtained for each 
trial using a fixed effects model.74 A weighted average of survival duration across studies was 
to be calculated. The chi-squared test for heterogeneity was to be used to test for statistical 
heterogeneity between studies.16 Assessment of clinical effectiveness
Where no RCT data were available, but non-randomised studies had reported relevant data for 
survival outcomes, assessment of the risk of bias and heterogeneity was to be undertaken using 
meta-regression analysis.
It was expected that few studies, if any, would report direct comparisons of the intervention and 
comparators, so (depending on feasibility and appropriateness) it was decided that, where non-
randomised evidence was available, meta-analysis models would be used to model survival rates 
for interventions and comparators. A ‘cross-design’ approach was to be adopted to allow non-
randomised evidence to be included, while avoiding the strong assumption of the equivalence 
of studies. Evidence suggests that this approach would allow data from RCTs, non-randomised 
comparative studies and case series to be included.75 Differences between treatments for survival 
outcomes were to be assessed via the corresponding odds ratio and 95% credible intervals. These 
results are ‘unadjusted odds ratios’, but meta-analysis models adjusting for study type were also to 
be used. The results from these models produce ‘adjusted’ odds ratios.76 Winbugs software (MRC 
Biostatics Unit, Cambridge, UK) was to be used for the analysis.
Any reported data on adverse effects of treatment and quality of life (QoL) that were collected 
were to be combined, using standardised mean difference, where appropriate.
In addition, and taking into account the type of evidence, the feasibility of using a mixed 
treatment comparison model for indirect comparisons was to be considered.
Results
Number of studies identified
We identified 3365 records from the primary searches for the review of clinical effectiveness. 
After title and abstract screening, 2441 articles were considered not to be relevant for this 
review and were excluded. The full-text papers of 924 records were obtained and screened. One 
hundred and twenty-three of these full-text papers were non-English language publications. 
In total, six full-text papers and 10 abstracts reporting four separate clinical trials and one 
additional retrospective cohort met our inclusion criteria. An additional 49 papers were retained 
for background information. The reasons for exclusion of assessed full-text papers are given 
in Table 1. A flow diagram of the screening process is outlined in Figure 1. Information on the 
reasons for excluding individual studies is provided in Appendix 5.
Included studies
See Appendix 6 for a list of studies that were included in the review of clinical effectiveness. We 
did not identify any RCTs, or non-randomised comparative studies, comparing the effectiveness 
of escalated doses of imatinib (600 or 800 mg/day) with sunitinib or BSC that met our inclusion 
criteria. One ongoing trial was identified comparing imatinib and sunitinib. However, this study 
was stopped owing to poor recruitment.53 We identified five full-text reports of three randomised 
trials of imatinib that contained relevant data for this review.14,38,39,41,44 The studies by Zalcberg et 
al.,44 Blanke et al. (S0033)41 and Blanke et al. (B2222)39 were designated as the primary reports 
for the EORTC-ISG-AGITG (62005) trial, the S0033 trial and the B2222 trial, respectively. The 
study by Debiec-Rychter et al.14 met our inclusion criteria and provided additional information 
from the EORTC-ISG-AGITG (62005) study on response following crossover, while the study 
by Demetri et al.52 met our inclusion criteria and provided interim data from the B2222 trial on 
response following crossover.
An additional three abstracts were identified, with two68,77 reporting interim data for the S0033 
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All of these included studies contained a treatment arm of 400 mg/day, and reported data 
separately for participants who received an escalated dose of imatinib upon progression at this 
randomised dose. One additional full-text paper detailing the results of a non-randomised 
retrospective study by Park et al.79 was also included. This study met our inclusion criteria as 
it also provided separate outcome data for patients with metastatic or unresectable GIST, who 
received escalated doses of imatinib on progression at an initial dose of 400 mg/day.
For the comparator treatment of sunitinib, we identified seven abstract reports meeting our 
inclusion criteria. All were interim results of an ongoing, open-label sunitinib trial reporting 
information on participants recruited to the trial following failure at different doses of imatinib, 
including doses of ≤ 400 mg/day.80–86 We designated the abstract by Seddon et al.86 to be the 
primary report for this trial, as it was thought to contain its most recent results.
For the comparator treatment of BSC, no randomised, non-randomised or case series studies 
were identified that compared either of the interventions (imatinib at a dose of 600 mg/day or 
TABLE 1  Reasons for exclusion of studies
Reason for exclusion No. of studies excluded 
Patient had resectable GIST 24
Outcomes not reported separately for patients with GIST 10
< 10 patients in relevant study population 46
Imatinib dose is 400 mg/day 13
No/insufficient data reported for escalated dose patients 65
No imatinib dose reported 84
No relevant interventions 15
Treatment not evaluated 11
No outcomes of relevance 10
Other reason 61
339
Retained for background information 49
Review articles 169
Letter/editorial/correspondence/symposium articles/meeting reports/expert views/comments 117
Case study/case series < 10 patients 64
Non-English language exclusions 123
Not obtained 47
Total 908
FIGURE 1  Flow diagram outlining the screening process for the review of clinical effectiveness.
908 articles excluded
(see Table 1 for reasons for exclusion)
3365 titles and abstracts identified from primary searches
924 selected for full text assessment
16 articles included
2441 excluded18 Assessment of clinical effectiveness
imatinib at 800 mg/day) with BSC, or provided data on relevant outcomes for the population of 
interest for BSC only. It should be noted that studies published on the clinical effectiveness of 
BSC prior to the licensing of imatinib18,19 were not eligible for this review as our population of 
interest was those who had failed on imatinib at 400 mg/day; therefore all studies published prior 
to the availability of imatinib automatically failed to meet our inclusion criteria because BSC at 
that time could not possibly have been provided following failure of treatment with imatinib at a 
dose of 400 mg/day.
Corresponding authors for each of the included trials were contacted in order to determine 
whether any additional data could be provided specifically for the population of interest (i.e. 
those participants failing on an imatinib dose of 400 mg/day and receiving either an escalated 
dose of imatinib 600 or 800 mg/day or, alternatively, sunitinib). For the ongoing, open-label 
sunitinib study, the corresponding author replied that no further information could be provided 
as the study was an official, ongoing trial by the manufacturer (Pfizer). For the imatinib trials, 
in the case of both studies by Blanke et al.39,41 our requests for information were forwarded to 
the statistics team involved in the trials. The requested data for the S0033 trial were provided 
on 17 February 2010. For the study by Zalcberg et al.,44 a response to our request was received, 
explaining that an official data request form must be completed. This was submitted, and a 
further response was received on 9 April 2010 explaining that the data could not be provided 
until September 2010 (and then only if the request were approved). It was decided not to pursue 
the request for data further, given the timelines for this project.
Two additional reports (CiC information has been removed) to the ones identified through our 
search strategy were provided for this review by the manufacturer and have been discussed in 
Chapter 3, and are also discussed below. Both of these reports were marked as CiC.
Excluded studies
A list of 340 studies, originally identified as potentially relevant but subsequently failing to meet 
our inclusion criteria, is provided in Appendix 5. The studies were excluded because they failed to 
meet one or more of the inclusion criteria in terms of the type of study, participants, intervention, 
comparator or outcomes reported. It should be noted that all full-text screened studies on plasma 
monitoring, as well as those on the use of FDG-PET technology for evaluating PD, did not meet 
our inclusion criteria. In addition, the types of participants were limited to an adult population, 
therefore studies involving children with GIST were excluded. However, it should be noted that 
the age range provided in the baseline data for the included study by Seddon et al.86 indicates that 
at least one child was recruited on to this trial, but, as the median age reported indicates that the 
majority of patients in this trial were adults, the study was not excluded.
Studies with a relevant population of fewer than 10 patients were also excluded. Changes to our 
original protocol were reported to NIHR in a progress report submitted on 9 December 2009.
In addition to the included studies identified above, nine studies (reported in 14 papers) reported 
sufficient information with regard to our inclusion criteria to be considered for potential 
inclusion in this review, subject to clarification from the study authors regarding specific aspects 
of the study. Corresponding authors for each of the nine studies were therefore contacted. 
Responses were received from four corresponding authors (GD Demetri, Ludwig Center at 
Dana-Farber/Harvard Cancer Center and Sarcoma Center, Boston, MA, USA, 2010; YK Kang, 
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 2010; P Rutkowski, 
Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Department of Soft 
Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland, 2010; P Wolter, UZ Leuven, Leuven, 
Belgium, 2010; personal communication). In the cases of two responses, this resulted in the 
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communication) In the remaining two studies (four papers), the responses did not result in 
clarification, as the authors requested that we wait for a further response from them or their 
colleagues (GD Demetri, YK Kang, personal communication). In the case of correspondence 
with YK Kang, it was decided that the study by Park et al.79 could be included in the review 
without further clarification from the corresponding author.
Of the correspondences that did not result in responses, one e-mail could not be sent 
successfully87 and the remaining four authors did not respond.88–91
Characteristics of the included studies
Study characteristics data were available for the four full-text included imatinib studies39,41,44,79 and 
the primary report of the included sunitinib trial.86 However, of these studies, only the studies by 
Zalcberg et al.44 and Park et al.79 gave specific baseline information for the crossover subgroup 
of interest. Therefore, Table 2 provides details of all characteristics information provided for 
each crossover group, while Table 3 provides details of the same characteristics for all patients 
in the treatment arms of interest (initial randomisation to a dose of 400 mg/day). In the case of 
the EORTC-ISG-AGITG trial reported by Zalcberg et al.,44 relevant study characteristic data for 
participants initially randomised to the 400 mg/day dose were not available. However, these data 
were reported in a paper by Verweij et al.42 for the same trial. The paper by Verweij et al.42 failed 
to meet the inclusion criteria for this review as it did not provide any outcome data for patients 
TABLE 2  Characteristics of the included studies for the population of interest
Zalcberg 200544 Blanke S003341 Blanke B222239 Park 200979 Seddon 200886
Drug assessed Imatinib Imatinib Imatinib Imatinib Sunitinib
Doses given 400 mg/day, 
800 mg/day
400 mg/day, 
800 mg/day
400 mg/day, 
600 mg/day
600 mg/day, 
800 mg/day
Cycle of 50 mg/day 
for 4 weeks, then 
0 mg/day for 
2 weeks
Start date (CiC information has 
been removed)
December 2000 July 2000 June 2001 Unspecified
End date April 2004 (CiC information has 
been removed)
May 2006 June 2006 December 2007
Study countries Australia, Belgium, 
Denmark, France, 
Germany, Italy, the 
Netherlands, New 
Zealand, Poland, 
Singapore, Spain, 
Switzerland, UK
Canada, USA Finland, USA Seoul, South Korea Unspecified but 
‘worldwide’ and 
‘multicentre’
No. of institutions involved 
(no. of countries involved)
(CiC information has 
been removed)
148 (2) 4 (2) 1 (1) 96 (33)
Length of follow-up at time 
of analysis
Median of 25 
months (maximum 
of 35 months)
Median of 4.5 years Median of 63 
months (maximum 
of 71 months)
Median of 8 months 
(range 1.4–22.3)
Median of 51 weeks 
(range 0.1–159)
Number receiving escalated 
dose of imatinib after failure 
of imatinib at 400 mg/
day, out of all of those 
randomised to receive 
400 mg/day
133/473 (28.1%) 118/345 (34.2%) 43/73 (58.9%) 24/24 (100.0%) NA
Number receiving sunitinib 
after failure of imatinib at 
≤ 400 mg/day, out of all of 
those receiving sunitinib
NA NA NA NA 351/1117 (31.4%)
NA, not applicable.20 Assessment of clinical effectiveness
receiving an escalated dose of 800 mg/day imatinib upon progression at a 400 mg/day dose, but as 
it provides information on the characteristics of all randomised patients (of whom a proportion 
went on to receive an escalated dose of 800 mg/day and formed the study population of the 
included study by Zalcberg et al.44), it was felt that the baseline data from this excluded study 
could still be used.
Four of the included trials reported data for imatinib,39,41,44,79 while the remaining trial reported 
data for sunitinib.86 Two of the imatinib trials randomised patients to imatinib doses of either 400 
or 800 mg/day,41,44 one randomised patients to imatinib doses of either 400 or 600 mg/day,39 and 
TABLE 3  Characteristics of the included studies for all participants randomised
Included in this analysis
aEORTC-ISG-
AGITG42 Blanke S003341
Blanke B222239 (CiC 
information has been 
removed) Park 200979 Seddon 200886
All those randomised to 400 mg/day
All those who 
received escalated 
doses of imatinib on 
progression at a dose 
of 400 mg/dayb
All those 
receiving 
sunitinib
Number included 473 345 73 24 1117
Age in years: median (range) 59 (49–67) 61.9 (18–87) (CiC information has 
been removed)
52 (31–73) 59 (10–92)
Sex: M/F 283/190 187/158 (CiC information has 
been removed)
18/6 665/451
ECOG/WHO 
Performance Status 
Score:
0 217 (CiC information has 
been removed)
4 420
1 191 (CiC information has 
been removed)
18 515
2 48 (CiC information has 
been removed)
2 134
≤ 2 (456) 332 (CiC information has 
been removed)
(1069)
> 2 17 13 (CiC information has 
been removed)
38
Missing 10
Race/ethnicity (n) NR NR NR
White 273 CiC information has 
been removed)
Black 37 (CiC information has 
been removed)
Asian 25 (CiC information has 
been removed)
Other/unknown 10 (CiC information has 
been removed)
Number having previous 
chemotherapy
156 (32.9%) NR (CiC information has 
been removed)
3 (12.5%) 225 (26.8%)
Number having previous 
radiotherapy
26 (5.5%) NR (CiC information has 
been removed)
NR 78 (7.9%)
Number having prior surgery 410 (86.7%) (CiC information has 
been removed)
20 (83.3%) NR
ECOG, Eastern Cooperative Oncology Group; NR, not reported.
a  Baseline data for only the crossover patients from this treatment arm were available and are reported in Appendix 8.
b  Participants in this study were part of a retrospective cohort. Treatment was not randomised. The population of interest received escalated 
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the other was a retrospective study looking only at patients with GIST who had received escalated 
doses of imatinib at either 600 or 800 mg/day on progression at a dose of 400 mg/day.79 The 
sunitinib trial is an ongoing, non-randomised, open-label study and participants are provided 
with a 6-week cycle of sunitinib, at a dose of 50 mg/day for 4 weeks followed by 2 weeks without 
the drug.86
The study start date was reported for three out of the four included imatinib trials39,41,79 and was 
made available for the study by Zalcberg et al.44 by the manufacturer (CiC information has been 
removed). From this it can be seen that the earliest study start date is that of the study (CiC 
information has been removed)39 (CiC information has been removed). The included sunitinib 
abstract did not report a start date.
Three out of the four included imatinib studies reported an end date,39,44,79 and in the case 
of the sunitinib study by Seddon et al.86 a date was reported for the most recent analysis. 
The manufacturer also made this information available for the study by Blanke et al.41 (CiC 
information has been removed). The ongoing sunitinib trial has the most recent update, while the 
study by Zalcberg et al. was completed first, in April 2004.44
With the exception of the study by Park et al.,79 which involved one centre in one country, all 
trials were international and multicentre,39,41,44,86 with the sunitinib trial involving the most 
countries85 and the S0033 trial involving the most institutions.41 The B2222 trial involved the 
fewest countries and fewest institutions.39
The longest length of follow-up occurred in the B2222 trial reported by Blanke et al.,39 in which 
patients were followed up for a median of 63 months, while the shortest length of follow-up was 
found in the study by Park et al.,79 which gave a median follow-up for the study population of 
8 months.
Among the imatinib trials, 133/473 (28.1%), 118/345 (34.2%) and 43/73 (58.9%) of those 
initially randomised to imatinib at 400 mg/day progressed and were given an escalated dose.39,41,44 
In the imatinib study by Park et al.,79 the study population comprised only those who were 
given escalated doses of imatinib so 24/24 (100%) received an escalated dose. In the sunitinib 
study by Seddon et al.,86 351/1117 (31.4%) of those who failed on imatinib and were entered 
into the trial had failed on a dose of 400 mg/day or less. Therefore, the study with the largest 
relevant population was the sunitinib trial,86 while the study by Park et al.79 had the smallest 
study population.
The Park study79 had the youngest population, whereas the S0033 trial41 had the oldest study 
population. In (CiC information has been removed) studies, the number of male patients was 
higher than the number of female patients, which concurs with the epidemiological trends in 
gender associated with this disease (see Chapter 1, Epidemiology and incidence).
(CiC information has been removed) studies reported data on the performance status score of 
participants, although the study by Blanke et al. for the S0033 trial41 had combined the Eastern 
Cooperative Oncology Group (ECOG) performance status categories 0–2. Doing the same for 
the remaining studies shows that the vast majority of participants, 456/473 (96.4%), 332/345 
(96.2%), (CiC information has been removed), 24/24 (100%) and 1069/1107 (96.6%) in the 
EORTC-ISG-AGITG trial,42 S0033 trial,41 B2222 trial,39 (CiC information has been removed) 
Park study79 and the sunitinib trial,86 respectively, had a performance status score of ≤ 2.
(CiC information has been removed.)22 Assessment of clinical effectiveness
In terms of prior treatment, (CiC information has been removed) two reported the number 
having previous radiotherapy,42,86 (CiC information has been removed). For the imatinib studies, 
3/24 (12.5%), 156/473 (32.9%) and (CiC information has been removed) of participants had 
undergone previous chemotherapy in the study by Park et al.,79 the EORTC-ISG-AGITG trial42 
and the B2222 trial39 (CiC information has been removed), respectively, while 26.8% (225/1117) 
of patients had received prior chemotherapy in the study by Seddon et al.86 With regard to 
radiotherapy, 26/473 (5.5%) of patients in the EORTC-ISG-AGITG trial42 and 78/1117 (7.9%) 
of patients in the sunitinib trial86 had received prior radiotherapy. (CiC information has been 
removed) of participants involved in the B2222 trial reportedly had received prior surgery, (CiC 
information has been removed) while this figure was 86.7% (410/473) for participants in the 
EORTC-ISG-AGITG trial,42 and 83.3% (20/24) in the study by Park et al.79
Quality of the included studies
Results of the quality assessment for all four included full-text papers are summarised in 
Figure 2. No third party arbitration for quality assessment was required. The results of the quality 
assessment for each individual study are provided in Appendix 9. Three full-text studies assessed 
for quality assessment were included in the review because they provided crossover data on 
a subset of patients who were originally randomised to a dose of 400 mg/day, but progressed 
and received an escalated dose of either 600 mg/day39 or 800 mg/day.41,44 The fourth study79 was 
assessed for quality because it included a retrospective analysis of a subgroup of a cohort of 
patients given treatment with imatinib at 400 mg/day. The subgroup were patients who received 
escalated doses of 600 mg/day and/or 800 mg/day after progression on the 400 mg/day dose.
As the study populations of interest were not the original randomised populations, but the 
crossover subgroup in three studies,39,41,44 and a subgroup of consecutively treated patients in the 
remaining study,79 quality was assessed using the checklist for non-randomised studies (detailed 
in Methods, above). Questions within this checklist that were specific to non-randomised 
comparative groups (i.e. Q6 and Q16) were not considered applicable to the crossover subset 
population included in our review, and were therefore not summarised (see Appendix 4).
FIGURE 2  Quality assessment results summary.
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However, two specific domains were assessed using the Cochrane Collaboration’s tool for 
assessing risk of bias, namely sequence generation and allocation concealment, as these would 
check for selection bias at trial level.
Sample definition and selection
In three studies39,41,44 the included subgroups of participants were randomised at trial level, 
but crossover patients were not randomly selected, and so it is unclear the extent to which this 
group can be considered representative of the relevant patient population (Q1). The other study 
provided inadequate information to allow judgement of the representativeness of the sample.79 
With regard to the randomisation process at trial level, the studies by Blanke et al.41 and Zalcberg 
et al.44 used methods that adequately generated the allocation sequence to avoid influence of 
confounding factors while Blanke et al.39 did not report sufficient data on the randomisation 
process. In the study by Zalcberg et al.,44 allocation to treatment was not concealed. Both the 
B222239 and S003341 studies by Blanke et al. reported inadequate information on allocation 
concealment. All four studies adequately described inclusion and exclusion criteria (Q2). To 
consider whether participants entered the study at a similar point in their disease progression, we 
looked at data on their performance status. Three of the studies39,41,79 involved participants whose 
performance status at the time of study entry was similar, while the study by Zalcberg et al.44 
included participants with different performance status at study entry (Q3), although most of the 
participants in all populations had a performance status of < 2, meaning they were ambulatory 
and awake for at least 50% of their waking hours. None of the studies undertook consecutive 
selection of patients (Q4). Data were collected prospectively in all of the four studies (Q5).
Description of the intervention
The intervention was adequately defined by all studies (Q7). However, no study provided 
sufficient data describing supervision of the intervention (Q8) and no information was provided 
describing the types of staff involved, or the facilities used (Q9).
Outcome assessment
The quality of all four studies was similar in terms of outcome assessment (Q10). None of the 
studies had considered all of the outcomes of interest, but all reported the objective response of 
escalated imatinib dosing in patients with GIST, while one41 reported OS and two41,44 measured 
PFS. The study by Park et al.79 reported time to progression, and the study by Zalcberg et al.44 was 
the only study that also reported adverse events for those on an escalated dose of imatinib. No 
study reported outcomes related to QoL.
All four studies used valid and reliable outcome measures (Q11), such as RECIST to assess 
objective response or Kaplan–Meier methods to estimate survival curves, minimising detection 
bias. Assessment of main outcomes was not blinded in any of the studies (Q12).
Follow-up and attrition bias
Follow-up was considered long enough to detect important effects on outcomes of interest in all 
but one study where follow-up information was not provided and so this was unclear79 (Q13). 
Information on those lost to follow-up was either not provided39 (and thereby likely to introduce 
bias) or not provided at a sufficient level of detail41,44,79 to judge whether those lost to follow-up 
would be likely to introduce bias (Q14 and Q15).
Performance of the analysis
For both studies by Blanke et al.,39,41 important prognostic factors such as sex, performance status, 
neutrophils counts, etc., were investigated and multivariate analyses were performed at trial level 
but this was not carried out for the subset of patients who crossed over. Similarly, Park et al.79 24 Assessment of clinical effectiveness
identified possible prognostic factors (but did not adjust for confounding factors during analysis). 
The study by Zalcberg et al.44 also did not identify any prognostic factors or their effect on 
analyses, or adjust for confounding factors (Q17 and Q18). Hence we considered the quality of 
reporting ambiguous in terms of the performance of the analyses.
Assessment of effectiveness
Response
For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, 
response is reported in the B2222 study by Blanke et al.39 and the study by Park et al.79 In the 
study by Blanke et al.,39 the median follow-up at this time was 63 months (maximum 71 months), 
and, at that time, 43 patients had crossed over from 400 to 600 mg/day. Of these 43 patients, 11 
(25.6%) showed either PR or stable disease (SD). However, it should be noted that one patient 
showed response only after further escalation from 600 to 800 mg/day. Some of the 43 patients 
who crossed over would have had an initial response to 400 mg/day before progression, as only 
11 patients in the 400 mg/day arm showed a best response of PD.39 Interim data for this study 
population are provided in the study by Demetri et al.,38 where, after a median follow-up of 
288 days (maximum 9 months), nine patients had crossed over, with one showing PR at that 
point, and two with SD.38
In the study by Park et al.,79 median follow-up was eight months (range 1.4–22.3 months) and, 
of the 12 patients who received an escalated dose of 600 mg/day of imatinib, five (41.7%) showed 
either PR or SD.
With regard to response data provided by the manufacturer, (CiC information has been 
removed). As a result, these data from the manufacturer’s submission were not used in 
our review.
For imatinib at a dose of 800 mg/day following progression at a dose of 400 mg/day, response data 
are available from the S0033 study by Blanke et al.,41 the EORTC-ITG-AGITG trial by Zalcberg 
et al.44 and the study by Park et al.79 Of the crossover populations in the S003341 and EORTC 
trials44 (117 and 133 patients, respectively), three patients in each trial (i.e. six in total) had a PR, 
while 33 patients in the S0033 trial41 and 36 patients in the EORTC-ISG-AGITG trial44 had SD 
as a best response. This means that out of a total of 250 patients, 75 (30%) had a response after 
escalation from 400 mg to 800 mg/day.
Response information from the study by Park et al.79 did not provide separate data for those 
with SD and those achieving PR. However, it did state that four out of the 12 patients (33.3%) 
receiving an escalated imatinib dose of 800 mg/day upon progression at the 400 mg/day dose 
achieved either PR or SD.79
Some of the patients receiving dose-escalated imatinib to 800 mg/day would have had an initial 
response to the 400 mg/day dose, because only 42/345 patients (12.2%) in the S0033 trial 400-mg 
arm had a best/only response of PD (or ‘early death’),41 and in the study by Zalcberg et al.44 this 
figure was 61/473 (12.9%).42
Interim data for the EORTC-ISG-AGITG trial were provided for a data cut-off point of 
7 December 2003, at which point there were 2/97 (2.1%) patients showing a PR, 30/97 (30.9%) 
patients with SD, and 65/97 (67.0%) patients with PD.78 Interim data for the S0033 trial, also from 
December 2003, showed that there were 5/68 (7.4%) patients with PR, and 20/68 (29.4%) patients 
with SD, during crossover treatment with 800 mg/day of imatinib, following failure of treatment 
at 400 mg/day.68© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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In addition, secondary analysis for the EORTC-ISG-AGITG trial in the study by Debiec-Rychter 
et al.14 indicated, without stating the number of patients involved, that response following 
crossover was significantly more likely to occur in patients with wild-type GIST than with KIT 
exon 11 mutation (p = 0.0012), and response following crossover was also significantly more likely 
to occur in patients with KIT exon 9 mutation compared with exon 11 mutation (p = 0.0017).14
No response data were provided for treatment with sunitinib at a dose of 50 mg/day (as part of a 
4 weeks-on-treatment/2 weeks-off-treatment 6-week cycle), following progression on an imatinib 
dose of 400 mg/day.
Overall survival
For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, 
OS data were not reported by Blanke et al.39 (CiC information has been removed) for the 
B2222 trial.
For imatinib at a dose of 800 mg/day following progression at a dose of 400 mg/day, the EORTC-
ISG-AGITG trial by Zalcberg et al.44 did not report OS outcomes. However, the S0033 trial by 
Blanke et al.41 reported relevant outcome data, and at the time of the analysis (median follow-up 
of 4.5 years) noted that 76/118 (64.4%) of patients had died.41 Median OS was 19 months (95% 
CI 13 to 23 months) starting from the commencement of crossover. Interim data for the S0033 
trial were also provided in the study by Rankin et al.,68 which stated that median OS at December 
2003 was 19 months.68
(CiC information has been removed.)
(CiC information has been removed.)
TABLE 4  (CiC information has been removed.)
(CiC information has been removed.)
(CiC information has been removed.)
TABLE 5  (CiC information has been removed.)
For sunitinib, OS data were available for those on 50 mg/day of sunitinib who failed on a prior 
imatinib dose of ≤ 400 mg/day from two abstracts of the same trial, taken at different follow-up 
periods.82,86 The data from the study by Reichardt et al.82 were analysed after a median of four 
cycles. Median survival at this point was 93 weeks (95% CI 72 to 100 weeks) and 231/339 (68.1%) 
of patients were still alive.82 The data from the report by Seddon et al.86 were analysed after a 
median of 51 weeks (range 0.1–159 weeks). Median survival at that time was 90 weeks (95% CI 
73 to 106 weeks) and 193/351 (55%) were still alive.86 It should also be noted that further interim 
OS data were provided in another study by Seddon et al.,85 but although the date of analysis is 
the same month as that reported by the studies by Reichardt et al.82 and Rutkowski et al.,83 the 
median OS reported differed, at 80.4 weeks (95% CI 60.3 to NA weeks), while the population 
who had failed on doses of imatinib of ≤ 400 mg/day was also less (307 patients).85
It was possible to compare OS with an escalated dose of 800 mg/day, from the S0033 trial 
reported by Blanke et al.,41 with that with sunitinib at a dose of 50 mg/day (provided in 26 Assessment of clinical effectiveness
4 weeks-on/2 weeks-off cycles of 6 weeks), for patients who had progressed on imatinib at a 
dose of 400 mg/day. Quarterly OS estimates for the sunitinib participants reported in a Kaplan–
Meier chart by Seddon et al.86 were obtained using the method proposed by Parmar et al.73 and 
compared with OS estimates for the S0033 trial provided by the authors. The results are provided 
in Figure 3.
The study by Zalcberg et al. did not report information on OS and was therefore not included 
in the comparison in Figure 3. However, data are available from the (CiC information has been 
removed), and data from the study by Seddon et al.86 on treatment with sunitinib are provided 
in Table 6.
Disease-free survival
No data were reported for this outcome on account of no patient in any of the included studies 
having a complete response.
FIGURE 3  Comparison of OS estimates for imatinib at 800 mg/day and sunitinib at 50 mg/day.
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TABLE 6  Comparison of OS estimates for imatinib at 800 mg/day and sunitinib at 50 mg/day
No. years 
elapsed
Seddon 200886 (n = 351) (CiC information has been removed)
Survival 
estimate 95% CI
(CiC information 
has been 
removed) (CiC information has been removed)
1 0.684 0.626 to 0.741 (CiC information 
has been 
removed)
(CiC information 
has been 
removed)
(CiC information 
has been 
removed)
2 0.441 0.379 to 0.503 (CiC information 
has been 
removed)
(CiC information 
has been 
removed)
(CiC information 
has been 
removed)
3 0.200 0.140 to 0.261 (CiC information 
has been 
removed)
(CiC information 
has been 
removed)
(CiC information 
has been 
removed)
4 NR (CiC information 
has been 
removed)
(CiC information 
has been 
removed)
(CiC information 
has been 
removed)
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Progression-free survival
For imatinib at an escalated dose of 600 mg/day following progression at a dose of 400 mg/day, 
PFS data were not reported by Blanke et al.39 (CiC information has been removed) for the 
B2222 trial.
For imatinib at an escalated dose of 800 mg/day following progression at a dose of 400 mg/day, 
data were reported for the S0033 trial by Blanke et al.,41 and for the EORTC-ISG-AGITG trial by 
Zalcberg et al.44
For the S0033 trial, at the time of the analysis, median follow-up of 4.5 years (54 months), 99/118 
(83.9%) of the crossover cohort for whom data were available had progressed.41 Median PFS was 
estimated to be 5 months (95% CI 2 to 10 months). Of the 99 patients who had PD or had died 
at the time of the analysis, 23/99 (23.2%) had progressed but were still alive. Interim data from 
this trial, at a data cut-off point of December 2003, gave median PFS to be 4 months following 
crossover, for 68 patients.68
For the EORTC-ISG-AGITG trial, median follow-up was 25 months (maximum follow-up was 
35 months), and, at that time, 108/133 (81.2%) of the crossover cohort with data available had 
progressed. Median PFS was 81 days. Sixty-seven patients (50.4%) had progressed or died within 
3 months (Kaplan–Meier survival estimate 0.467). At 1 year, the Kaplan–Meier survival estimate 
was 0.181.44
(CiC information has been removed.)
The estimates of PFS provided at 3-month intervals by the authors of the S0033 study,41 and 
available as a Kaplan–Meier chart in the published paper of this study by Blanke et al.,41 were 
compared with PFS estimates at 3-month intervals that were measured from an enlarged copy 
of the plot of the Kaplan–Meier survival function estimate given in the paper by Zalcberg et al.44 
The number of events in each time period was then calculated using the method proposed by 
Parmar et al.,73 corrected to ensure that the total number of patients censored was consistent with 
the number reported in the published paper.44 For both trials the standard error of the survival 
function estimates was estimated from the quarterly numbers for events and patients at risk using 
Greenwood’s formula. Figure 4 shows the survival functions from each trial, together with 95% 
CIs for each.
FIGURE 4  Kaplan–Meier plot for PFS with 800 mg/day imatinib.
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A meta-analysis of these two survival curves was attempted, using the methods described in 
Arends et al.92 However, no valid results could be achieved owing to the lack of data.
For sunitinib at a dose of 50 mg/day for a 6-week cycle, no progression data were available 
specifically for trial participants who had failed on a prior dose of imatinib at ≤ 400 mg/day.
Time to treatment failure
Data on the duration of response/time to treatment failure were available from the study by Park 
et al.,79 which showed that, of the 12 patients who had their imatinib dose escalated to 600 mg/day 
following progression at the 400 mg/day dose, one patient died of a cause unrelated to both 
their disease and imatinib treatment, while the remaining 11 patients eventually progressed on 
imatinib treatment at the escalated dose after a median of 1.7 months (range 0.7–24.9 months).
For those receiving an escalated dose of 800 mg/day of imatinib following progression at an initial 
dose of 400 mg/day, data were available from the EORTC-ISG-AGITG trial showing that, of those 
who achieved PR or SD after crossover, the median duration of ‘stabilisation’ (i.e. PR or SD after 
crossover) was 153 days (range 37–574 days).44 Interim data from this trial (7 December 2003 
data cut-off) gave a median time to progression of 78 days.78
For the sunitinib trial, the specific median treatment duration for those given sunitinib after 
failure on imatinib at a dose of ≤ 400 mg/day was not provided, but interim median treatment 
duration for the whole cohort was reported at 126 days (range 1–618), and at that time point 
(median follow-up not stated) it was noted that median treatment duration ‘did not significantly 
differ based on the dose of prior imatinib therapy (≤ 400 vs > 400 mg/day).80
Health-related quality of life
No data were reported for this outcome by any of the included studies.
Adverse events
Data on adverse events were not reported for participants receiving an escalated dose of 
600 mg/day of imatinib following progression at an initial dose of 400 mg/day.
For those receiving an escalated dose of 800 mg/day of imatinib following progression at an 
initial dose of 400 mg/day, data were available from the EORTC-ISG-AGITG trial reported by 
Zalcberg et al.,44 and there was some information on dose reductions in the S0033 trial report by 
Dileo et al.77
The number of discontinuations due to adverse events was not explicitly stated for the EORTC-
ISG-AGITG trial44 reported in the study by Zalcberg et al., but they did report that the vast 
majority of discontinuations (88.4%, i.e. approximately 86/97 withdrawals) were due to disease 
progression, suggesting that the maximum possible adverse event withdrawals possible would be 
11.6% of all 97 withdrawals, i.e. 11 patients. Interim data for this trial at a December 2003 data 
cut-off point showed that there were two toxicity withdrawals at that time.78
Data from this trial on specific adverse events following crossover are shown in Table 7 for those 
patients with 60 days’ follow-up data.
A higher proportion of those with skin rash, nausea, leucopenia, neutropenia and 
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dose of imatinib, compared with the proportion who had increased severity from these effects 
following crossover (though, with the exception of neutropenia, these differences were not 
significant at the 0.05 level). The same proportion of people with infection had increased and 
decreased severity from this following crossover. For all other adverse events, a higher proportion 
of sufferers had increased severity from these effects than improvement, and in the case of 
anaemia and fatigue the increase in severity following crossover was significant at the 0.05 level.44
Interim data reported by Zalcberg et al.78 for this trial showed that 31% of patients (exact number 
not calculable) required a dose reduction (note: stated as ‘cumulative incidence’). No information 
was provided on the dose given following dose reduction.
Interim data for the S0033 trial reported by Dileo et al.77 showed that, of the 77 patients who had 
crossed over from an imatinib dose of 400 to 800 mg/day at that time, 18 (23.3%) had at least 
one dose delay, and 12 (15.6%) had at least one dose reduction, due to oedema and rash. No 
information was provided on the dose given following dose reduction.
(CiC information has been removed.)
(CiC information has been removed.)
TABLE 8  (CiC information has been removed.)
TABLE 9  (CiC information has been removed.)
For sunitinib at a dose of 50 mg/day for a 6-week cycle, no progression data were available 
specifically for trial participants who had failed on a prior dose of imatinib at ≤ 400 mg/day.
A summary of the results for all outcomes with the exception of adverse events is provided in 
Table 10.
TABLE 7  Adverse event data from the study by Zalcberg et al.44
Adverse event No. with adverse event
Less severe after 
crossover (n, %)
More severe after 
crossover (n, %)
No. achieving new grade 
3- to grade 4-level 
adverse event
Oedema 99 25/99 (25.3) 33/99 (33.3) 7
Skin rash 45 23/45 (51.1) 19/45 (42.2) 2
Fatigue 102 21/102 (20.6) 47/102 (46.1) 10 (p < 0.001)
Dyspnoea 30 8/30 (26.7) 14/30 (46.7) 1
Infection 20 9/20 (45.0) 9/20 (45.0) 1
Nausea 82 38/82 (46.3) 26/82 (31.7) 3
Leucopenia 56 25/56 (44.6) 16/56(28.6) 0
Neutropenia 49 30/49 (61.2) 13/49 (26.5) 0 (p = 0.002)
Thrombocytopenia 7 4/7 (57.1) 2/7 (28.6) 0
Anaemia 119 15/119 (12.6) 51/119 (42.9) 17 (p = 0.015)30 Assessment of clinical effectiveness
TABLE 10  Summary of results
Drug/dose
Median 
follow-up 
(range): 
months
n (%) with 
PR or SD
Duration of 
response/
time to 
treatment 
failure
Median OS 
(95% CI)
n (%) still 
alive
Median 
progression-
free survival 
(95% CI)
n (%) 
progression 
free
Reference 
source
Sunitinib at 
50 mg/day
4.5 (0–22.1) Median 
treatment 
duration did 
not differ 
based on 
prior imatinib 
dose
Kang 200780
< 6 ? 20.1 months 
(15.1 to N/A 
months)
?/307 Seddon 
200785
6 23.3 months 
(18–25 
months)
231/339 
(68.1)
Reichardt 
200882
Imatinib at 
600 mg/day
8 5/12 (41.6) 1.7 months 
(range 
0.7–24.9 
months)
Park 200979
Imatinib at 
800 mg/day
8 4/12 (33.3) Park 200979
Imatinib at 
600 mg/day
9.5 (?–9) 3/9 (33.3) Demetri 
200238
Sunitinib at 
50 mg/day
12 (0–39.8) 22.5 months 
(18.3–26.5 
months)
193/351 (55) Seddon 
200886
Imatinib at 
800 mg/day
< 25 (< ? to 
< 35)
32/65 (49.2) 2.8 months Zalcberg 
200478
25 (?–35) 39/133 
(29.3)
5.5 months 
(range 
1.3–20.5 
months)
2.9 months 25/133 
(18.8)
Zalcberg 
200544
< 54 25/68 (36.8) 19 months 
(not stated)
Rankin 
200468
54 36/117 
(30.8)
19 months 
(13–23 
months)
42/118 
(35.6)
5 months (2–
10 months)
19/118 
(16.1)
Blanke 
S003341
Imatinib at 
600 mg/day
63 (?–71) 11/43 (25.6) Blanke 
B222239
Imatinib at 
800 mg/day
Significantly 
more likely 
to occur in 
patients with 
wild-type 
and exon 9 
mutations 
than exon 11 
mutations
Debiec-
Rychter 
200614
All units of measurement for time have been converted into months by dividing by four for weeks, by dividing by 28 for days, and multiplying by 
12 for years. All figures that were originally in units of measurement other than months are therefore approximate.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Chapter 5  
Assessment of cost-effectiveness
T
he aim of this chapter is to assess the cost-effectiveness of alternative treatment strategies for 
people with KIT (CD117)-positive unresectable and/or metastatic GISTs, whose disease has 
progressed on treatment with imatinib at a dose of 400 mg/day.
The specific objectives are:
1.  To determine, by undertaking a systematic review of the literature, the cost-effectiveness of 
using imatinib at an escalated dose of 600 or 800 mg/day to treat patients with unresectable 
and/or metastatic GISTs (whose disease has progressed with imatinib at a dose of 
400 mg/day), compared with treatment with sunitinib (within its recommended dose range) 
or BSC.
2.  To develop an economic model to compare the cost-effectiveness and cost–utility of imatinib 
at a dose of 600 or 800 mg/day; the use of sunitinib (within its recommended dose range); or 
BSC only, for people with KIT (CD117)-positive unresectable and/or metastatic GISTs whose 
disease has progressed on treatment with imatinib at a dose of 400 mg/day or those whose 
treatment with imatinib has failed owing to intolerance.
Systematic review of existing cost-effectiveness evidence
The purpose of the review of economic evaluation studies was to identify published studies 
and assess their quality and usefulness for comparisons of treatments of GISTs; inform 
the methodology of the proposed economic model; and identify data on the parameters 
of the proposed economic model (e.g. utilities for different health states, costs and 
epidemiological data).
Methods
Search strategy for identification of published reports
A comprehensive search was undertaken to identify studies that assessed the cost or cost-
effectiveness of the alternative treatments used for GISTs. Databases searched included: 
MEDLINE, MEDLINE In-Process, EMBASE, SCI, Health Management Information Consortium, 
NHS Economic Evaluation Database (NHS EED), the HTA database, Cost-effectiveness Analysis 
(CEA) Registry and the Research Papers in Economics (RePEc). There were no language 
restrictions in the search strategy and all databases were searched from 2000 onwards.
The search strategy used is provided in Appendix 10. The abstracts of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) conferences from 2006 were also searched 
and, in addition, websites of key professional organisations, GIST Support International and the 
drug manufacturers Pfizer and Novartis were scrutinised.
The reference lists of all identified studies and evidence syntheses, as well as submissions from 
industry and other consultees, were also checked for additional potentially relevant references. 
The methods for how the industry submissions were to be handled are described below, although, 
as noted in Chapter 3, no industry submission was reviewed for this technology assessment 32 Assessment of cost-effectiveness
review (TAR). The full texts of potentially relevant reports were obtained and assessed in terms of 
their relevance to the economic evaluation or cost analysis.
Quality assessment
Included studies were assessed using the guidelines of the Centre for Reviews and 
Dissemination.69 Modelling studies were assessed against the Philips checklist.93
Inclusion and exclusion criteria
To be included, studies had to include a cost analysis or a cost-effectiveness analysis (CEA) of 
alternative treatments for GISTs. Non-English language studies were excluded.
Data extraction
Information and relevant data were extracted by an economist according to the guidelines 
produced by the Centre for Reviews and Dissemination for the critical appraisal of economic 
evaluations. Where an economic evaluation was based on a modelling exercise, additional data 
extraction criteria developed by Philips et al. were applied.93,94
Handling industry submissions
Information from the manufacturer was to be considered if it was submitted in accordance with 
the 3 December 2009 deadline set by NICE. Any economic evaluations included in the company 
submission, provided they complied with NICE’s guidance on presentation, would be assessed 
for clinical validity, reasonableness of assumptions and appropriateness of the data used in the 
economic model, using the methods outlined above. The strengths and weaknesses in terms 
of the methodology adopted, and reporting of results and conclusions, would be described. 
The conclusions derived from the company submissions were then to be compared with those 
provided by the review of the other existing evidence and the model reported in Economic 
modelling (below), highlighting any differences in results. Any ‘CiC’ data taken from a company 
submission were to be reported in accordance with NICE guidelines.94
Synthesising evidence
Data from the included studies on economic analysis and economic evaluation were summarised 
in order to identify common results, and to summarise the variations and differences between 
studies. The studies that used economic modelling were critically reviewed with regard 
to, for example, model structure use, and how these models dealt with uncertainties while 
predicting results.
Results
Results of literature search
In total there were 250 papers identified from the initial search (Table 11). Of these, 18 were 
selected as potentially relevant abstracts, and 13 were included for further screening. From these 
papers, nine were selected for the review. Appendix 11 summarises the included studies.
As already noted no submission was received from industry reporting relevant evidence.
Characteristics of included studies
Out of the nine studies, seven55,95–100 reported a full economic evaluation that assessed both the 
costs and cost-effectiveness of the alternatives compared. Of the remaining two studies, the study 
by Reddy54 is a review reporting information related to costs and health outcomes reported in 
other studies and did not undertake an economic evaluation. The other study,101 which is also a 
review of the management of GIST with sunitinib, reports on, amongst other things, the cost of 
treatment with sunitinib. © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Five studies55,95,96,99,100 conducted a modelling exercise rather than incorporating data from 
actual patient follow-up. Two studies96,98 used non-randomised or non-trial patient data (from 
retrospective cohorts) to inform their economic evaluations.
One study55 reported an economic evaluation in a UK context, which was based on an industry 
submission to NICE for a previous TAR. Two studies95,98 reported a Canadian context, and 
one study was from a US context.97 The remaining three studies were conducted in the context 
of Mexico,96 Spain99 and Brazil,100 respectively. Table 12 summarises the main features of the 
included studies.
Comparative studies
Imatinib and best supportive care
Three studies55,97,98 compared imatinib with BSC. The study by Wilson et al.55 used the 
manufacturer submissions (Novartis model) and compared imatinib and BSC, but in the imatinib 
group allowed for escalation of doses from 400 to 600 mg/day for those who failed to respond 
or were intolerant to imatinib at the 400 mg/day dose. The study by Mabasa et al.98 noted that 
patients included from retrospective cohorts in their analysis were given imatinib 400 mg/day 
until disease progression, and later were allowed escalated doses of between 600 and 800 mg/day. 
Six out of 56 patients in the imatinib groups of patients considered in this economic evaluation 
were then allowed to switch to sunitinib therapy. The economic evaluation by Huse et al.97 
considered imatinib at 400 mg/day (see Table 12).
Imatinib, sunitinib and best supportive care
Two studies96,100 compared sunitinib, escalated doses of imatinib, and BSC or palliative care as 
comparators for their economic evaluations. The Contreras-Hernandez et al.96 study compared 
treatment with imatinib, sunitinib and palliative care. Both treatments (sunitinib and imatinib) 
were compared with BSC in a model-based analysis. The doses for both the treatments were 
clearly specified (imatinib at 800 mg/day and sunitinib at 50 mg/day) as the study was based on 
primary data collected from hospital records. The study did not include dose escalation with 
imatinib at a 600 mg/day dose. Teich et al.100 compared sunitinib, imatinib at 800 mg/day and BSC 
(see Table 12).
Sunitinib and best supportive care
The studies by Chabot et al.95 and Paz-Ares et al.99 compared treatment with sunitinib and 
BSC for patients with GIST who were imatinib resistant or intolerant. Chabot et al.95 did not 
specify the dose of sunitinib used, or mention whether patients who were imatinib resistant or 
TABLE 11  Search results
Database No. retrieved
MEDLINE (2000 – October, week 4, 2009), EMBASE (2000 – week 44, 2009) 227
MEDLINE In-Process (3 November 2009) (after de-duplication in Ovid) 0
SCIa (2000 to 3 November 2009) 16
Health Management Information Consortiuma (September 2009) 0
NHS EEDa (October 2009) 0
HTA database (October 2009) 0
ISPOR conference abstracts 2006–9 7
Total 250
a  Numbers retrieved after de-duplication against MEDLINE and EMBASE search.34 Assessment of cost-effectiveness
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intolerant were initially treated with 400 mg/day and then with escalated imatinib doses (e.g. 600 
or 800 mg/day). Paz-Ares et al.99 specified a dose of 50 mg/day for the patients in the sunitinib 
group. The patients in the sunitinib group were provided with BSC. Therefore, this study 
compared sunitinib plus BSC with BSC alone. BSC in this study included diagnostic tests and 
routine palliative treatment.99
The definition of BSC in the economic evaluation studies was not the same across the studies. 
Chabot et al.95 did not clearly define what BSC included, while Contreras-Hernandez et al.96 
defined clearly that BSC included treatment with imatinib. Paz-Ares et al.99 defined BSC 
as essentially consisting of diagnostic tests and routine palliative care. In the other three 
studies,55,97,98 the control group of patients, who are considered as effectively being treated with 
BSC, were not provided with treatment with imatinib. As a full-text paper of the study by Teich et 
al.100 was not available, information on how this study defined BSC was not available.
All treatments
We did not find any studies that conducted an economic evaluation of all of the alternative 
treatments (e.g. escalated doses of imatinib 600 mg/day or imatinib 800 mg/day, sunitinib and 
BSC) for patients who failed on imatinib at a dose of 400 mg/day.
Study design
Among the seven studies that conducted a full economic evaluation, five used Markov 
modelling.55,95,96,99,100 Huse et al.97 used a very simple modelling framework and Mabasa et al.98 also 
used patient-level data and had 46 and 47 patients in their imatinib and BSC (historical group) 
groups, respectively. Contreras-Hernandez et al.96 also used patient-level data (for 21 patients) 
collected at the Hospital de Oncología to estimate the costs of care associated with imatinib, BSC 
and other procedures, and used these costs in their model.
Perspective
Three studies55,99,100 adopted the perspective of a national health-care system. The study by 
Contreras-Hernandez et al.96 was from Mexico’s health insurance system’s perspective. The study 
by Huse et al.97 did not specifically mention whether it was from a health insurance system 
perspective; however, it mentioned that it had been conducted from a US societal perspective. 
The studies by Chabot et al.95 and Mabasa et al.98 considered a provincial health authority and 
a specialised agency (British Columbia Cancer Agency) perspective, respectively, for their 
economic evaluations. None of the seven studies55,95–100 that conducted full economic evaluations 
reported indirect non-medical resource use, or indirect costs to society in terms of productivity 
loss, costs to carers, and other indirect costs associated with GIST.
Health outcome measures
The major outcome measures used in the seven studies reporting full economic evaluations were 
PFS,95,96,98–100 OS,95,98 life-years gained95,96,98–100 and quality-adjusted life-years (QALYs).55,95,97,99 
Four studies55,95,97,99 reported the incremental cost per QALY gained. The remaining three 
studies96,98,100 used incremental cost per life-year gained, and incremental cost per progression-
free life-year gained.
Data sources
Most of the studies,95,96,99 which were based on modelling exercises, used effectiveness or health 
outcome data from major trials38,52,102–104 and adapted them for their specific contexts. The sources 
of cost data were mainly from relevant patients’ records, and health-care cost databases. Wilson 
et al.55 used data from an industry submission (Novartis trial). Table 13 summarises the data 
sources used for the studies. A full paper of the study by Teich et al.100 was not available and so 
information on the data sources used was unknown.36 Assessment of cost-effectiveness
Time horizon
The studies that used models in their economic evaluations used different time horizons and 
treatment cycle lengths for the Markov model. The two studies95,99 that had sunitinib and BSC as 
comparator treatments used a time horizon of 6 years and a treatment cycle length of 6 weeks in 
the modelling exercise. Of the other studies, the study by Contreras-Hernandez et al.,96 which 
had sunitinib as a comparator along with imatinib and BSC, used a lifetime time horizon and 
also a 6-week cycle of treatment (to be consistent with the sunitinib treatment cycle of 6 weeks). 
Huse et al.97 used a 10-year time horizon for the analysis, while Teich et al.100 used a 6-year time 
horizon, and a 6-week treatment cycle.
Discount rate
A 5% discount rate for costs and health outcomes was used in two studies.95,96 Wilson et al.55 in 
their model discounted costs by 6% and QALYs by 1.5%, as per NICE methods guidance at the 
time the work was conducted. Paz-Ares et al.99 and Huse et al.97 used 3% and 3.5%, respectively. 
Mabasa et al.98 used 3% for discounting costs and outcomes. The abstract by Teich et al.100 did not 
report the discount rate used in their modelling exercise.
Findings on costs and cost-effectiveness
The cost of treatment and cost per different health outcome under different alternatives are 
presented in Table 14. As regards cost in relation to the health outcomes, the incremental cost-
effectiveness ratios (ICERs) from the studies are noted in the table with respect to the main 
TABLE 13  Data sources
Study Unit costs Resource use for treatment Effective/health outcomes
Chabot 200895 Published literature and Canadian government 
benefit schedule and medical oncologist
Published literature and 
Canadian government 
benefit schedule and medical 
oncologist
Phase III trial NCT0007521852
Contreras-
Hernandez 
200896
Hospital records (Hospital de Oncología) 
for 21 patients in Mexico, IMSS pricing 
and reimbursement procedure, and cost of 
sunitinib from Pfizer Laboratories
Patients’ medical charts, 
associated information from 
IMSS (Mexican insurance 
system)
Phase III trial52,104
Mabasa 200898 BCCA BCCA registry Patients’ data in two arms (imatinib 
groups and 46 non-imatinib group) were 
compared with Demetri 200238 and 
Verweij 2003102
Paz-Ares 200899 Health costs database eSalud (for 
administration, radiotherapy, nephrectomy 
and monitoring costs). General Council of 
Pharmacists Official Colleges for drug costs. 
Ojeda et al. (2003)105 for unit costs of adverse 
events
Data reported by expert panel 
on number of visits to oncology 
clinic, laboratory tests, CT 
scans, nurse visits and visits to 
palliative units, and analgesic 
drugs
Demetri 2006,52 adverse events105
Huse 200797 Drug acquisition costs: published average 
wholesale price (Red Book: Pharmacy’s 
Fundamental Reference. Montvale, NJ: 
Thomson Health Care; 2005, and Physicians’ 
Desk Reference 2005. Montvale, NJ: 
Thomson PDR; 2005)
Based on the resources used 
by patients with pancreatic 
cancer (not advanced in US 
context) to determine the 
resources used for medical 
management in the absence of 
data on resource use by GIST 
patients
Demetri 2002,38 Phase II and Blanke 
2006103
Wilson 200555 Industry submission: Novartis model – 
Novartis submission to NICE 2003
Novartis model – Novartis 
submission to NICE 2003
QoL based on ECOG data from B2222 
trial,39 and Goss study (data AiC)
AiC, academic in confidence; BCCA, British Columbia Cancer Agency; IMSS, Instituto Mexicano del Seguro Social.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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outcomes, i.e. life-year saved (LYS), PFS and QALYs. Although the Contreras-Hernandez et al. 
study96 considered three alternative treatments (sunitinib, imatinib and BSC), it did not report an 
ICER for imatinib versus BSC.
Higher doses of imatinib versus BSC
The Contreras-Hernandez et al.96 study suggested that a higher dose of imatinib (800 mg/day) 
might be cost-effective compared with BSC (where BSC included treatment with imatinib at a 
lower dose). Wilson et al.,55 using the modified Novartis model in a UK context and from an 
NHS perspective, estimated the incremental cost per QALY gained at £51,515–98,889 at 2 years, 
and £27,331–44,236 at 5 years compared with BSC.
Sunitinib versus higher dose of imatinib and/or BSC
Sunitinib treatment was associated with an estimated gain of 0.7 years and 0.4 QALYs compared 
with BSC.95 Sunitinib treatment also resulted in a higher number of progression-free months 
(PFMs) than both the imatinib and BSC therapies. The mean number of PFMs was found to be 
5.64 for sunitinib, while it was 5.28 and 2.58, respectively, for imatinib and BSC. The incremental 
effectiveness of sunitinib therapy compared with BSC was 3.1 PFMs and compared with a high 
TABLE 14  Summary of cost of treatment from studies reviewed
Study Comparator Mean cost of treatment per patient ICER1 ICER2
Chabot 200895
Costs in Canadian $ at 
2005 prices
Sunitinib C$46,125 SUN vs BSC
C$49,826 per life-year saved
SUN vs BSC
C$79,884 per QALY
BSC  C$11,632
Contreras-Hernandez 
200896
Costs in US$ at 2006 
prices
Sunitinib US$17,806
Standard deviation US$695
95% CI US$15,377 to 19,816
SUN vs BSC
$15,734 per patient treated 
with sunitinib and $56,612 
per year of PFS, and 
$46,108 per life-year gained
Imatinib US$35,057
SD US$1253
95% CI US$31,381 to 38,705
BSC US$2071
Standard deviation US$473
95% CI US$1543 to 2869
Mabasa 200898
Costs in Canadian $ at 
2006 prices
Imatinib C$79,839 Imatinib vs BSC (control)
C$15,882 per life-year saved
BSC C$1743
Paz-Ares 200899
Costs in € at 2007 
prices
Sunitinib €23,259 SUN vs BSC
€30,242 per life-year saved
SUN vs BSC
€4090 per PFM
€49,090 per QALY gained
BSC €1622
Huse 200797
Cost in US$ at 2005 
price
Imatinib US$416,255
BSC US$341,886
Wilson 200555
Cost in £ at 2004 
prices
Imatinib £18,896 (400 mg/day)
£24,368 (600 mg/day)
Other cost of treatment £1136
Cost per QALY: £70,206 
(year 2), £51,514 (year 
3), £36,479 (year 5) and 
£25,859 (year 10)
BSC £562
PFM, progression-free month; SUN, sunitinib.38 Assessment of cost-effectiveness
dose of imatinib was 0.3 PFMs. Over the 5-year treatment horizon, Contreras-Hernandez et al.96 
found that patients with sunitinib had a mean life-year gain (LYG) of 1.4 compared with 1.31 and 
1.08 for imatinib and BSC, respectively. The study also suggested that patients taking imatinib 
at a dose of 800 mg/day had the highest mean costs of treatment. Teich et al.100 reported that 
sunitinib was cost-effective compared with imatinib at a dose of 800 mg/day for a 6-year time 
horizon. Their study suggested that sunitinib increased life-years and progression-free life-years 
by 0.3 and 0.26, respectively, with an incremental cost of R$86,756 (Brazilian dollars) [US$61,968 
purchasing power parity (PPP) 2005] in comparison with BSC. They found that sunitinib was 
both more effective showing a gain in life-years of 0.02 and progression-free life-years of 0.47, 
and less costly than imatinib over 6 years.
Assessment of uncertainty
All six full-text studies55,95–99 used some form of sensitivity analysis. Chabot et al.95 varied the 
most influential model parameters, i.e. utility of progression and no progression, OS (HR), PFS, 
positron emission tomography (PET) at initiation of sunitinib treatment, the cost of palliative 
care and the cost of PET. The model assumed the acquisition cost of sunitinib was certain and 
did not vary this in the sensitivity analysis. The sensitivity analysis suggested that the results of 
the economic evaluation were most sensitive to the health-state utility value and rate of OS and 
PFS. The sensitivity analysis also suggested that the results were robust. Contreras-Hernandez 
et al.96 conducted probabilistic sensitivity analysis with data obtained from the Markov model. 
An acceptability curve was derived and reported the cost-effectiveness ratios for sunitinib in 
comparison with palliative care. In the absence of any threshold for cancer therapy in Mexico, 
they used three hypothetical re-imbursement cut-points equivalent to US$27,723, US$36,364 
and US$45,455 to derive acceptability curves. These hypothetical values were based on taking 
5%, 14% and 40% of the upper threshold that NICE reimburses for imatinib as first-line 
treatment. Mabasa et al.98 varied the median OS rate, the rate of PFS and years of life expectancy, 
and conducted univariate sensitivity analysis. They found that the model used for the analysis 
remained robust. The ICER for each median life-year gained was found to be within the range 
of C$0–550 (Canadian dollars), and for each median progression-free year it ranged from C$0 
to C$75,505. Paz-Ares et al.99 also conducted univariate sensitivity analysis. Their model results 
were calculated in a probabilistic analysis considering the impact of uncertainty on the values 
of each variable included in the model, by assuming different distributions of these variables. 
The study conducted sensitivity analysis of the results by adding the cost of imatinib to the BSC 
group, by assuming all patients in the palliative care group would be given imatinib 400 mg/day. 
The most sensitive variables affecting the results were efficacy of treatment, and the unit cost of 
sunitinib. The study by Huse et al.97 also used univariate sensitivity analysis and examined the 
impact of considering the upper and lower values of the cost of the drugs, the cost of treatment, 
the utilities of successful treatment and PD, the time horizon and the annual rate of discount in 
their analysis. They used imatinib at a 600 mg/day dose to examine the impact of results variation 
as an alternative scenario for the sensitivity analysis. The study by Wilson et al.55 fitted a Weibull 
curve to estimate progression and death due to GIST in their sensitivity analysis and found that 
the ICER, based on a Weibull curve, was £26,427, and with an exponential fitting was £21,707.
Summary of the review
We found that most of the economic evaluation studies reviewed used a modelling exercise. 
However, only two studies96,100 compared both imatinib and sunitinib with BSC for patients who 
had failed or become resistant to imatinib 400 mg/day. The full paper for only one of these96 was 
available. Among the five studies55,95,96,99,100 that used modelling exercises, Contreras-Hernandez 
et al.96 and Teich et al.100 did not use QALYs as health outcome measures. Although Contreras-
Hernandez et al.96 used patient-level data as the basis of their cost estimates, they used survival 
and PFS as effectiveness measures in their model, which was based on the studies by Motzer et 
al.104 and Demetri et al.52© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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The two studies95,99 that used modelling exercises to compare the cost-effectiveness of sunitinib 
only with BSC used the same trial data (A6181004).52 Their utility data were based on responses 
to the EQ-5D instrument provided by participants in this trial.
In our review we did not identify any published economic evaluation studies in a UK context 
comparing all the relevant interventions. The study that included an economic evaluation of 
higher dose imatinib in a UK context55 did not actually have as a comparator those who failed 
with imatinib 400 mg/day; rather the model allowed patients who failed on 400 mg/day to cross 
over to a higher dose of imatinib 600 mg/day rather than 800 mg/day.
The definition of BSC in the economic evaluation studies reviewed was not the same across 
the studies and cost-effectiveness of treatments compared with that of BSC cannot be easily 
compared. In addition, the pattern of resources used including the drugs for treatment was 
reported in different ways in different studies.
For a comprehensive economic evaluation of the alternative treatments for GIST patients who 
fail on or become resistant to imatinib 400 mg/day, further evidence is needed to fill in gaps in 
the evidence base. The challenge is to obtain appropriate and sufficient information on survival 
rates and responses to treatments with escalated doses of imatinib, and sunitinib. The economic 
evaluations which were identified based on modelling exercises have limitations. For example, all 
extrapolated clinical trial data from a short time horizon were used to predict cost-effectiveness 
results for a longer period. There is a need for empirical patient-level data for future economic 
evaluations. The outcome measures for disease severity can be considered as important surrogate 
end points. In cases where the patients in placebo groups or in BSC arms of trials are allowed 
to cross over to an experimental group (either escalated doses of imatinib or sunitinib) it 
could be argued that an intention to treat analysis would result in an underestimation of the 
survival benefit of patients randomised in the treatment groups, and the cost of the treatment 
for these patients who were assigned to placebo/BSC groups is often not accounted for in 
economic evaluations.
There has been no consideration of the patients’ and society’s costs/resource use in the studies 
reviewed. A wider perspective might be informative. However, NICE’s guidance94 suggests that 
costs and resources falling to the NHS and Personal Social Services (PSS) should be used. This 
approach by NICE is not universally accepted and costs and benefits falling on other groups may 
be relevant, for example in helping to illustrate additional choices and trade-offs that a decision-
maker may wish to consider.
Economic modelling
Model structure
The structure of the model was informed by the modelling studies identified as part of the 
systematic review of economic evaluations, the review of clinical effectiveness, and other existing 
evidence including previous NICE TARs. We have also drawn upon advice from health-care 
professionals within the research team in this regard.
The model was developed to compare the alternative treatment strategies for people with KIT 
(CD117)-positive unresectable and/or metastatic GISTs whose disease has progressed on 
treatment with imatinib at a dose of 400 mg/day or those whose treatment with imatinib has 
failed owing to intolerance. According to the scope for the review the treatment strategies to be 
compared in the models were:40 Assessment of cost-effectiveness
1.  treatment with an escalated dose of 600 mg/day, regulating symptoms with BSC
2.  treatment with an escalated dose of 800 mg/day, regulating symptoms with BSC
3.  treatment with sunitinib (within its recommended dose range), regulating symptoms 
with BSC
4.  regulating symptoms with BSC only.
The assumed pathway of the model
We considered a range of different alternative pathways for patients who progressed on imatinib 
at a dose of 400 mg/day, which led to the creation of nine alternative pathways, and, following 
advice from our clinical advisers, we determined seven clinically plausible pathways (Figure 5). 
The model is based on these seven clinically plausible care pathways. Circles represent health 
states that individuals may return to, rectangles represent health states during which treatment is 
administered, and the arrows show the possible directions in which individuals could move at the 
end of each cycle, depending on the transition probabilities. The states considered in the model 
were those thought to reflect care pathways for people with GIST. Patients entering the pathways 
are those who failed on imatinib 400 mg/day. The alternative treatments considered were dose 
T1 = imatinib 600 mg/day, T2 = imatinib 800 mg/day, T3 = sunitinib (with recommended dose 
50 mg/day) and BSC.
A Markov model was developed to model these care pathways using Treeage Pro 2009 (TreeAge 
Software Inc., Williamstown, MA, USA). In this model, patients whose disease has progressed 
on treatment with imatinib at a dose of 400 mg/day or those whose treatment with imatinib 
has failed owing to intolerance enter one of the seven care pathways. Figure 6 is an illustrative 
example of the model structure for Path-4, where patients are treated with imatinib 600 mg/day, 
and if the disease progresses on this treatment the patients are treated with BSC. Appendix 12 
illustrates the model for all seven pathways of alternative treatments.
Path-1 shows the patients with BSC treatment. It is assumed that the patients with BSC are still 
treated with imatinib and palliative care. Path-2 represents treatment options where escalated 
doses of imatinib (600 and 800 mg/day) and treatment with sunitinib are provided to the cohort 
of patients. All patients start the treatment with imatinib 600 mg/day. If they survive and respond 
to imatinib 600 mg/day then they will continue with the dose until they move to a state of stable 
condition with complete response or PR (CR/Stable IM 600). From this point, a proportion 
of patients will survive and continue to respond to treatment. Those who stop responding to 
imatinib 600 mg/day move to a state where they receive imatinib 800 mg/day (PD at IM 600). A 
proportion of patients will remain with the escalated dose of imatinib 800 mg daily (CR/Stable 
IM 800). If patients fail to respond on imatinib 800 mg daily, they are switched to treatment 
with sunitinib (PD with sunitinib). If they respond to sunitinib then they will continue with the 
treatment and move to a state of stable condition with complete response or PR (CR/Stable with 
sunitinib). From this point, a proportion of patients may continue to respond to the treatment 
and remain stable, or they may stop responding to sunitinib and receive BSC for the remainder of 
their life.
Path-3 represents treatment options through which an escalated dose of imatinib (imatinib 
600 mg/day only) and treatment with sunitinib are provided. In this pathway, all patients also 
start the treatment with imatinib 600 mg/day (PD initial treatment IM 600). If they respond to 
imatinib 600 mg/day then they will continue with the dose and move to a state of stable condition 
with complete response or PR (CR/Stable IM 600). If a patient treated with imatinib 600 mg/day 
fails to respond, or ceases to respond, then instead of trying further dose escalation with imatinib 
they are switched to treatment with sunitinib (PD with sunitinib). If they respond to sunitinib 
they will continue with the treatment and move to a state of stable condition with complete © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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response or PR (CR/Stable with sunitinib). Should they fail to respond to sunitinib or if at some 
point they cease to respond they continue with BSC for the remainder of their life.
In Path-4, all patients start the treatment with imatinib 600 mg/day and no switching to other 
treatments is considered. If they respond to imatinib 600 mg/day then they continue with this 
treatment until the GIST progresses or they die (CR/Stable IM 600). If at any point they do not 
respond to imatinib 600 mg/day they continue with BSC for the remainder of their life. This 
option has been considered as a treatment option in the model, although actual clinical practice 
may favour further escalation to 800 mg/day. Nevertheless, for this model, care pathways were 
developed with clinical advice on plausible pathways of care, some of which may be more typical 
of current practice than others.
The remaining care pathways are variants of earlier pathways. Path-5 is similar to Path-3 with 
respect to the combination of escalated dose of imatinib and sunitinib, the main difference in this 
case is that the escalated dose is imatinib 800 mg/day. Apart from this difference the pathways 
are identical. Path-6 is similar to Path-4. However, in this pathway the escalated dose is imatinib 
800 mg/day instead of imatinib 600 mg/day. Path-7 is similar to Path-4. In this pathway, however, 
instead of being treated with imatinib 600 mg/day, patients receive sunitinib. Apart from this 
change, the care pathways are identical (see Appendix 12).
The care pathways chosen for our model are not exhaustive and do not include every single 
possible clinical intervention available to oncologists treating GIST after failure at 400 mg/day 
of imatinib, but the care pathways chosen reflect the scope of this research as agreed with NICE. 
Other possible treatments (e.g. surgery for those whose tumours become resectable following 
treatment with escalated doses of imatinib) were not considered.
Key assumptions of the modelling exercise
The key assumptions of the model are:
1.  The time horizon of the model is 10 years, over which time all patients are expected to die, 
and the cycle length is 1 month.
2.  The model assumes that patients entering a pathway will remain in a health state and on 
the treatment for one cycle only. If they respond and remain stable they continue on the 
treatment in the next cycle. If they do not respond but survive in the treatment arm they 
are considered to move to an escalated dose, move to another alternative (if allowed by a 
treatment pathway) or continue with BSC for the remaining time horizon of the model.
3.  The model assumes that the probabilities of progressing and dying do not change over time. 
This assumption was made because of the limited data available.
4.  The utilities of the health outcome from treatment with imatinib 600 mg/day, imatinib 
800 mg/day and sunitinib are assumed to be the same. This assumption was made because of 
the limited data available.
FIGURE 6  Example of model structure for care pathway Path-4 (imatinib 600 mg/day – BSC).
Imatinib
(600 mg/day)
Stable on imatinib
(600 mg/day)
Death Progressive disease
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5.  All patients failing or not responding to the treatment in any of the treatment arms of the 
model continue with BSC for the remainder of the model time horizon or until they die, and 
are assumed to derive the same utility as from the health state of progression. Owing to lack 
of data, time-dependent changes in transition rates of response were not built into the model.
Data requirements and model inputs
For our model, data on the clinical effectiveness of interventions were based upon the systematic 
review of clinical effectiveness described earlier. These data were combined within the model 
with health-state utilities data to provide estimates of QALYs for the alternative treatment 
strategies for patients with GIST.
With respect to clinical effectiveness, data were required for the model on the probability of death 
per cycle and the probability of not responding to treatment per cycle.
Probability of death
As described in the systematic review of effectiveness few data were available for any of the 
treatments, few of which were based on direct comparisons. Therefore, the data available are 
imprecise and potentially biased. The direction and magnitude of any bias is unknown. As a 
consequence the data used to derive probabilities of death for each therapy under consideration 
should be treated cautiously.
Probability of death for BSC
The data for BSC were taken from two studies106,107 and a pooled weighted estimate suggested 
that 87.9% (51/58) died during the observation period of 60 months. A monthly rate was derived 
using an exponential function which assumes the probability of death per month is constant over 
time. The same value was used in circumstances where patients moved on to BSC after previously 
being treated with imatinib at an escalated dose or with sunitinib. The data from the review of 
clinical effectiveness were not appropriate to populate the BSC states in the model, as no BSC 
studies met the inclusion criteria. The second best source of data would have been information 
on follow-up of non-crossover patients following failure at 400 mg/day, but these patients were 
not followed up in any of the included studies looking at dose escalation of imatinib. The only 
other data available on BSC come from the pre-imatinib era (where it would not have been 
possible for people to have failed on 400 mg/day of imatinib). The two sources chosen from 
the studies identified (see Appendix 13) were chosen because they had larger sample sizes and 
longer median follow-up times. However, one of the sources relates to a study conducted before 
there was awareness of GIST as being a distinct tumour. Alternative data for this parameter are 
outlined in Appendix 13; however, it is likely that these data would provide similar, imprecise and 
potentially biased estimates for this probability.
Probability of death for imatinib at 600 and 800 mg/day
The data on mortality for the imatinib 600 mg/day treatment groups were taken from the 
available trial data39 and 55% (6/11) of those who crossed over to imatinib 600 mg/day died 
over the trial period of 60 months. Although the sample size is very small, in the absence of any 
better alternative it has been used in the model. The data on mortality for imatinib 800 mg/day 
were taken from Blanke et al.41 [where the data suggest that 64.41% (76/118) died in the imatinib 
800 mg/day group]. Again the monthly mortality rate was derived as an exponential rate. It 
should be noted that the study was not designed to assess dose escalation, and the use of data 
from the crossover groups from the studies used are not ideal estimates for probability of death 
for these patients. In the absence of other suitable data we have used these data for our model.44 Assessment of cost-effectiveness
Probability of death for sunitinib
The mortality data for those treated with sunitinib came from Reichardt et al.81 In this study 
231/331 patients receiving sunitinib survived. The monthly mortality rate was derived assuming 
an exponential rate. In the analysis it was also assumed that the mortality rate for those receiving 
sunitinib was the same regardless of any possible differences in prior treatment. It should also 
be noted that the survival estimate from this trial was based on those who failed on imatinib at 
doses of ≤ 400 mg/day, but it is not clear whether the patients failed on the 400 mg/day dose or at 
lower doses.
Response rates for the treatments
For our model, response to treatment was also taken to include PR, complete response and those 
reported to be in a stable condition.
The response rate for imatinib 600 mg/day was based upon data from the B2222 trial.39 This study 
reported that 25.5% (11/43) of patients had responded and remained stable during a median 
follow-up of 63 months. The sample size of this study was small, but these were the only data 
available for the specific population of interest. It should be noted that the B2222 trial39 was not 
designed to assess dose escalation and there was no randomisation of patients at the point of 
disease progression.
The S003341 and EORTC44 trials data were used to provide evidence of the response rate for 
imatinib 800 mg/day. These studies reported that 30% (75/250) of patients responded to 
treatment with imatinib 800 mg/day and showed PR or stable condition after a median follow-up 
of 54 months.
For sunitinib none of the studies meeting the inclusion criteria for the review of effectiveness 
reported data on response rate. Therefore, this parameter was estimated from the weighted 
average response rate from two studies reporting this outcome.38,108 In these two studies in total 
266/382 patients responded, and a simple weighted mean was used to derive the pooled response 
rate. This response rate was assumed to be unaffected by prior treatment received. It should be 
noted that the patient groups in these two studies may not be the same. The Prior et al. study108 
does not report the previous imatinib dose for participants, whereas in Demetri et al.38 most of 
the population failed on 800 mg/day imatinib. As there was no statistically significant difference 
in the response rates, we took these two studies as a second-best source. The non-response 
data for each treatment were converted into monthly transition probabilities by assuming an 
exponential function.
Cost data
Resources used by the selected treatment strategies were identified from relevant sources [e.g. 
NHS reference costs, the British National Formulary (BNF), etc.] and the review of economic 
evaluations. Costs have been considered from a NHS perspective only. An identification of the 
potential direct and indirect resource costs for the NHS and PSS that would be expected from the 
introduction of the technology is presented.
We included the costs of drugs, i.e. costs of imatinib 400 mg/day, 600 mg/day, 800 mg/day and 
sunitinib 50 mg/day. As the sunitinib treatment process involved taking medication for 4 weeks 
and then no medication for the following 2 weeks, we estimated the yearly medication costs of 
this drug and then equally proportioned this cost to each month within that year. Data on cost 
of drugs were obtained from the BNF no. 58.109 It has been assumed that patients on BSC still 
receive medications and it has been assumed that the cost of these is equivalent to the cost of 
imatinib at 400 mg/day.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Resource use by the treatments was based on the study by Wilson et al.,55 which suggested 
that there are GP visits (£40 per year), outpatient visits including tests (£440 per year) and CT 
scans (£656 per year) and cost of management of adverse events (£159 per year), at 2004 prices. 
These cost estimates were used for our model after adjusting for inflation with the Hospital and 
Community Health Services (HCHS) Index for pay and prices inflation for the year 2008–9.110 
Based on these estimates, the total monthly cost of management with imatinib treatment is 
£128.16. These other treatment costs represent approximately 5% of the total cost of the drug 
itself. In the absence of better data these costs have been used for imatinib at both 600 and 
800 mg/day.
For the sunitinib group we have used the resources based on the Pfizer single technology 
assessment submission60 for patient monitoring, outpatient and GP visits (£799.73 per year), CT 
imaging (£336 for 7.3 months) and management of adverse events (£159 per year). These costs 
are at 2008 prices and were adjusted to 2009 prices using the same methods as described above. 
Based on these data the estimated total monthly cost of this care used within the model is £185.
For BSC, data from the Pfizer submission were again used:60 the suggested costs in 2008 prices 
for patient monitoring, outpatient and GP visits were £249 per year, and £105 per year for CT 
imaging. These costs were inflated to 2009 prices using the same methods described above.
The different estimates for the costs of CT scanning between the two drugs can be accounted for 
by the fact that different sources were used to derive the costs of CT scanning. When inflated to 
2008–9 prices, this gave the monthly cost of CT scans as £15.01 for BSC groups, £64.92 for the 
imatinib groups and £48.04 for the sunitinib groups.51,55
The monthly cost of adverse events in the model is £13.25 for the imatinib groups (600 and 
800 mg/day) and £21.78 for sunitinib, which is about 10% of all other costs for imatinib and 12% 
of all other costs for sunitinib. There were insufficient data on disutility to incorporate this as a 
parameter within the model, despite evidence to suggest differences in the adverse event profiles 
of imatinib and sunitinib that could influence disutility.111
Utility data
There were few data relating to health-state utilities. Our model has used data in which the 
health-state valuations are derived from the EQ-5D, and the values used were taken from Wilson 
et al.55 and Chabot et al.95 The utility associated with PFS for those responding to imatinib 
(regardless of dose) was 0.935.55 The utility for those receiving BSC was taken from Chabot et al.95 
and was taken to be 0.577. In the absence of alternative data it has been assumed that the 
utility for those who have not progressed on sunitinib is the same as that assumed for imatinib, 
i.e. 0.935.
Table 15 describes the parameter inputs used within the model. It also describes the sources 
of data, alternative valuations and data used to inform the probabilistic sensitivity analysis 
(described in more detail below).
In a sensitivity analysis, the high value of the costs of drugs (imatinib and sunitinib) has been 
assumed to be similar to the value based on the BNF price,109 which we used in our model for 
the base-case analysis. For the lower value, we have taken an average of the price of the higher 
and lower doses assuming that there may be a need to lower the dose in the treatment pathways 
assumed in our model. For sunitinib, during the sensitivity analysis the price of the lower dose 
is assumed.46 Assessment of cost-effectiveness
TABLE 15  Model parameters, values and data sources
Parameters Description Value
For sensitivity 
analysis
Distribution Values
Data source and 
assumptions Low High
Cost parameters (£)
cImat600 Cost of drugs: imatinib 600 2406 2005 2406 BNF 58:109 low value 
is average of imatinib 
400 and 600 mg
cImat800 Cost of drugs:
imatinib 800
3208 2807 3208 BNF 58:109 low value 
is average of imatinib 
600 and 800 mg
CNott Cost of
BSC
1604 1283 1604 Includes cost of 
imatinib 400 mg 
(BNF 58109)
CSunb Cost of drugs: sunitinib 3138.8 2092.5 3138.8 BNF 58:109 low value 
is average of reduced 
dose of sunitinib 
OthCostBSC Other costs and management 
of treatment in BSC arm
50.61 Resource use in the 
treatment was based 
on the study by Wilson 
200555
OthCostIm Other costs and management 
of treatment in imatinib 
treatment arm
128.16 Resource use in the 
treatment was based 
on the study by Wilson 
2005.55 Assumed to 
be same for imatinib 
600 and imatinib 800
OthCostSun Other costs and management 
of treatment in sunitinib 
treatment arm
185.11 Resource use in the 
treatment was based 
on the study by Wilson 
200555 and single 
technology appraisal 
of Pfizer60
Mortality and response to treatment
deathBSC Probability of death in the 
BSC treatment arm
0.014627 Beta α = 0.8448898
β = 57.775
Pooled weighted 
rate106,107
dth600 Probability of death in 
imatinib 600 treatment arm
0.007472 Beta α = 0.08162
β = 10.91838
B2222 study39
dth800 Probability of death in 
imatinib 800 treatment arm
0.011857 Beta α = 1.39948
β = 116.600
S0033 study41
Dthsun Death due to GIST: sunitinib 0.026706 Beta α = 9.3284
β = 341.62
Reichardt 200881
nonrespIm600 Transition probability of non-
response to imatinib 600
0.011743 Beta α = 0.504949
β = 42.495051
B2222 study39
nonrespIm800 Transition probability of non-
response to imatinib 800
0.012879 Beta α = 3.21875
β = 246.780
S0033 study41 and 
Zalcberg 200544
nonrespSun Transition probability of non-
response to sunitinib
0.080959 Beta α = 12.30
β = 139.6945
Weighted average 
response rate52,108
uImat600 Utility with imatinib 600 0.935 0.712 0.939 Wilson 200555
uImat800 Utility with imatinib 800 0.935 0.712 0.939 Wilson 200555
uProg Utility for PD 0.577 0.52 0.712 Chabot 200895 and 
Wilson 200555 for 
lower level values for 
sensitivity analysis
uSun Utility with sunitinib treatment 0.935 0.712 0.939 Chabot 200895© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Time horizon for the model
The model looked at the costs and consequences directly attributable to GIST. As reported 
earlier the typical survival of such patients is relatively short and hence the time horizon of the 
model was limited to 10 years. The cycle length was 1 month to reflect the natural history of 
the condition.
Analysis methods
The results of the model are presented in terms of the incremental cost per QALY. The costs and 
outcomes were discounted at 3.5% in accordance with NICE guidelines. As described below, both 
deterministic and probabilistic sensitivity analyses were conducted with a net benefit framework 
being used to compare the different treatment strategies.
Sensitivity analysis
Probabilistic sensitivity analyses
Probabilistic sensitivity analyses of the base-case scenario were conducted by assuming a beta 
distribution of the probability of death and non-response to treatment in the different treatment 
strategies. The values used to define these distributions are reported in Table 15 and are derived 
from the data reported in Data requirements and model inputs, above.
The beta distribution as defined above might arguably be considered to be too precise and to 
not truly reflect the degree of uncertainty that exists. To examine the uncertainties around the 
distribution assumed for the base-case scenario, sensitivity analysis was conducted by assigning 
a uniform distribution to these parameters, where the low and high value of probability of death 
and non-response rate were assumed to be 90% less than and 90% more than the mean value 
used in our model, respectively. The justification for this distribution was that comparisons of 
interventions that are based on non-randomised and non-comparative data are potentially biased 
and that both the magnitude and direction of bias are uncertain.
Deterministic sensitivity analyses
Sensitivity analysis was conducted with respect to methodological and structural assumptions. 
First, the discount rate for costs and effectiveness was changed to 0% and 6% in the sensitivity 
analysis. The time horizon was also varied between 6 and 12 years (data are presented in the 
results for 6- and 12-year time horizons).
Sensitivity analysis was also conducted to examine the uncertainties around the values used for 
the cost of drugs (which are major components of the cost of treatment for different treatment 
Parameters Description Value
For sensitivity 
analysis
Distribution Values
Data source and 
assumptions Low High
Structural and methodological parameters
Cycle length Time period that utilities, 
costs and probabilities 
relate to
1 month  Assumption
Length of run No. of cycles model is run for 120 (10 
years)
72 (6 
years)
144 (12 
years)
Assumption
DR Discount rate  0.002917 0 0.005 NICE guideline94
TABLE 15  Model parameters, values and data sources (continued)48 Assessment of cost-effectiveness
strategies) and the utility values for the different health states of the model. The values used in the 
sensitivity analysis are reported in Table 15.
A further area of uncertainty relates to the very limited data available for imatinib 600 mg/day. 
In the base-case analysis the effectiveness (in terms of survival and response rates) is better for 
imatinib 600 mg/day than with imatinib at 800 mg/day. As this was based on non-randomised, 
non-comparative data the relative difference is potentially biased. Therefore, in this sensitivity 
analysis a more conservative assumption was taken that the survival rate and the response rate for 
treatment with imatinib 800 mg/day also applied to imatinib 600 mg/day.
Results
Base-case analysis
Table 16 shows the mean estimates of cost and effectiveness of the seven alternative treatment 
strategies modelled. As this table shows, effectiveness has been reported in two ways: life-years 
and QALYs. Path-4, imatinib 600 mg/day has an incremental cost per QALY that is < £30,000 
compared with Path-1, BSC. The only other non-dominated or non-extendedly dominated 
strategy is Path-2, imatinib 600 to imatinib 800 mg/day to sunitinib. However, in this case the 
incremental cost per QALY (compared with the next most costly option of Path-4, imatinib 
600 mg/day) is in excess of £40,000.
Of note is that in the base-case analysis treatment with sunitinib for those who failed with 
imatinib 400 mg/day (Path-7) was estimated to have a lower life expectancy than BSC but 
greater QALYs. The reason for this was that the estimates of survival for sunitinib were based 
upon limited non-randomised and non-comparative data (as was the case for all the other 
comparators). Hence, any comparison should be treated cautiously.
The finding that sunitinib was dominated by BSC when effectiveness was measured in life-years 
but not dominated when effectiveness was measured in QALYs illustrates the importance of 
TABLE 16  Base-case analysis and incremental cost–utility of the alternative treatment pathways
Strategies  Cost (£)
Incremental 
cost (£) Life-years
Incremental 
life-years QALYs
Incremental 
QALYs
Incremental cost 
per QALY (£)
Path-1 BSC 92,811 4.154 2.397
Path-7 Sunitinib 96,688 3877 3.716 (Dominated) 2.411 0.014 272,365
Path-4 Imatinib 
600 mg
147,060 50,372 5.211 1.057 4.256 1.845 27,304
Path-3 Imatinib 
600 mg to sunitinib
149,200 2139 5.032 Dominated 4.286 0.030 71,723
Path 6 Imatinib 
800 mg
153,901 4702 4.506 Dominated 3.635 –0.651 Dominated
Path-5 Imatinib 
800 mg to sunitinib
155,828 6628 4.336 Dominated 3.659 –0.627 Dominated
Path-2 Imatinib 
600 mg to 800 mg to 
sunitinib
172,152 22,953 5.278 0.067 4.803 0.517 44,359
With dominated and extendedly dominated options removed
Path-1 BSC 92,811 4.154 2.397
Path-4 Imatinib 
600 mg
147,060 54,249 5.211 1.057 4.256 1.859 29,181
Path-2 Imatinib 
600 mg to 800 mg to 
sunitinib
172,152 25,092 5.278 0.067 4.803 0.547 45,850© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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the utility estimates used within the model. Again, such data were sparse and, particularly 
for sunitinib, do not reflect the potentially worse side effect profile. Other things remaining 
unchanged the inclusion of side effects would have reduced the QALYs obtained from pathways 
containing sunitinib and potentially led to Path-7 being dominated by BSC (at the very least the 
incremental cost per QALY would have increased from the £272,365 reported in Table 16).
The results reported in Table 16 are surrounded by considerable imprecision. One of the main 
sources of the imprecision in the analysis surrounds the clinical effectiveness data. Therefore, 
a partial probabilistic sensitivity analysis was conducted, with the imprecision surrounding 
response rates and mortality rates being characterised by beta distributions. Figure 7 shows 
the cost-effectiveness acceptability curve and illustrates that the pathway with the highest 
likelihood of being considered cost-effective when society’s willingness to pay for a QALY is 
less than approximately £25,000 is Path-1, BSC. When society’s willingness to pay for a QALY 
is between approximately £25,000 and £45,000 then Path-4, imatinib 600 mg/day, is most likely 
to be considered cost-effective. Beyond a threshold of approximately £45,000, Path-2, imatinib 
600 mg/day to imatinib 800 mg/day to sunitinib, is most likely to be cost-effective.
Sensitivity analysis
Uncertainty around the distributions used for mortality and response 
rates
The beta distributions used to generate Figure 7 potentially do not fully characterise the extent 
of the uncertainty surrounding the estimates of mortality and response used within the model. 
As noted in the previous section (see Probabilistic sensitivity analyses), this is because the data 
are used essentially as if they came from non-randomised, non-comparative sources, and hence 
any comparisons drawn may be highly biased. For this reason, in this sensitivity analysis uniform 
distributions were substituted for the beta distributions (Figure 8). It should be noted that these 
uniform distributions were assumed to be symmetrical around the point estimates used in the 
base-case analysis.
As Figure 8 illustrates, the basic pattern of the cost-effectiveness acceptability curve is the same as 
that depicted in Figure 7. At low threshold values for the willingness to pay for a QALY, Path-1, 
BSC, is still the most likely to be considered cost-effective. However, Path-7, sunitinib, is more 
FIGURE 7  Cost-effectiveness acceptability curve for alternative treatments over the 10-year time horizon. Pathways 
with a low probability of being cost-effective over the range of willingness to pay for a QALY values considered have not 
been shown.
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likely to cost-effective at low thresholds. It should be noted that even though the distributions 
surrounding mortality weights are very wide in this analysis sunitinib is still associated with a 
trend towards a slightly higher mortality rate than BSC. As previously noted this trend is based 
upon sparse and potentially unreliable data on the performance of sunitinib. At a threshold value 
of approximately £36,000 Path-3, imatinib 600 mg daily to sunitinib, has a similar probability 
of being considered cost-effective as Path-1, BSC, and Path-4, imatinib 600 mg/day. Between a 
threshold of £36,000 and £48,000, Path-4, imatinib 600 mg/day, is most likely to be cost-effective, 
and beyond that threshold value Path-2, imatinib 600 mg/day to imatinib 800 mg/day to 
sunitinib, is most likely to be cost-effective.
Uncertainty surrounding structure and methodological assumptions 
around distribution
Two different discount rates have been applied to costs and benefits to examine the sensitivity 
of the results to plausible changes in the discount rate (Table 17). At a 0% discount rate there is 
no change in the options that are dominated or extendedly dominated, and the incremental cost 
per QALY for Path-4, imatinib 600 mg/day, compared with Path-1, BSC, increases to £31,183. 
The incremental cost per QALY for Path-2, imatinib 600 mg/day to 800 mg/day to sunitinib, 
compared with Path-4, imatinib 600 mg/day, increases to £54,715.
When the discount rate is changed to 6%, the incremental cost per QALYs for the non-dominated 
strategies falls compared with the base-case analysis. The key change is that Path-3, imatinib 
600 mg/day to sunitinib, is no longer extendedly dominated by Path 4, imatinib 600 mg/day. 
Furthermore, the incremental cost per QALY for this comparison is < £30,000. Overall, the 
sensitivity analysis around discount rates illustrates that the results are sensitive to the choice of 
discount rate.
Table 18 reports the results of the sensitivity analysis around the time horizon of the model. 
When the time horizon is reduced to 6 years (base case = 10 years) the incremental cost 
per QALYs associated with the non-dominated options increases slightly. When the time 
horizon increases, the incremental cost per QALY for Path-4, imatinib 600 mg/day, compared 
with Path-1, BSC, increases slightly. The incremental cost per QALY for Path-2, imatinib 
FIGURE 8  Cost-effectiveness acceptability curve for alternative treatments over the 10-year time horizon assuming 
uniform distributions for mortality and response rates. Pathways with a low probability of being cost-effective over the 
range of willingness to pay for a QALY values considered have not been shown.
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TABLE 17  Sensitivity around the discount rate and length of run
Strategy Cost (£) QALYs
Incremental cost per 
QALY (£)
Base case, i.e. discount 
rates = 3.5% on cost and 
benefit; time horizon = 10 years
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 147,060 4.256 27,304
Path-3 Imatinib 600 mg to sunitinib 149,200 4.286 71,723
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.803 44,359
Sensitivity analysis 1, i.e. 
discount rates = 0% on cost 
and benefit; time horizon = 10 
years
Path-1 BSC 93,137 2.706
Path-7 Sunitinib 97,719 2.672 Dominated
Path-4 Imatinib 600 mg 159,462 4.833 31,183
Path-3 Imatinib 600 mg to sunitinib 163,601 4.859 Extendedly dominated
Path 6 Imatinib 800 mg 165,641 4.087 Dominated
Path-5 Imatinib 800 mg to sunitinib 169,210 4.105 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 195,193 5.486 54,715
Sensitivity analysis 2, i.e. 
discount rates = 6%; time 
horizon = 10 years
Path-1 BSC 92,614 2.209
Path- 7 Sunitinib 96,007 2.254 Extendedly dominated
Path-4 Imatinib 600 mg 139,473 3.908 27,593
Path-3 Imatinib 600 mg to sunitinib 140,394 3.940 28,801
Path 6 Imatinib 800 mg 146,627 3.360 Dominated
Path-5 Imatinib 800 mg to sunitinib 147,542 3.387 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 158,271 4.392 39,480
TABLE 18  Sensitivity around the time horizon of the model
Strategy Cost (£) QALYs
Incremental cost per 
QALY (£)
Base case, i.e. discount 
rates = 3.5% on cost and 
benefit; time horizon = 10 
years
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 147,060 4.256 27,304
Path-3 Imatinib 600 mg to sunitinib  149,200 4.286 71,723
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.803 44,359
Sensitivity analysis 3, i.e. 
discount rates = 3.5%; time 
horizon = 6 years
Path-1 BSC 73,246 1.960
Path-7 Sunitinib 79,720 2.032 Extendedly dominated
Path-4 Imatinib 600 mg 114,433 3.402 28,560
Path-3 Imatinib 600 mg to sunitinib  117,729 3.455 Extendedly dominated
Path-6 Imatinib 800 mg 126,750 3.017 Dominated
Path-5 Imatinib 800 mg to sunitinib 129,873 3.066 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 131,848 3.758 48,969
Sensitivity analysis 4, i.e. 
discount rates = 3.5%; time 
horizon = 12 years
Path-1 BSC 98,464 2.510
Path-7 Sunitinib 101,589 2.509 Dominated
Path-4 Imatinib 600 mg 156,943 4.489 29,553
Path-3 Imatinib 600 mg to sunitinib 158,421 4.507 Extendedly dominated
Path-6 Imatinib 800 mg 161,295 3.790 Dominated
Path-5 Imatinib 800 mg to sunitinib 162,637 3.803 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 183,961 5.093 44,73652 Assessment of cost-effectiveness
600 mg/day to imatinib 800 mg/day to sunitinib, compared with Path-4, imatinib 600 mg/day, is 
virtually unchanged.
Uncertainty surrounding transition probabilities of survival and 
response to treatment with imatinib 600 mg/day
The data available for imatinib given at a dose of 600 mg/day were sparse and what few data 
there were suggested a superior effectiveness compared with imatinib 800 mg/day. These data are 
(1) potentially unreliable because they are based upon non-randomised and non-comparative 
data and (2) potentially counterintuitive (in a direct comparison would we expect imatinib 
800 mg/day to perform worse than imatinib 600 mg/day?). Therefore, in this sensitivity analysis 
it was assumed that the mortality and response to treatment with imatinib 600 mg/day was the 
same as that with imatinib 800 mg/day.
As Table 19 shows the incremental cost per QALY for Path-4, imatinib 600 mg/day, compared 
with Path-1, BSC, falls. This is because there is a reduction in the cost of medications as the 
probabilities that patients die or make the transition to BSC increases, which more than 
compensates for the fall in QALYs. The QALYs associated with Path-3, imatinib 600 mg/day to 
imatinib 800 mg/day to sunitinib, fall but the incremental cost per QALY compared with Path 4, 
imatinib 600 mg/day, is virtually unchanged.
As noted in Data requirements and model inputs (above), the two sources106,107 of mortality data 
that we have used for BSC were chosen because these studies had larger sample sizes and longer 
median follow-up times (Appendix 13). We conducted sensitivity analysis using different sources 
of mortality data for BSC, i.e. using a pooled mortality estimate of 19.8% that is based on survival 
estimates from Pierie et al.,107 Dougherty et al.112 and Artyan et al.113  The monthly mortality rate 
would be higher (0.02349) than what we have used in the base case (0.014627). As mortality for 
BSC increases, the cost and QALYs for the pathways fall because BSC is part of each pathway. 
As a consequence the incremental cost per QALYs do not change greatly although all slightly 
increase compared with less costly but less effective pathways because the increase in mortality 
for BSC has proportionately a greater effect on costs than on QALYs.
Uncertainty surrounding utility values
The sensitivity of a lower and higher value of utility for the health status of disease progression 
was examined. In this analysis the lower value was 0.52 and a higher utility value for those 
patients who progressed with GIST of 0.712 was assumed instead of 0.577, as was used in the 
base case (Table 20). Reducing the utility value increased the QALYs for treatments that had 
higher probabilities of response. The incremental cost per QALY for Path-4, imatinib 600 mg/day, 
compared with Path-1, BSC, slightly falls and the incremental cost per QALY for Path-2, imatinib 
600 mg/day to imatinib 800 mg/day to sunitinib, compared with Path-4, imatinib 600 mg/day, 
falls to approximately £40,000.
Conversely, increasing the utility associated with PD reduced the opportunity for pathways that 
are clinically more effective to generate additional QALYs. As a consequence, in this sensitivity 
analysis the incremental cost per QALYs for the non-dominated pathways increase.
Uncertainty surrounding the cost of imatinib and sunitinib
In this set of sensitivity analyses reductions in the cost of imatinib 600 mg/day, imatinib 
800 mg/day and sunitinib are explored (Table 21). Over most of these sensitivity analyses the 
pathways that are dominated or are extendedly dominated do not change. As would be expected 
reducing the costs of each medication individually reduces the cost of pathways involving 
that medication. Over all these sensitivity analyses there are only relatively modest changes in 
the ICERs reported. One of the more substantive changes is that when the cost of sunitinib is © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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TABLE 19  Changes to mortality and response rates
Strategy Cost (£) QALYs
Incremental cost per 
QALY (£)
Base case Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 147,060 4.256 27,304
Path-3 Imatinib 600 mg to sunitinib 149,200 4.286 71,723
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.803 44,359
Sensitivity analysis 5: survival 
rate and response rate to 
imatinib 600 mg treatment 
same as that with imatinib 
800 mg
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 126,074 3.635 24,019
Path-3 Imatinib 600 mg to sunitinib 128,001 3.659 80,476
Path-2 Imatinib 600 to 800 mg to sunitinib 149,703 4.145 44,603
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 to sunitinib 155,828 3.659 Dominated
Sensitivity analysis 6: survival 
rate for BSC = 0.02349
Path-1 BSC 65,412 1.729
Path-7 Sunitinib 77,669 1.954 Dominated
Path-4 Imatinib 600 mg 137,060 4.022 31,239
Path-3 Imatinib 600 mg to sunitinib 142,643 4.134 Extendedly dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 144,349 3.411 Dominated
Path-6 Imatinib 800 mg 149,517 3.512 Dominated
Path-5 Imatinib 800 to sunitinib 170,340 4.762 44,603
TABLE 20  Sensitivity analysis around the utility assumed for disease progression
Strategy Cost (£) QALYs
Incremental cost per 
QALY (£)
Base case: utility of progressive 
state = 0.577
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 147,060 4.256 27,304
Path-3 Imatinib 600 mg to sunitinib  149,200 4.286 71,723
Path 6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.803 44,359
Sensitivity analysis 6: utility of 
progressive state = 0.52
Path-1 BSC 92,811 2.160
Path-7 Sunitinib 96,688 2.242 Extendedly dominated
Path-4 Imatinib 600 mg 147,060 4.158 27,156
Path-3 Imatinib 600 mg to sunitinib  149,200 4.219 34,911
Path 6 Imatinib 800 mg 153,901 3.543 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.596 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.782 40,759
Sensitivity analysis 7: utility of 
progressive state = 0.712
Path-1 BSC 92,811 2.958
Path-7 Sunitinib 96,688 2.812 Dominated
Path-4 Imatinib 600 mg 147,060 4.488 35,440
Path-3 Imatinib 600 mg to sunitinib  149,200 4.444 Dominated
Path 6 Imatinib 800 mg 153,901 3.853 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.808 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.853 68,83754 Assessment of cost-effectiveness
reduced, Path-7, sunitinib, becomes the least costly option. This is primarily because this pathway 
uses potentially unreliable data on mortality for sunitinib which means that patients on this 
pathway do not survive long enough to incur higher costs.
Summary
The systematic review of economic evaluations reported in this chapter was not especially 
informative. This was anticipated at the outset and hence an economic modelling exercise was 
planned. The modelling exercise compared alternative treatment pathways for patients with 
unresectable GIST who failed to respond to imatinib 400 mg/day. Over almost all the sensitivity 
analyses Path-1, BSC, is the least costly and least effective intervention. Similarly, Path-4, imatinib 
600 mg/day, typically has an incremental cost per QALY that is less than £30,000 compared with 
Path-1, BSC. Path-2 (imatinib 600 mg/day to imatinib 800 mg/day to sunitinib) is the only other 
pathway which is not dominated or extendedly dominated over most of the analyses conducted. 
However, in this case the incremental cost per QALY (compared with the next most costly option 
– Path-4: imatinib 600 mg/day) tends to be in excess of £40,000.
TABLE 21  Sensitivity around the costs of imatinib and sunitinib
Strategy Cost (£) QALYs
Incremental cost per 
QALY (£)
Base case:
Imatinib 600 mg £2406
Imatinib 800 mg $3208
Sunitinib £3138.8 
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 272,365
Path-4 Imatinib 600 mg 147,060 4.256 27,304
Path-3 Imatinib 600 mg to sunitinib  149,200 4.286 71,723
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 172,152 4.803 44,359
Sensitivity analysis 8 (change 
in imatinib 600 mg price):
Imatinib 600 mg £2005
Imatinib 800 mg $3208.16
Sunitinib £3138.8
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 Extendedly dominated
Path-4 Imatinib 600 mg 130,272 4.256 20,150
Path-3 Imatinib 600 mg to sunitinib  132,412 4.286 Extendedly dominated
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 155,364 4.803 45,850
Path-5 Imatinib 800 mg to sunitinib 155,828 3.659 Dominated
Sensitivity analysis 9 (change 
in imatinib 800 mg price):
Imatinib 600 mg £2406
Imatinib 800mg $2807
Sunitinib £3138.8
Path-1 BSC 92,811 2.397
Path-7 Sunitinib 96,688 2.411 Extendedly dominated
Path-6 Imatinib 800 mg 139,988 3.635 Extendedly dominated
Path-5 Imatinib 800 mg to sunitinib 141,915 3.659 Extendedly dominated
Path-4 Imatinib 600 mg 147,060 4.256 29,181
Path-3 Imatinib 600 mg to sunitinib  149,200 4.286 Extendedly dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 166,000 4.803 34,609
Sensitivity analysis 10 (change 
in sunitinib price):
Imatinib 600 mg £2406
Imatinib 800mg $3208.16
Sunitinib £2092
Path-7 Sunitinib 87,533 2.411
Path-1 BSC 92,811 2.397 Dominated
Path-3 Imatinib 600 mg to sunitinib 144,524 4.286 30,400
Path-4 Imatinib 600 mg 147,060 4.256 Dominated
Path-5 Imatinib 800 mg to sunitinib 151,560 3.659 Dominated
Path-6 Imatinib 800 mg 153,901 3.635 Dominated
Path-2 Imatinib 600 to 800 mg to sunitinib 170,364 4.803 49,940© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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When society’s willingness to pay for a QALY is less than approximately £25,000 Path-1, BSC, is 
the most cost-effective. When society’s willingness to pay for a QALY is between approximately 
£25,000 and £45,000 then Path-4, imatinib 600 mg/day, is most likely to be considered cost-
effective. Beyond a threshold of approximately £45,000, Path-2, imatinib 600 mg/day to imatinib 
800 mg/day to sunitinib, is most likely to be cost-effective.
The results of the economic analysis are based upon sparse data that are potentially biased and 
are surrounded by considerable imprecision. In particular, data for sunitinib and for imatinib 
600 mg/day are the most suspect. The analysis has also not considered two main areas of 
uncertainty due to lack of data:
  ■ The considerable uncertainty around the extrapolation from the sparse data on death and 
response rate and the impact of alternative assumptions about how probabilities of death and 
response change over time.
  ■ Reductions in utility associated with adverse effects of treatment.
By assuming constant probabilities over time, death may be overestimated at earlier time points 
and underestimated at later stages of the time horizon of the model. The probability of death 
may increase over time as the disease progresses. Similarly the probability of non-response may 
increase over time and patients may have an increasing need for an escalated dose of imatinib, 
or sunitinib. The assumption of constant probability over time generally delays the transition 
to patients’ deaths. This means that our analysis has a bigger impact on the most effective 
treatments. These treatments will also incur high treatment costs over a longer period. The net 
impact of these two changes on cost-effectiveness is unclear.
The net impact of adjusting scores for adverse effects is also uncertain but it might be expected 
that it will reduce the QALYs associated with each medication and, although there are limited 
data available from the systematic review of clinical effectiveness, this reduction may be greater 
for pathways involving sunitinib because its adverse effect profile is believed to be worse than that 
of imatinib.111
Owing to sparse data for this analysis, few data were available on the utility values for defined 
disease states in the model. Furthermore, the disease states selected in the model may not 
be complete and exhaustive as data on alternative plausible disease states were not available. 
Sensitivity analysis explored uncertainty in key parameter estimates but clearly this does not 
investigate the influence of structural assumptions such as the limited number of disease states 
chosen for the modelling. A more sophisticated model would have allowed further sensitivity 
analysis but without at least some data to guide assumptions we would have needed to identify 
threshold values for many individual parameters and combinations of parameters. This would 
have resulted in a substantially expanded economics chapter reporting extensive speculative 
results that would have been very difficult to interpret.
A further factor not considered by the economic model was the cost-effectiveness of treatment 
for those with specific gene mutations. Again this was not addressed owing to lack of data, and 
as there were also no data available to assess the impact of plasma monitoring on the study 
population of interest, this was also not considered by the economic model.
Finally, the economic evaluation has assumed that patients who move on to BSC remain on 
treatment to prevent tumour flare. This has the impact of increasing the cost of BSC. It is further 
assumed that there is no impact on effectiveness (the implicit assumption is that discontinuing 
the medication would reduce life expectancy). Within the analysis it has been assumed that all 56 Assessment of cost-effectiveness
patients on BSC or moving on to BSC after failing to respond on a medication would receive 
imatinib 400 mg/day. This assumption appears reasonable for Path-1, BSC, but may not be 
appropriate for the other pathways where patients would move on to BSC after failing to respond 
on an escalated dose of imatinib or on sunitinib. Should these patients continue with the last 
active medication that they received then costs, and incremental costs per QALY, would increase.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Chapter 6  
Assessment of factors relevant to the 
NHS and other parties
G
astrointestinal stromal tumours are a rare cancer, accounting for < 1% of all cancers of the 
GI tract. The incidence and subsequent overall burden on the NHS is not large, and only 
a small proportion of patients with GIST will have unresectable and/or metastatic disease that 
progresses on imatinib at a dose of 400 mg/day. NICE guidance on imatinib for the treatment of 
unresectable and/or metastatic GIST does not recommend an increase in the dose of imatinib 
for people receiving imatinib who develop PD after initially responding at the 400 mg/day dose.50 
Some guidelines, however, do advocate dose escalation for such patients, particularly those with 
KIT exon 9 mutations, indicating that escalated doses may help this group of GIST patients and 
offer them the opportunity to continue with a normal life for a longer period of time.15,114,115
Since the availability of sunitinib, guidance on the treatment of patients with unresectable and/
or metastatic GIST has been adapted to take account of this drug as a possible second-line 
treatment15 in circumstances where patients either are intolerant to imatinib, or have progressed 
on treatment with imatinib at a 400 mg/day dose. NICE guidance recommends sunitinib as a 
treatment option for people with unresectable and/or metastatic malignant GIST if imatinib 
treatment has failed because of resistance or intolerance, and the drug cost of sunitinib for the 
first treatment cycle is met by the manufacturer.
In clinical practice the treatment of patients with unresectable and/or metastatic GIST is 
generally decided on a case-by-case basis by multidisciplinary teams. Many clinicians advocate 
initial dose escalation of imatinib and then consider sunitinib on subsequent progression, 
although practice will vary depending on the specific needs of individual patients.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Chapter 7  
Discussion
Statement of principal findings
Review of clinical effectiveness
This review is a part update of a previous review on imatinib for the treatment of patients with 
unresectable and/or metastatic GISTs.55 We focused on patients with KIT (CD117)-positive, 
unresectable and/or metastatic GISTs whose disease had progressed on treatment with 
imatinib at a dose of 400 mg/day. Five studies involving 669 patients from within the relevant 
treatment arms met the inclusion criteria. Of these studies, four involving 318 patients reported 
imatinib outcomes and one involving 351 patients, who had received a prior imatinib dose of 
≤ 400 mg/day, reported sunitinib outcomes. No studies reporting BSC were identified that met 
our inclusion criteria.
Although the study designs for most of the included trials were RCTs (plus one retrospective 
cohort study) none of these trials had, as their primary objective, the assessment of the effects of 
dose escalation following progression on 400 mg/day imatinib. Only a proportion of the overall 
patient populations received an escalated dose, and these patients were not randomised at the 
point of dose escalation to receive either an escalated dose of imatinib or remain on 400 mg/day. 
Therefore, the nature of the evidence base for patients who progress on 400 mg/day imatinib and 
receive escalated doses of 600 or 800 mg/day is observational and open to bias.
The sample sizes of the studies from which the 669 patients were drawn from ranged from 2479 
to 111786 participants. Each study had more male than female participants. The vast majority 
of participants in each study had an ECOG performance status of ≤ 2, meaning that they were 
ambulatory and confined to bed for less than 50% of their waking hours.116 Of the studies that 
reported the proportion of the study population receiving prior surgery,39,44,79 most patients had 
undergone prior surgery for treatment of their disease. Information on the characteristics of all 
the 669 patients relevant to this review was not provided separately.
From the data on imatinib it can be seen that approximately one-third of patients progressing 
on 400 mg/day of imatinib will respond to escalated doses. With 600 mg/day, between 25.6% 
(11/43)39 and 41.7% (5/12)79 of patients with unresectable and/or metastatic GIST, who had 
previously progressed on a dose of 400 mg/day of imatinib, either developed a PR or maintained 
SD. With 800 mg/day, the proportions achieving PR or SD ranged between 29.3%44 and 33.3%.79 
These data were used to inform transition probabilities of non-response to imatinib at escalated 
doses of 600 and 800 mg/day, respectively. However, response data were not available for patients 
receiving sunitinib following treatment with imatinib at a dose of ≤ 400 mg/day. As an alternative 
to excluding sunitinib entirely, which could arguably have been appropriate given the lack of 
data, the economic model used data that did not meet the inclusion criteria for the review of 
clinical effectiveness because it failed to report response data separately for those progressing on 
a 400 mg/day dose. A further assumption made in the economic model was that response was 
unaffected by prior treatment received. This assumption was made because of a lack of data on 
how response might change over time and be affected by prior treatments other than imatinib at 
400 mg/day.60 Discussion
Median OS data were not reported for those receiving an escalated imatinib dose of 600 mg/day 
upon progression at a 400 mg/day dose. Therefore, the economic model calculated the probability 
of death from the available trial data on median OS according to best response, and the 
proportion of patients receiving escalated doses who will have had a response to imatinib at the 
initial 400 mg/day dose prior to eventual progression and dose escalation.
For those receiving an escalated imatinib dose of 800 mg/day upon progression, median OS was 
reported to be 19 months (95% CI 13 to 23 months) in the S0033 trial.41 Median OS was not 
reported for the EORTC-ISG-AGITG study44 for the population of interest, (CiC information has 
been removed). For those receiving sunitinib after a prior imatinib dose of ≤ 400 mg/day, median 
OS was reported as 22.5 months (95% CI 18.3 to 26.5 months).86
Figure 3 provided a visual comparison of the median OS times for imatinib at an escalated dose 
of 800 mg/day and sunitinib, showing overlapping CIs until 33 months from commencement of 
treatment, at which point the estimated proportion of sunitinib patients surviving appeared to 
be less than the proportion surviving on the 800 mg/day imatinib dose. (CiC information has 
been removed.) It is difficult to draw any conclusions with regard to possible differences in OS 
between imatinib at an escalated dose of 800 mg/day and sunitinib at 50 mg/day (with a 4-weeks-
on/2-weeks-off cycle), owing to the lack of data, but as the 95% CIs for median OS overlap, there 
does not appear to be any significant difference in median OS with dose escalation, compared 
with sunitinib.
The median time to progression and PFS was reported for imatinib 600 mg/day as 1.7 months 
(range 0.7–24.9 months),79 and for imatinib 800 mg/day it ranged between 2.9 months (reported 
without CIs as ‘81 days’)44 and 5 months (95% CI 2 to 10 months).41 A visual representation of 
these data for imatinib 800 mg/day in Figure 4 gives 95% CIs that do not overlap, for all time 
points between 12 and 21 months, indicating that PFS was significantly shorter in the EORTC-
ISG-AGITG study reported by Zalcberg et al.44 than in the S0033 trial reported by Blanke et al.41
In addition, those studies looking at an 800 mg/day dose of imatinib reported that between 
16.1% (19/118) and 18.8% (25/133) of patients were progression free at the time of the analysis. 
This represented a proportion of between 52.8% (19/36) and 64.1% (25/39) of all of those 
achieving PR and SD on the 800 mg/day dose. This suggests that a small proportion (i.e. < 20%) 
of those receiving an escalated dose of 800 mg/day of imatinib on progression may maintain 
their response/SD for a median time period of at least 25 months (i.e. the shorter of the median 
follow-up times reported by these trials), and those who achieve a response or maintain SD on 
the escalated dose may have a greater than 50% likelihood of maintaining this in the longer term.
For those receiving an escalated dose of 800 mg/day, the study by Zalcberg et al.44 reported 
a median duration of ‘stabilisation’ among those showing response or SD with treatment of 
153 days (range 37–574 days). For sunitinib, the treatment duration for all patients receiving 
sunitinib (i.e. regardless of the dose of prior imatinib therapy) was 126 days (range 1–618 days).86
Data on adverse events were not available from any of the studies where the population of interest 
received imatinib at 600 mg/day or sunitinib following progression at 400 mg/day. For the trials 
reporting outcomes following dose escalation from 400 to 800 mg/day after progression at the 
lower dose, it was reported that the vast majority (88.4%) of study discontinuations were due to 
disease progression and not study drug toxicity.44 (CiC information has been removed.)
Nevertheless, it was also reported that between 15.6%77 and 31%78 of patients receiving an 
escalated imatinib dose of 800 mg/day required a dose reduction. It was also reported that 
23.3% (18/77) of patients required at least one dose delay.77 However, it was not possible to take © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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possible dose reductions into account with regard to any of the outcomes. This was because 
information on the dose provided following reduction, the median duration of any dose delay or 
dose reduction, and any other factors, besides toxicity, contributing to any of the dose delays or 
reductions were not reported.
These data on discontinuations and dose modifications indicate that, although disease 
progression is far more likely than adverse events to contribute to the decision to stop escalated 
imatinib treatment at the 800 mg/day dose, approximately one-third of patients will require dose 
modifications (i.e. dose reduction or interruption) during treatment at this escalated dose.
With regard to specific adverse events, data were reported by Zalcberg et al.44 showing 
that a higher proportion of patients with skin rash, nausea, leucopenia, neutropenia and 
thrombocytopenia reported a reduction in the severity of these events following dose escalation 
compared with the proportion of patients reporting an increase in these events. This reduction 
was significant in the case of neutropenia (p = 0.002). However, the proportion of patients with 
oedema, fatigue, dyspnoea and anaemia who reported an increase in severity of these events 
following dose escalation was greater than the proportion of patients who reported a reduction 
in these events. This increase in severity was significant in the case of fatigue (p < 0.001) and 
anaemia (p = 0.015).44 (CiC information has been removed.) It is difficult to draw any conclusions 
about specific adverse events from these data, aside from noting that fatigue and anaemia may 
significantly increase upon dose escalation from 400 mg/day imatinib to 800 mg/day.
The only data available for any of the prespecified subgroups of interest were reported by Debiec-
Rychter et al.14 for the EORTC-ISG-AGITG trial, which looked at imatinib dose escalation from 
400 to 800 mg/day following progression at the lower dose. They noted that patients with wild 
type, and those with exon 9 mutations, were significantly more likely to have a response to dose 
escalation than those with exon 11 mutations, but no numerical data were reported for the 
population of interest. (CiC information has been removed.) Furthermore, it has been argued 
that subgroups with certain exon mutations might have improved response and/or survival 
outcomes if they initially receive an escalated imatinib dose, rather than receiving dose escalation 
only if there is progression at the 400 mg/day dose.114
It was outwith the remit of this review to consider outcomes for patients receiving escalated 
dosing other than following progression on the initial 400 mg/day dose. The lack of data available 
meant it was not possible to assess for specific mutational population subgroups the effects of 
escalation to an imatinib dose of 800 mg/day following progression at the initial 400 mg/day dose.
Review of cost-effectiveness
The economic component of this study included both a review of the existing economic 
evaluations and an economic modelling exercise. The evidence from the review of economic 
evaluations was sparse and there was no published economic evaluation conducted for a UK 
context that compared all of the interventions for the patient group of interest.
The modelling exercise compared alternative treatment pathways for patients with unresectable 
GIST who failed to respond to imatinib 400 mg/day. Over almost all the sensitivity analyses, 
Path-1, BSC, is the least costly and least effective intervention. Similarly, Path-4, imatinib 
600 mg/day, typically has an incremental cost per QALY that is less than £30,000 compared with 
Path-1, BSC. Path-2 (imatinib 600 mg/day to 800 mg/day to sunitinib) is the only other pathway 
that is not dominated or extendedly dominated over most of the analyses conducted. However, 
in this case the incremental cost per QALY (compared with the next most costly option: Path-4, 
imatinib 600 mg/day) tends to be > £40,000.62 Discussion
When society’s willingness to pay for a QALY is < ~£25,000, Path-1, BSC, is the most cost-
effective intervention. When society’s willingness to pay for a QALY is between approximately 
£25,000 and £45,000, Path-4, imatinib 600 mg/day, is most likely to be considered cost-effective. 
Beyond a threshold of approximately £45,000, Path-2, imatinib 600 mg/day to imatinib 
800 mg/day to sunitinib, is most likely to be cost-effective.
As discussed below, these data should be treated cautiously, as the data used are observational 
and non-comparative. Furthermore, the data on sunitinib and imatinib 600 mg/day are 
particularly sparse and potentially unreliable. For example, data on treatment with sunitinib 
show a lower life expectancy than those on treatment with BSC (although sunitinib has greater 
QALYs). This means that when the cost of sunitinib is reduced it becomes more cost-effective 
than BSC, as the potentially unreliable source data for life expectancy on sunitinib mean that 
patients on sunitinib will not survive long enough to incur higher costs of treatment. Although 
sufficient evidence on the effectiveness of sunitinib compared with BSC following treatment 
on imatinib at a 400 mg/day dose was not available, evidence on the effectiveness of sunitinib 
compared with BSC regardless of prior imatinib dose suggests that life expectancy with sunitinib 
is superior.
In addition, the data available for imatinib at a dose of 600 mg/day suggested superior 
effectiveness compared with the 800 mg/day dose. This is because the evidence on imatinib at 
the 600 mg/day dose was based on a smaller sample size (43 patients), making the model results 
for this pathway potentially counterintuitive if we expect higher drug doses to have greater 
effectiveness than lower doses.
Strengths and limitations of the assessment
In terms of strengths, the review of the evidence base was detailed and thorough. It was unclear 
from the information provided in a substantial number of abstracts whether the studies met 
the inclusion criteria and full-text papers for all of these reports were obtained and assessed. 
Non-English language studies were not excluded. Authors were contacted in an attempt to 
obtain additional information concerning their studies. For the review of economic evaluations, 
a rigorous systematic approach was adopted. The economic model considered a large number 
of plausible alternative treatments and also incorporated both probabilistic and deterministic 
estimates of cost effectiveness. The former was limited to clinical effectiveness parameters but this 
limitation was chosen specifically to draw attention to the uncertainties surrounding these data.
In terms of limitations, there was a dearth of evidence available on the specific population of 
interest, despite the overall large evidence base on the treatment of GISTs with imatinib or 
sunitinib. The quality of reporting of dose information in reports of imatinib or sunitinib for 
GISTs was poor and the data on the population of interest for the studies that were included 
were non-randomised, non-comparative and therefore observational. Therefore, lack of quality 
data, as well as lack of data itself, severely limited both assessments of clinical effectiveness and 
cost-effectiveness.
There was also a lack of evidence on QoL outcomes, which may be of fundamental importance 
to patients given the potentially palliative nature of treatment following progression, and there 
was also a lack of evidence on BSC. This is important as since the development of imatinib and 
sunitinib, it no longer represents the only treatment option for those with unresectable/metastatic 
disease. There was little evidence on response to escalated doses of imatinib based on mutational 
status, specifically for those who had already failed on an initial imatinib dose of 400 mg/day. It © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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was also not possible to account for the effects of required dose interruptions and reductions, or 
the effects of sunitinib on those intolerant to imatinib, owing to the lack of available data. This 
lack of data also prevented comparative analysis of adverse events between the intervention and 
comparator treatments.
For sunitinib, it was also necessary to assume that the vast majority of those receiving sunitinib 
after imatinib treatment at ≤ 400 mg/day had actually received imatinib at 400 mg/day, which may 
not be a valid assumption. However, it was not possible to confirm the validity of the assumption 
despite contacting the study authors (P Reichardt, HELIOS Klnikum Bad Saarow, Germany, 
2010, personal correspondence). In addition, much of the evidence base for sunitinib generally 
relates to its use following the failure of escalated doses of imatinib rather than failure on 
400 mg/day, suggesting that the role of sunitinib is seen more as a third-line treatment rather than 
a potential comparator to 600 mg/day or 800 mg/day imatinib treatment. This was highlighted by 
the manufacturer of imatinib in their submission for this technology appraisal, and is noted in 
Chapter 3 of this report.
For the economic model, sufficient sound comparative data for the different plausible treatments 
were not available, despite conducting an extensive review of relevant studies. This necessitated 
a number of simplifying assumptions being made with respect to the model and also the use of 
data that were potentially unreliable. The model assumes that patients entering a pathway will 
remain in that treatment for one cycle only if they do not respond and survive in the treatment 
arm. In these cases they are considered to move to the escalated doses, move to another 
alternative (if allowed by a treatment pathway) or continue with BSC for the remainder of the 
model time horizon or until they die. The care pathways considered in the economic model are 
not an exhaustive list of all possible treatment options available but represent plausible treatment 
scenarios. Some are likely to be more representative of clinical practice than others. Whilst 
additional clinical advice during the development of the care pathways might have increased the 
extent to which the chosen scenarios reflect true clinical practice, it may also have increased the 
level of complexity required within the model. Given the lack of robust data it was felt that a more 
sophisticated model would be difficult to populate.
Within the model, several simplifying assumptions had to be made for individual parameters. 
For example, it was necessary to consider the costs and utilities associated with BSC as consistent 
across all care pathways despite the fact that in clinical practice the costs of BSC may increase as 
an individual’s health deteriorates. Unfortunately, there were no data available to model how costs 
of BSC might increase and QoL might fall over time.
A further simplifying assumption was not to model the complications and side effects of therapy. 
This latter assumption was made owing to the very limited evidence available. This is coupled 
with the assumption made that the utility associated with stable response or progression did 
not vary between treatments. One impact of this assumption is that no utility decrement has 
been assumed for the arguably worse side effect profile of sunitinib. This means that pathways 
involving sunitinib may overestimate QALYs.
Perhaps a more important limitation is caused by the limited evidence base available. With 
respect to the clinical effectiveness data used to derive transition probabilities these data, 
as already noted, were based upon non-randomised, non-comparative data. Such data are 
potentially biased as well as being imprecise. In particular, it is worth noting that point estimates 
of death and response used within the model may be misleading, for example the point estimates 
used suggest that sunitinib has a higher mortality rate than BSC.64 Discussion
Uncertainties
For the assessment of clinical effectiveness:
  ■ The diagnosis of GIST as stated in the final scope document was based on a positive KIT 
(CD117) test. However, this is not a perfect test and in a small (< 5%) number of cases a 
patient can have a GIST despite having a negative KIT (CD117) test.4,7,25 More recent tests 
(e.g. PDGRFA and DOG1) may clarify diagnosis. However, the WHO classification of GI 
tumours recommends that a diagnosis of GIST should only apply to those patients testing 
positive for the KIT (CD117) protein.
  ■ It was not possible to conduct any subgroup analysis for patients with particular mutations, 
or consider the methods used to identify response (e.g. FDG-PET or CT scanning), or 
possible factors related to the provision of dose-escalated imatinib in an adjuvant or 
neoadjuvant setting.
  ■ It was not possible within the time frame of this review for sufficient information to be 
provided that would have enabled meta-analysis of outcomes for the 800 mg/day dose 
of imatinib. This evidence may have enabled more robust estimates of survival following 
dose escalation to 800 mg/day. However, the data would still be prone to bias (being taken 
from data from a non-randomised patient population) and uncertainty surrounding other 
parameters (e.g. BSC, sunitinib and imatinib at 600 mg/day) would still be likely to make the 
model difficult to interpret.
  ■ Following progression, the proportion of patients subsequently progressing on escalated 
doses, who are kept on the study drug on the basis that progression of disease might be 
slower than if the patient were to be taken off the drug, is not known. It is also not clear 
whether there is a standard dose used for this purpose. Within the economic model it has 
been assumed that this would be the case (400 mg/day).
  ■ This review only considered drug treatments that were licensed for patients with GISTs 
and did not consider other drugs that may be being used in the treatment of GISTs, or 
licensed drugs that are being used ‘off licence’ to treat GIST (e.g. imatinib at doses exceeding 
800 mg/day, or sunitinib provided in a continuous daily dosing regime).
  ■ Surgical interventions were also not considered even though surgery is an important 
treatment option for GIST patients, and even though those with unresectable disease may be 
eligible for surgery if their tumours become resectable following treatment with an escalated 
dose of imatinib. The role of emergency surgery as part of BSC was also not considered.
The economic model has also not considered three main areas of uncertainty due to lack of data:
  ■ alternative assumptions about how probabilities of death and response change over time
  ■ reductions in utility associated with side effects of treatment
  ■ impact on cost-effectiveness for people with different gene mutations.
The impact of making alternative assumptions about how probabilities for death and response 
change is unknown but it is anticipated that the assumption of constant probabilities over time 
will exaggerate estimated life expectancy (and hence QALYs and cost) for all pathways. The net 
impact on relative cost-effectiveness is unclear as it depends upon the magnitude of any changes 
in both costs and QALYs that might occur.
A further uncertainty is the probability of death for BSC. No studies for this comparator met the 
inclusion criteria for the review. The only sources available for this parameter were from studies 
published in the pre-imatinib era where the population could not have been exposed to a prior 
400 mg/day dose of imatinib, and the proportion of the study populations with KIT-positive © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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GIST was not known. With regard to the impact of this uncertainty on the economic model, it 
is reasonable to assume that if, for example, there was an increase in mortality for BSC, the costs 
and QALYs associated with each of the pathways would fall because BSC is included within 
each pathway.
The net impact of adjusting utility scores for side effects is also uncertain but it might be expected 
that it will reduce the QALYs associated with each medication and, although there are limited 
data available from the systematic review of effectiveness, this reduction may be greater for 
pathways involving sunitinib because its side effect profile is believed to be worse than that 
of imatinib.
A further factor not considered by the economic model was the cost-effectiveness of treating 
patients with specific gene mutations. Again this was not addressed owing to lack of data.
No studies looking at plasma monitoring met our inclusion criteria, but its potential, along 
with that of mutation testing, as an early predictor of the need for escalated imatinib dosing 
may have implications for both the costs and effects of escalated doses, because it may allow 
the identification of those people who are expected to respond better to escalated doses quickly 
and hence they may be given escalated doses immediately rather than waiting for progression 
to occur at the 400 mg/day dose. If either of these practices become widely adopted within the 
NHS then the evidence on the effect of imatinib dose escalation following progression at the 
standard 400 mg/day dose will become less relevant to clinical practice. Should mutation testing 
and plasma monitoring allow the tailoring of dose escalation then we might expect the benefits 
to those who receive therapy to be increased, particularly at earlier stages of treatment (although 
this also means that there may be fewer remaining treatment options following failure at the 
escalated dose). Costs would also increase owing to both the cost of mutation testing or plasma 
monitoring, and also the costs of escalated doses that are incurred earlier. The net impact of this 
on cost-effectiveness is unclear.
Finally, the economic evaluation has assumed that patients who move on to BSC still receive 
medication to prevent tumour flare. This has the impact of increasing the cost of BSC. It is further 
assumed that there is no impact on effectiveness (the implicit assumption is that discontinuing 
the medication would reduce life expectancy). Within the analysis it has been assumed that all 
patients on BSC or moving on to BSC after failing to respond to a medication would receive 
imatinib 400 mg/day. This assumption appears reasonable for Path-1, BSC only, but may not be 
appropriate for the other pathways where patients would move on to BSC after failing to respond 
to an escalated dose of imatinib, or on sunitinib. Should these patients continue with the last 
active medication that they received then costs, and incremental costs per QALY, would increase.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Chapter 8  
Conclusions
Implications for service provision
  ■ There was very limited evidence available from very few studies on the effects of escalated 
doses of imatinib 600 mg/day and 800 mg/day or treatment with sunitinib for people with 
unresectable and/or metastatic GIST, whose disease had progressed on the 400 mg/day dose. 
The evidence that was available was essentially observational in nature and subject to the 
biases associated with such data, consisting mostly of reporting of subgroups of patients in 
RCTs that were not designed to assess the effects of dose escalation.
  ■ The limited evidence base suggests that around one-third of patients with unresectable 
and/or metastatic GIST who have failed on a dose of 400 mg/day may show response or SD 
with escalated doses of imatinib, and those who do respond may have a reasonable chance 
of maintaining this response over a longer period of time than would otherwise have been 
the case.
  ■ For all patients receiving either dose-escalated imatinib or sunitinib, the median OS, where 
reported, was < 2 years.
  ■ There is a need to interpret all results from the economic model with caution owing to 
the limitations of the evidence base. The results themselves indicate that should society’s 
threshold for willingness to pay be less than £25,000 per QALY a pathway of BSC only has 
the highest probability of being cost-effective. Between a threshold of £25,000 and £45,000 
provision of an escalated dose of imatinib would be most likely to be cost-effective. Above 
a threshold of £45,000 a pathway of escalated doses of imatinib followed by sunitinib, if 
necessary, would be most likely to be cost-effective.
  ■ In terms of policy-making, the results of this review and economic model show that the 
current evidence available on the effectiveness of imatinib dose escalation for GIST patients 
following progression on the standard 400 mg/day dose is characterised by such a high 
degree of uncertainty that, in the authors’ opinion, it would be inappropriate to conclude that 
dose escalation of imatinib would be a cost-effective strategy for the NHS.
Recommendations for research
Further evidence is needed in order to provide a comprehensive assessment of the effectiveness 
and cost-effectiveness of the alternative treatments for patients with GIST who fail on or become 
resistant to imatinib 400 mg/day. Ideally, such data would come from RCTs involving patients 
who progress on 400 mg/day of imatinib, where patients are randomised to 600 mg/day imatinib, 
800 mg/day imatinib or sunitinib, or to remain on 400 mg/day imatinib. However, such a study 
may be difficult to organise, as neither patients nor practitioners may be in equipoise. Dose 
escalation appears to be used within the NHS already and hence health-care professionals may 
not find it acceptable that their patients could be randomised to ‘BSC’. Therefore, alternative 
quasi-experimental or observational designs should be considered but with sufficient focus on 
understanding and controlling for selection biases.
The pathways most likely to be cost-effective at thresholds society might be willing to pay and 
hence potentially the most useful to assess would be dose escalation with imatinib and dose 68 Conclusions
escalation with imatinib followed by sunitinib if necessary. Such studies should as a matter of 
course include an economic evaluation and measurement of health-state utilities (where there is 
currently a dearth of evidence for each of the relevant health states for GIST patients), and would 
need to measure outcomes over a sufficiently long time period to capture the main impact on 
costs and outcomes. Where possible further studies should also report outcomes for subgroups of 
patients with specific KIT mutations.
With respect to costs, should further comparative studies be conducted, estimates of the usage 
of health services might usefully be collected. A wider perspective on the consideration of costs 
might also be informative, for example costs that fall on PSS (which would be relevant for NICE 
to consider) and costs for patients and their families (which goes beyond NICE’s reference case).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 1  
Search strategies
MEDLINE (2000 – September, week 3, 2009), EMBASE (2000–9, 
week 39), MEDLINE In-Process (25 September 2009)
Ovid Multifile Search URL: https://shibboleth.ovid.com/
1.  Gastrointestinal Stromal Tumors/use mesz
2.  Gastrointestinal Stromal Tumor/use emez
3.  gastrointestinal neoplasms/use mesz
4.  exp digestive system tumor/use emez
5.  gist.tw
6.  ((gastro$or gastric) adj3 stromal).tw.
7.  (3 or 4) and (kit or cd117 or cd 117).tw.
8.  (3 or 4) and (stromal or connective or mesenchymal).tw.
9.  or/1-2,5-8
10.  imatinib.tw,rn.
11.  gleevec.tw,rn.
12.  glivec.tw,rn.
13.  (sti571 or sti 571).tw,rn.
14.  or/10-13
15.  sunitinib.tw,rn.
16.  sutent.tw,rn.
17.  (su11248 or su 11248).tw,rn
18.  or/15-17
19.  dt.fs
20.  9 and 19
21.  20 not (14 or 18)
22.  Palliative Care/
23.  ((palliative or support$) adj3 (care or treatment)).tw.
24.  (symptom$adj3 control$).tw.
25.  or/21-24
26.  9 and 14
27.  9 and 18
28.  9 and 25
29.  or/26-28
30.  exp clinical trial/
31.  randomized controlled trial.pt.
32.  controlled clinical trial.pt.
33.  randomization/use emez
34.  randomi?ed.ab.
35.  placebo.ab.
36.  drug therapy.fs.
37.  randomly.ab.
38.  trial.ab
39.  groups.ab.
40.  or/30-3982 Appendix 1
41.  comparative study/use mesz
42.  follow-up studies/use mesz
43.  time factors/use mesz
44.  Treatment outcome/use emez
45.  major clinical study/use emez
46.  controlled study/use emez
47.  clinical trial/use emez
48.  (preoperat$or pre operat$).mp. use mesz
49.  (chang$or evaluat$or reviewed or baseline).tw
50.  (prospective$or retrospective$).tw. use mesz
51.  (cohort$or case series).tw. use mesz
52.  (compare$or compara$).tw. use emez
53.  or/41-52
54.  29 and (40 or 53)
55.  animals/not (humans/and animals/)
56.  nonhuman/not (human/and nonhuman)
57.  54 not (55 or 56)
58.  remove duplicates from 57
59.  limit 58 to yr=“2000 -Current”
SCI (2000 – 26 September 2009), BIOSIS (2000 – 24 September 
2009), ISI Proceedings (2000 – 26 September 2009)
Web of Knowledge URL: http://wok.mimas.ac.uk/
#1 ts=gist
#2 ts=((gastric or gastro*) SAME stromal)
#3 ts=((gastric or gastro*) AND (KIT or cd117 or cd 117))
#4 ts=((gastic or gastro*) and mesenchymal)
#5 #1 OR #2 OR #3 OR #4
#6 ts=(imatinib or gleevec or glivec or sti571 or sti 571)
#7 #5 AND #6
#8 ts=(sunitinib or sutent or su11248 or su 11248)
#9 #5 AND #8
#10 ts=(palliative same (care or treatment))
#11 #5 AND #10
#12 ts=(support* SAME (care or treatment))
#13 #5 AND #12
#14 ts=(symptom* SAME control*)
#15 #5 AND #14
#16 #15 OR #13 OR #11 OR #9 OR #7
#17 #16 CPCI-S Timespan=2000–2009
CINAHL (September 2009)
EBSCOhost URL: http://web.ebscohost.com/
S1 (MH “Gastrointestinal Neoplasms+”)
S2 TX gastric or gastro*
S3 S1 OR S2
S4 TX (stromal or connective or mesenchymal)
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S6 TX kit or cd117 or cd 117
S7 S3 and S6
S8 S5 or S7
S9 TX gist
S10 (S8 or S9)
S11 TX (imatinib or gleevec or glivec or sti571 or sti 571)
S12 S10 and S11
S13 TX (sunitinib or sutent or su11248 or su 11248)
S14 S10 and S13
S15 (MH “Palliative Care”)
S16 (MH “Hospice and Palliative Nursing
S17 TX (palliative N3 care) OR (palliative N3 treatment)
S18 TX (support* N3 care) OR (support* N3 treatment)
S19 TX (symptom* N3 control*)
S20 (S15 or S16 or S17 or S18 or S19)
S21 S10 and S20
S22 S12 OR S14 OR S21
Cochrane Library Issue 3, 2009 [Cochrane Central Register of 
Controlled Trials (CENTRAL) and CDSR]
URL: www3.interscience.wiley.com/cgi-bin/mrwhome/106568753/HOME
#1 MeSH descriptor Gastrointestinal Stromal Tumors, this term only
#2 (gist)
#3 (gastric or gastro*) NEAR/3 stromal
#4 MeSH descriptor Gastrointestinal Neoplasms explode all trees
#5 (kit or cd117 or cd 117) or (stromal or connective or mesenchymal)
#6 (#4 AND #5)
#7 (#1 OR #2 OR #3 OR #6)
#8 (imatinib or gleevec or glivec or sti571 or sti 571) or (sunitinib or sutent or su11248 or 
su 11248)
#9 (#7 AND #8)
#10 Any MeSH descriptor with qualifier: DT
#11 (#7 AND #10)
#12 MeSH descriptor Palliative Care, this term only
#13 (symptom* NEAR/3 control*) or (palliative NEAR/3 (care or treatment)) or (support* 
NEAR/3 (care or treatment))
#14 (#7 AND (#12 OR #13))
#15 (#9 OR #11 OR #14)
DARE and HTA Databases (October 2009)
NHS Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/
welcome.htm
# 1 MeSH Gastrointestinal Stromal Tumors EXPLODE 1 2 3
# 2 gist
# 3 (gastric OR gastro*) AND (kit OR cd117 OR cd AND 117)
# 4 (gastric OR gastro*) AND (stromal OR connective OR mesenchymal)
# 5 #1 or #2 or #3 or #4
# 6 (imatinib OR gleevec OR glivec OR sti571 OR sti AND 571)84 Appendix 1
# 7 #5 and #6
# 8 (sunitinib OR sutent OR su11248 OR su AND 11248)
# 9 #5 and #8
# 10 MeSH Palliative Care EXPLODE 1 2
# 11 palliative
# 12 #5 and (#10 or #11)
# 13 #7 or #9 or #12
Health Management Information Consortium (September 2009)
Ovid Multifile Search URL: http://gateway.ovid.com/athens
1.  gist.tw.
2.  ((gastro$or gastric$) adj3 stromal).tw.
3.  gastrointestinal cancer/94
4.  3 and (kit or CD117 or cd 117).tw.
5.  3 and (stromal or connective or mesenchymal).tw.
6.  or/1–2,4–5
Clinical Trials (September 2009)
URL: http://clinicaltrials.gov/ct/gui/c/r
“GIST”:Topic
CCT (September 2009)
URL: www.controlled-trials.com/
Gastro% stromal OR GIST
WHO International Clinical Trials Registry Platform (ICTRP) 
(September 2009)
URL: www.who.int/ictrp/en/
Gastro% stromal OR GIST
Clinical Study Results Database (September 2009)
URL: www.clinicalstudyresults.org/
Sutent and GIST
Gleevec and GIST
Glivec and GIST
Association of the British Pharmaceutical Industry (ABPI) 
(September 2009)
URL: www.cmrinteract.com/clintrial
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International Federation of Pharmaceutical Manufacturers & 
Associations (IFPMA) (September 2009)
URL: http://clinicaltrials.ifpma.org
Sutent or gleevec or glivec
Conference proceedings
American Society of Clinical Oncology
Annual Meeting, Chicago, 1–5 June 2007.
Annual Meeting, Chicago, 30 May to 3 June 2008.
Annual Meeting, Orlando, 29 May to 2 June 2009.
European Society for Medical Oncology
9th World Congress on Gastrointestinal Cancer, Barcelona, 28 June to 1 July 2007.
10th World Congress on Gastrointestinal Cancer, Barcelona, 25–28 June 2008.
33rd Congress, Stockholm, 12–16 September 2008.
European Cancer Organisation
ECCO 14: European Cancer Conference, Barcelona, 22–27 September 2007.
ECCO 15: European Cancer Conference, Berlin, 24–29 September 2009.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 2  
Full-paper screening tool
Escalated dose of imatinib for patients with gastro intestinal stromal tumours 
Assessor initials:        Date:       
Study identifier (Surname of first author + year of 
publication) 
 
 
Yes 
 
Unclear 
 
No 
     
Type of study 
Is the study an RCT in which all participants are randomised to imatinib, 
sunitinib or best supportive care (either provided in addition to imatinib or 
sunitinib or as only care)? 
OR 
Is the study a non-randomised comparative study on patients using either 
imatinib or sunitinib or best supportive care? 
OR 
Is the study case series or case study of more than one patient on same type of 
diagnosis? 
Go to next 
question 
Exclude 
 
Yes 
 
Unclear 
 
No 
            
 
                                    
                     
Participants in the study 
Does the study contain participants with KIT (CD117) positive unresectable 
and/or metastatic malignant gastrointestinal stromal tumours (GIST)? 
 Unresectable 
 Metastatic 
Does the study state that disease has progressed on treatment with imatinib at a 
dose of 400 mg/day?              Yes           No 
Go to next 
question 
Exclude 
 
Yes 
 
Unclear 
 
No 
                                                                     
Doses and other comparisons  
Does the study contain at least one group using escalated doses of imatinib 
(600mg or 800mg per day)? 
OR 
Does the study contain at least one group using sunitinib within its 
recommended dose range (i.e. 25-75 mg/day)? 
OR 
Does the study contain at least one group receiving best supportive care  
 
Go to next 
question 
Exclude 
 
Yes 
 
Unclear 
 
No 
                                                                     
Outcomes reported 
Does the study report any one of the following outcomes? 
 Overall response  
 Overall survival 
 Disease-free survival 
 Progression-free survival 
 Time to treatment failure 
 Health-related quality of life   
 Adverse effects of treatment 
 
Go to next 
question 
Exclude 88 Appendix 2
Include 
 
Unclear 
 
Exclude 
 
Decision 
 
 
Clarification 
required 
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Appendix 3  
Data extraction form90 Appendix 3
Reviewer ID:             Date:        
 
Administration Details for Study 
 
Study Design: 
 
 - RCT  
 
 - Crossover study 
 
 - Non-randomised comparative study 
 
 - Prospective case series 
 
 - Registry-based study 
 
 
 
Study ID:       
(Surname of 1
st Author and Year of Publication) 
 
 
Possibly related studies in this review:       
 
 
Multicentre Study:  
Yes. Number of centres ________ 
No. 
 
 
Country/countries:       
 
 
Funding Details: 
Government  
Private  
Manufacturer  
Other (specify):       
 
 
Additional Info:       
 
 
 
Duration of Study:       
 
 
 
Study start/end dates:       
 
 
 
Length of follow up:       
Aim of Study 
 
      
 
 
 
Interventions investigated 
 
Interventions: 
 
 
 - Imatinib at 600 mg per day 
 
 
 
 - Imatinib at 800mg per day 
 
Comparators: 
 
 
 - Sunitinib (specify dose):       
 
 
 
 - Best supportive care, defined as:       
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Outcomes Reported 
Outcome:  Tool Used in Assessment/Outcome defined as: 
 - Overall response 
 
      
 
 - Overall survival 
 
      
 
 - Disease free survival 
 
      
 
 - Progression-free survival 
 
      
 
 - Time to treatment failure 
 
      
 
 - Health-related quality of life 
 
      
 
 - Adverse effects of treatment 
 
      
 
Inclusion Criteria 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion Criteria 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 92 Appendix 3
Characteristics of Participants 
Characteristic  Intervention 1  Comparator 1  Comparator 2  All 
Enrolled                             
Randomised                             
Analysed                             
Number lost to follow up                             
Age (mean/median, 
SD/IQR/range)       
                           
Sex:  F:       
M:       
F:       
M:       
F:       
M:       
F:       
M:       
Stage of disease: 
 - Unresectable 
 - Metastatic 
 - Recurrent 
 - Advanced 
No (%) at stage: 
      
      
      
No (%) at stage: 
      
      
      
No (%) at stage: 
      
      
      
No (%) at stage: 
      
      
      
Mutations of c-KIT present: 
 
 - exon 9 
 - exon 11 
 - exon 13 
 - exon 17 
No (%) with 
mutation 
      
      
      
      
No (%) with 
mutation 
      
      
      
      
No (%) with 
mutation 
      
      
      
      
No (%) with 
mutation 
      
      
      
      
Previous imatinib use: 
 
      mg/day 
      mg/day 
      mg/day 
 
No (%) on this 
dose 
      
      
      
 
No (%) on this 
dose 
      
      
      
 
No (%) on this 
dose 
      
      
      
 
No (%) on this 
dose 
      
      
      
 
Used imatinib at       mg/day 
as: 
 - neoadjuvant treatment 
 - adjuvant treatment 
 
No (%) affected 
 
      
      
No (%) affected 
 
      
      
No (%) affected 
 
      
      
No (%) affected 
 
      
      
 
Number/proportion of KIT positive patients (if not 100%):       
 
Method of GIST diagnosis (if specified):       
 
Method used to determine progression/response:  
 - CT scan 
 - FDG – PET scan 
 
 
Additional Information on Participants 
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Interventions  
Description of intervention 
(e.g. dose, number of times 
taken per day, care provided 
etc) 
Intervention 1  Comparator 1  Comparator 2  All 
 
 
 
 
 
 
 
 
 
 
 
       
Results 
Outcome: 
 
Intervention 1  Comparator 1  Comparator 2  All 
Overall Response 
 
 
 
                           
Overall Survival 
 
 
 
                           
Disease-free survival 
 
 
 
                           
Progression-free survival 
 
 
 
                           
Time to treatment failure 
 
 
 
                           
Health-related QoL 
 
 
 
 
                           
Adverse Events 
General Information on Adverse Events: 
 
 
 
 
 94 Appendix 3
Adverse Events Reported  Intervention 1  Comparator 1  Comparator 2  All 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
Additional Study Information 
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Appendix 4  
Quality assessment tool
TABLE 22  Quality assessment tool for non-randomised studies (comparative studies and case series)a
Criteria Yes No Unclear Comments
Participants: sample definition and selection
1.  Were participants a representative sample selected from a relevant patient 
population? 
2.  Were the inclusion/exclusion criteria of participants clearly described?
3.  Were participants entering the study at a similar point in their disease 
progression?
4.  Was selection of patients consecutive?
5.  Was data collection undertaken prospectively?
6.  Were the groups comparable on demographic characteristics and clinical 
features?
Intervention
7.  Was the intervention (and comparison) clearly defined?
8.  Was the intervention undertaken by someone experienced at performing the 
procedure?
9.  Were the staff, place and facilities where the patients were treated 
appropriate for performing the procedure? (e.g. access to back-up facilities)
Outcome measures
10. Were all the important outcomes considered?
11. Were objective (valid and reliable) outcome measure/s used?
12. Was the assessment of main outcomes blind?
Follow-up
13. Was follow-up long enough to detect important effects on outcomes of 
interest?
14. Was information provided on non-respondents, dropouts?
15. Were participants lost to follow-up likely to introduce bias? (e.g. high drop-
out rate; differential dropout; no description of those lost)
16. Was length of follow-up similar between comparison groups?
Analysis
17. Were important prognostic factors identified?
18. Were the analyses adjusted for confounding factors?
a  Items specific to comparative studies are in italic text.96 Appendix 4
TABLE 23  Checklist for quality assessment at trial entry if study itself is randomised
Quality criteria Yes No Unclear Comments
1.  Was the allocation sequence adequately generated? (RevMan5, selection bias)
  ■ Yes = adequate, e.g. random number table, use of computer random number 
generator, shuffling cards or envelopes
  ■ No = inadequate, e.g. use of alternation, case record numbers, birth dates, 
date of admission
  ■ Unclear = insufficient information to permit judgement of yes or no
2.  Was allocation adequately concealed? (quality of random allocation 
concealment)
  ■ Yes (adequate, A) = good attempt at concealment; method should not allow 
disclosure of assignment (telephone randomisation, third party involvement in 
allocation procedure, etc.)
  ■ Unclear (B) = states concealment but no description given
  ■ No (inadequate, C) = definitely not concealed (open random numbers tables 
or quasi-randomised, e.g. day of week, date of birth, alternation) or an 
attempt at concealment but real chance of disclosure of assignment prior 
to formal entry (envelopes without third party involvement, random numbers 
table but procedures not described)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 5  
Information on the reasons for 
exclusion
Resectable GIST (n = 24)
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imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer 
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Plain English summary
Gastrointestinal stromal tumours (GISTs) are a rare type of cancerous tumours that most 
commonly arise in the stomach or small intestine. People will be diagnosed with this type of 
cancer only if a biopsy of their tumours tests positive for a particular protein (called ‘KIT’ or 
‘CD117’). In around half of all cases it is possible to remove the tumour surgically; however, 
overall at least 50% of those operated on will develop recurrent disease within 5 years. In these 
patients with recurrence, and other patients with inoperable disease at diagnosis, survival beyond 
a period of 2 years is uncommon without further treatment. The usual treatment for patients 
with inoperable GISTs is the drug imatinib, prescribed at a dose of 400 mg per day. Over 75% 
of patients will show either response or stable disease (SD) with the standard dose of imatinib, 
which typically provides control of the GISTs for a period of 2–3 years. Approximately 50% of 126 Appendix 7
patients will survive 5 years or more with this treatment. However, in all patients, resistance of the 
GISTs to imatinib will eventually occur and the disease will then progress. Genetic differences, 
for example whether certain mutations in the c-KIT or CD117 gene are present in patients or 
not, may help clinicians’ understanding of who is more likely to be able to tolerate the drug and/
or have least resistance to it. Fluorodeoxyglucose-positron emission tomography (FDG-PET) 
scans may also be useful to detect early response or resistance to imatinib and these measures 
may allow more individualised treatment approaches. At present, increasing the dose of imatinib, 
when 400 mg per day ceases to improve a patient’s condition, is not officially recommended 
(although in practice it is usually tried). An alternative drug (sunitinib) is recommended to be 
prescribed in cases where imatinib has failed. The only other alternative to these treatments for 
patients with inoperable GISTs is to provide BSC through management of the patient’s pain and 
other symptoms, and attend to their needs and general well-being, without providing treatment 
to actively fight the cancer itself. However, in reality it is likely that all patients (including those 
receiving active treatment) will receive supportive care as part of this treatment.
This review will look at two alternative doses of imatinib (600 and 800 mg per day) and compare 
these with the current recommended treatment alternatives (i.e. sunitinib and/or BSC) for those 
patients with inoperable GISTs whose disease progresses while on imatinib at a dose of 400 mg 
per day.
Decision problem
Gastrointestinal stromal tumours are tumours of the connective tissue of the gastrointestinal 
(GI) tract arising in the interstitial cells of Cajal. They are rare cancers and estimated to account 
for 1% of all tumours arising in the GI tract.1 It is estimated that the vast majority (between 60% 
and 70%) will arise in the stomach, though they can also occur in the small bowel (25–35%), 
colon and rectum (5%), and, to a lesser extent, the oesophagus.2 Estimates of the number of 
people affected by GIST vary, but it is thought that the annual incidence is unlikely to exceed 
240.3 However, previous estimates have suggested that it could be as high as 2000 cases per year.3 
The median age at time of first presentation is approximately 60 years.4 Prognosis for patients 
with GISTs is highly dependent on the resectability of the tumour and approximately half of 
patients with GISTs will have resectable disease at first presentation. GISTs are resistant to the 
‘conventional’ oncology treatments of cytotoxic chemotherapy and radiotherapy. For resectable/
non-metastatic tumours, prognosis gives a 10-year survival rate of 30–50% of patients, and 
at least 50% will relapse within 5 years,5 but for unresectable tumours prognosis is poor, with 
survival generally < 2 years without further treatment.6
For a GIST to be diagnosed, it is widely accepted that a positive test result (at protein level) for 
the marker KIT (CD117) is required. KIT (CD117) is a tyrosine kinase receptor that provides a 
major pathogenic drive for the majority of GISTs by promoting tumour growth and inhibiting 
tumour cell death. There has been some debate on the definition of a GIST, as it has been noted 
that in extremely rare cases (< 5%) a patient can have a GIST despite testing negative for c-KIT 
protein expression and in most of these cases a mutation of the platelet-derived growth factor 
receptor alpha (PDGFRA) gene has been detected.7–9 However, the World Health Organization 
(WHO) classification of GI tumours recommends that a diagnosis of GIST should only apply to 
those patients testing positive for the KIT (CD117) protein.10
Imatinib is manufactured by Novartis under the names Glivec (in Europe) and Gleevec (in the 
USA). Having originally been licensed as a treatment for chronic myeloid leukaemia, it was first © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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licensed for treatment of GIST in 2002 and is now the standard first-line treatment for ‘locally 
advanced, inoperable patients and metastatic patients’ with GIST.11 The 2004 National Institute 
for Health and Clinical Excellence (NICE) Technology Appraisal no. 86 on the use of imatinib for 
the treatment of unresectable and/or metastatic GISTs recommends 400 mg per day as first-line 
management. At present the NICE guidance does not recommend dose escalation of imatinib 
for those whose disease progresses after initially responding at the 400 mg per day dose, although 
dose escalation has been noted to be the standard approach to disease progression where patient 
non-adherence or intolerance to imatinib are not factors in disease progression.11
The alternative treatments available for unresectable and/or metastatic GISTs are sunitinib 
(manufactured by Pfizer) and best supportive care (BSC). Sunitinib is recommended for patients 
with unresectable and/or metastatic GISTs if treatment with imatinib has failed because of 
resistance or intolerance, and the drug cost for the first treatment cycle will be met by the 
manufacturer.12 BSC is less well defined or standardised in different clinical trials or treatment 
protocols, and has also been referred to as ‘active symptom control’.2 It has been said to involve 
interventions to manage pain, treat fever, anaemia (due to GI haemorrhage) and GI obstruction,1 
and can include palliative measures.13 In a Cochrane review of supportive care for patients with 
GI cancer, supportive care was defined as ‘the multi-professional attention to the individual’s 
overall physical, psychosocial, spiritual and cultural needs’.14 It was argued that this type of care 
should ethically be made available to all treatment groups, meaning that in practice for patients 
with GISTs, treatment with imatinib or sunitinib would not be provided without supportive care 
as well, though it is possible that treatment with BSC could be provided without additional drug 
treatment with either imatinib or sunitinib.
The survival of patients with GISTs is largely dependent on whether or not the tumour is 
resectable. For patients with unresectable and/or metastatic disease, the treatment options are 
imatinib, sunitinib or BSC. Guidance is available on the effectiveness of imatinib at the 400 mg 
per day dose.1 However, assessment is required of the clinical effectiveness of imatinib at higher 
dosages (i.e. 600 and 800 mg per day) in patients whose disease has progressed on treatment 
with the 400 mg dose, given that an estimated 16% of patients will experience primary resistance 
to imatinib, and all will develop resistance and progressive disease (PD) at a later stage.15 In 
evaluating the effectiveness of escalated doses of imatinib or other alternate treatments it is 
also necessary to consider subgroups of patients with specific KIT mutations who may respond 
differently to treatment, and also note how rapidly, and by what method (e.g. FDG-PET scans), 
these patients were identified.
This review will assess the clinical effectiveness and cost-effectiveness of imatinib at escalated 
doses of 600 mg per day, and 800 mg per day, compared with treatment using sunitinib, or BSC, 
in patients with KIT (CD117)-positive unresectable and/or metastatic malignant GISTs, whose 
disease has progressed on treatment with imatinib at a dose of 400 mg per day.
Report methods for synthesis of evidence of clinical 
effectiveness
A systematic review of the evidence of the clinical effectiveness of imatinib at escalated doses 
of 600 or 800 mg per day will be undertaken following the general principles of the guidance of 
the Centre for Reviews and Dissemination (CRD) for undertaking reviews in health care16 and 
reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement.17128 Appendix 7
Inclusion and exclusion criteria
Types of studies
The types of studies considered will be randomised controlled trials (RCTs), non-randomised 
comparative studies and case series. If the number of studies meeting our inclusion criteria is 
sufficiently large, we may consider limiting them by type of study design and taking into account 
the importance of other factors, such as sample size.
Scoping searches have already been conducted and fewer than 40 potentially relevant studies 
were found looking specifically at either of the named interventions (i.e. imatinib at 600 or 
800 mg per day).
Population
The population considered will be people with KIT (CD117)-positive unresectable and/or 
metastatic malignant GISTs, whose disease has progressed on treatment with imatinib at a dose 
of 400 mg per day.
If there is sufficient evidence, subgroup analysis will be undertaken for those patients with 
different mutations of CD117 that are likely to affect their response to escalated doses of imatinib. 
Data will also be recorded on the methods used to identify response or resistance (e.g. FDG-PET 
or CT scanning), and whether or not imatinib had been prescribed in a neoadjuvant or adjuvant 
setting for patients with previously resectable GIST.
Intervention
The intervention considered will be imatinib at escalated doses of 600 and 800 mg per day, being 
prescribed in addition to BSC.
Comparators
The comparators considered will be sunitinib, prescribed within its recommended dose 
range of 27–75 mg, and provided with BSC, and BSC only. BSC has been defined above (see 
Decision problem).
Outcomes
The following outcomes will be considered:
  ■ overall response
  ■ overall survival (OS)
  ■ disease-free survival
  ■ progression-free survival (PFS)
  ■ time to treatment failure
  ■ health-related quality of life (HRQoL)
  ■ adverse effects of treatment.
Exclusion criteria
We will exclude the following types of studies:
  ■ animal models
  ■ preclinical and biological studies
  ■ reviews, editorials, opinions
  ■ case reports
  ■ reports investigating technical aspects of the intervention.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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In addition, we may consider excluding non-English language papers, and/or reports published 
as meeting abstracts, if the evidence base containing English language and/or full-text reports is 
sufficiently large.
Search strategy
Extensive sensitive electronic searches will be conducted to identify reports of published and 
ongoing studies on the clinical effectiveness of imatinib. The searches will also be designed to 
retrieve clinical effectiveness studies of the comparator treatments. Databases to be searched 
will include: MEDLINE, MEDLINE In-Process, EMBASE, Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Science Citation Index (SCI), BIOSIS, Health Management 
Information Consortium, and the Cochrane Controlled Trials Register for primary research and 
the Database of Abstracts of Reviews of Effects (DARE), the Cochrane Database of Systematic 
Reviews (CDSR) and the HTA database for relevant evidence synthesis.
A preliminary MEDLINE search strategy is provided in the appendix* and will be adapted for use 
in the other databases. Current research registers, including Clinical Trials, Current Controlled 
Trials, UK Clinical Research Network Study Portfolio, WHO International Clinical Trials 
Registry Platform, International Federation of Pharmaceutical Manufacturers & Associations 
Clinical Trials and the Association of the British Pharmaceutical Industry (ABPI) database will 
be searched to identify ongoing and recently completed trials. Recent conference proceedings of 
key oncology and GI organisations will also be screened and will include the American Society 
for Clinical Oncology, the International Society of Gastrointestinal Oncology, and the National 
Cancer Research Institute.
In addition, an Internet search using copernic agent will be undertaken, and will include 
the websites of key professional organisations, GIST Support International, and the drug 
manufacturers Pfizer and Novartis.
There will be no language restriction and all databases will be searched from 2000 onwards.
The reference lists of all identified studies and evidence syntheses, as well as submissions from 
industry and other consultees, will be checked for additional references.
Data extraction strategy
One reviewer will screen the titles (and abstracts if available) of all reports identified by the 
search strategy. Full-text copies of all studies deemed to be potentially relevant will be obtained, 
and two reviewers will independently assess them for inclusion. Any disagreements will be 
resolved by consensus or arbitration by a third party.
A data extraction form will be developed and piloted. One reviewer will extract details of study 
design, participants, intervention, comparator and outcomes. A second reviewer will check the 
data extraction. Any disagreements will be resolved by consensus or arbitration by a third party.
Quality assessment strategy
Two reviewers will independently assess the methodological quality of the included studies. Any 
disagreements will be resolved by consensus or arbitration by a third party. Studies will not be 
included or excluded on the basis of methodological quality.
Randomised controlled trials will be assessed using the Cochrane Collaboration’s tool for 
assessing risk of bias.18 The tool addresses six specific domains: sequence generation, allocation 
concealment, blinding, incomplete outcome data, selective outcome reporting and ‘other issues’. 
* Protocol appendices were not provided but are available from the authors on request.130 Appendix 7
Non-randomised comparative studies will be assessed using an 18-question checklist, with 
the same checklist minus four questions used to assess the quality of case series. The checklist 
for non-randomised studies and case series was adapted from several sources, including the 
CRD’s guidance for those carrying out or commissioning reviews,16 Verhagen et al.,19 Downs 
and Black20 and the Generic Appraisal Tool for Epidemiology (GATE), which assesses bias 
and generalisability, sample definition and selection, description of the intervention, outcome 
assessment, adequacy of follow-up and performance of the analysis. The checklist was developed 
through the Review Body for Interventional Procedures (ReBIP). ReBIP is a joint venture 
between Health Services Research at Sheffield University and the Health Services Research 
Unit at the University of Aberdeen, and works under the auspices of the NICE Interventional 
Procedures Programme (IPP).
Methods of analysis/synthesis
For relevant outcomes from randomised studies, where appropriate, meta-analysis will be used 
to estimate a summary measure of effect. Dichotomous outcome data for the overall response 
outcome will be combined using the Mantel–Haenszel relative risk (RR) method and continuous 
outcomes will be combined using the inverse-variance weighted mean difference (WMD) 
method. For the estimates of RR and WMD 95% CIs and p-values will be calculated. Chi-squared 
tests and I2-statistics will be used to explore statistical heterogeneity across studies. Possible 
reasons for heterogeneity will be explored using sensitivity analysis. Where there is no obvious 
reason for heterogeneity, the implications will be explored using random effects methods.
Pooled weighted ratio of median survival will be derived for OS, disease-free survival and PFS. 
The hazard ratio (HR) is the most appropriate statistic for time-to-event outcomes (i.e. for time to 
treatment failure). If available, the HR will be extracted directly from the trial publications. If not 
reported the HR will be extracted from other available summary statistics or from data extracted 
from published Kaplan–Meier curves using methods described by Parmar et al.21 A pooled HR 
from available RCTs will be obtained by combining the observed (O) minus expected (E) number 
of events and the variance obtained for each trial using a fixed effects model.22 A weighted average 
of survival duration across studies will then be calculated. The chi-squared test for heterogeneity 
will be used to test for statistical heterogeneity between studies. If no RCT data are available, but 
non-randomised studies have reported relevant data for this outcome, then assessment of the risk 
of bias and heterogeneity will be undertaken using meta-regression analysis.
Data on adverse effects of treatment and quality of life (QoL) will be collected and combined, 
ideally using standardised mean difference to compare QoL, where there are available data to 
do so.
It is expected that studies with direct comparisons of the intervention and comparators are 
likely to be limited. If feasible, and appropriate where we have non-randomised evidence, 
meta-analysis models will be used to model survival rates for interventions and comparators. A 
‘cross-design’ approach will be adopted to allow non-randomised evidence to be included, while 
avoiding the strong assumption of the equivalence of studies. This approach will enable evidence 
from RCTs, non-randomised comparative studies and case series to be included.23 Differences 
between treatments for survival outcomes will be assessed by the corresponding odds ratio and 
95% credible intervals. These results will be ‘unadjusted odds ratios’, but meta-analysis models 
adjusting for study type will also be used. The results from these models will produce ‘adjusted’ 
odds ratios using winbugs software.24
If appropriate, and where there are sufficient data to do so, we will consider using a mixed-
treatment comparison model for indirect comparisons.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Where a quantitative synthesis is considered to be inappropriate or not feasible, a narrative 
synthesis of results will be provided.
Report methods for synthesising evidence of cost-effectiveness
Economic evaluation
The economic impact of GISTs for the UK NHS is associated with its incidence rate, and the 
proportion of patients who may have unresectable disease (and the consequent resource use by 
the health systems), and burden in terms of patient outcome. Information from the work on an 
economic model for the UK, mainly from an industry submission, is based on the assumption 
that the incidence rate is 15 per million population, and 10–30% of all patients with GISTs are 
likely to have resectable disease. If these patients (between 80 and 240 people) are treated with 
imatinib, the annual drug costs per patient to the NHS have been estimated at £18,896 and 
£24,368 for patients on 400 and 600 mg per day, respectively. Other associated yearly costs with 
the treatment (including the treatment of adverse events) were estimated at £2730. The model 
estimates suggest that in 2 years it would cost the NHS £31,160 to treat a patient with imatinib, 
and in 10 years it would cost the NHS £56,146.2,25 An estimate suggests that the total yearly 
cost to the NHS (England and Wales) for treating with imatinib would be between £5.6M and 
£11.2M. The cost to the NHS would differ when patients who fail to progress with imatinib are 
provided with higher doses, or other alternative treatments (e.g. treatment with sunitinib). NICE 
estimates suggest the number of new cases of unresectable and/or metastatic GISTs to be around 
240 people per year.3 The economic impact of different treatment strategies needs thorough 
investigation for a robust economic evaluation.
Objectives
The aim is to assess the clinical effectiveness and cost-effectiveness of alternative treatment 
strategies for people with KIT (CD117)-positive unresectable and/or metastatic gastrointestinal 
tumours (GISTs), whose disease has progressed on treatment with imatinib at a dose of 400 mg 
per day.
The specific objectives are:
1.  To determine, by undertaking a systematic review of the literature, the clinical effectiveness 
and cost-effectiveness of using imatinib at an escalated dose of 600 or 800 mg per day to treat 
patients with GISTs (whose disease has progressed with imatinib at a dose of 400 mg per 
day), compared with treating them with sunitinib and BSC.
2.  To develop an economic model to compare the cost-effectiveness and cost–utility of use 
of imatinib at a dose of 600 or 800 mg per day, or use of sunitinib, or BSC only, for treating 
people with KIT (CD117)-positive unresectable and/or metastatic gastrointestinal tumours 
(GISTs) whose disease has progressed on treatment with imatinib at a dose of 400 mg 
per day.
The economic assessment will be a comparison of alternative treatments for people with GISTs 
whose disease has progressed despite treatment with imatinib at a dose of 400 mg per day, or 
those whose treatment with imatinib has failed owing to resistance or intolerance. The alternative 
treatments that will be considered are (1) treating with escalated doses of 600 or 800 mg per day; 
(2) treating with sunitinib (within its recommended dosage); and (3) providing BSC to manage 
symptoms. It should be noted here that BSC is often not provided exclusively. For treatment with 
imatinib, and treatment with sunitinib, it will be assumed that BSC would be provided alongside 
these treatments.132 Appendix 7
The economic assessment will be based on two components: (1) a systematic review of existing 
economic evaluations of the above alternative treatments and (2) an economic evaluation 
modelling exercise. More specifically, the economic assessment will consider alternative 
treatment strategies used for treatment of GISTs (particularly for patients whose disease has 
progressed with imatinib at a dose of 400 mg per day).
The purpose of the review of studies on economic analysis, or economic evaluation, will be to 
identify published studies and assess their quality and usefulness for comparisons of alternative 
treatment of GISTs; inform the methodology of the proposed economic model; and identify data 
on the parameters of the proposed economic model (e.g. utilities for different health states, costs 
and epidemiological data).
Data sought
With respect to costs, data will be sought to gather information on costs to the health services 
(NHS) in treating patients with GISTs and on costs to patients, in order to estimate overall 
mean costs. Specific information will also be collected on (1) the cost of treating the different 
clinical outcomes (e.g. cost of achieving total survival for patients with GISTs whose disease has 
progressed on treatment with imatinib at a dose of 400 mg per day – the base case); (2) the costs 
of maintaining patients with GISTs at a disease progression-free state for a specific period of time 
under alternative treatment strategies; and (3) the cost per life-year gained under alternative 
treatment strategies. Data will be sought on the costs associated with each alternative. For costs 
to the health services this will include, for example, the mean number of visits to the oncologist, 
number of laboratory tests and examinations, radiology examinations, the number of inpatient-
days and the costs of drugs. Costs associated with the treatment of adverse effects will be included 
within the costs of treatment under different strategies (most of the adverse effects noted in the 
literature include fatigue and fever, hypertension, GI illnesses, dermatological, haemorrhagic 
events, etc.), and data will be sought accordingly. Data on costs to patients in seeking care and for 
BSC under different strategies will also be collected.
With respect to effectiveness, data will be sought on the same outcomes (OS, disease-free survival 
or PFS, adverse effects of the treatments, time to treatment failure or time to tumour progression, 
and overall response rate) as noted in the review of effectiveness of different strategies (see 
Inclusion and exclusion criteria, above). This will aid comparison of the results of individual 
economic evaluations with pooled estimates of effectiveness. In addition to this, we will also seek 
information on the quality-adjusted life-years (QALYs) associated with each treatment strategy, 
and for different relevant health states noted.
More specifically, we will seek to identify any data on the QALY loss caused by GI cancer or 
GISTs, tumour progression, and adverse effects of the different treatment strategies.
Types of studies
Economic evaluations and cost analyses comparing the above mentioned alternative treatment 
strategies will be included. Non-UK studies will also be included provided that they report 
interventions or involve populations relevant to the scope of the study.
Search strategy for identification of published reports
A comprehensive search will be undertaken to identify studies that assess the cost or cost-
effectiveness of the alternative treatments used for GISTs. Databases to be searched will include 
MEDLINE, MEDLINE In-Process, EMBASE, SCI, Health Management Information Consortium, 
NHS EED, the HTA database, the Cost-effectiveness Analysis (CEA) Registry and the Research 
Papers in Economics (RePEc). There will be no language restriction and all databases will be 
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A preliminary MEDLINE search strategy is provided in the Appendix and will be adapted for use 
in the other databases. In addition, an Internet search using copernic agent will be undertaken 
and will include the websites of key professional organisations, GIST Support International and 
the drug manufacturers Pfizer and Novartis.
The references lists of all identified studies and evidence syntheses, as well as submissions from 
industry and other consultees, will be checked for additional potentially relevant references.
The description of how the industry submissions will be handled is described below [see 
Handling the company submission(s)].
Quality assessment
All included studies will be assessed using the guidelines of the CRD.16 Modelling studies will also 
be quality assessed against the Philips checklist.26
Report methods for synthesising evidence of cost-effectiveness
The titles and abstracts of all published reports, literature and industry submissions identified by 
the search strategy will be examined to select relevant studies. The full texts of potentially relevant 
reports, publications and industry submissions will be obtained and assessed in terms of their 
relevance to the economic evaluation or cost analysis. Data will be extracted by an economist 
according to the guidelines produced by the CRD for the critical appraisal of economic 
evaluations. Where the economic evaluation has been based on a modelling exercise, additional 
data extraction criteria developed by Philips et al. will apply.26,27
Data from the included studies on economic analysis and economic evaluation will be 
summarised in order to identify common results, and to summarise the variations and 
weaknesses between studies. The studies that use economic modelling will be critically reviewed 
with regard to, for example, model structure use, parameterisation and how these models have 
dealt with uncertainty. This critical review will assist us in developing methods that can be used 
to structure our model.
Economic modelling
Model structure
The structure of the model will be informed by the modelling studies identified as part of the 
systematic review of economic evaluations, the review of clinical effectiveness and other existing 
evidence including previous NICE TARs. We will also draw upon advice from health-care 
professional members of our research team. However, the scope of the study suggests that 
treatment strategies to be compared in the model are:
1.  Treatment of GIST patients (whose disease has progressed on treatment with imatinib at 
a dose of 400 mg per day) with an escalated dose of 600 mg per day, regulating symptoms 
with BSC.
2.  Treatment of GIST patients (whose disease has progressed on treatment with imatinib at 
a dose of 400 mg per day) with an escalated dose of 800 mg per day, regulating symptoms 
with BSC.
3.  Treatment with sunitinib (within its recommended dose range), regulating symptoms 
with BSC.
4.  Regulating symptoms with BSC only.
The model will consider the above treatment strategies as different types of intervention, and will 
consider the costs and consequences of patients following these different pathways of care. When 
building the model we will also consider whether the use of FDG-PET to predict non-response 134 Appendix 7
should be built into the model. The inclusion of this imaging technology may alter estimates 
of cost-effectiveness because (1) it is costly and (2) it may provide an early indication of non-
responders who may benefit from the early introduction of an alternative therapy.
Consideration will be given to estimating relative differences between treatments based on non-
directly comparative data, if direct evidence is not identified within the literature.
The model used will be a Markov model, where the following health states will be considered (all 
are associated with clinical effectiveness): OS, treatment failure, time to tumour progression, and 
PFS. In an earlier HTA of imatinib at a dose of 400 mg per day,2 and other studies,28 the health 
states within the economic model were (1) ‘imatinib treatment’ with different doses or ‘sunitinib 
treatment’ that stops disease progression, or at least leads to a partial response (PR); (2) PD; and 
(3) death. It is likely that the health states used in our model will be similar to these analyses, 
although the final choice will depend upon advice and also the literature as described in the 
section Economic evaluation. Where evidence is available, subgroup analysis will be undertaken 
on patients with different gene mutation types that may affect their response to escalated doses 
of imatinib.
Data requirements
For our model, data on the relative effectiveness of interventions will be based upon the 
systematic review. Resource use of the selected treatment strategies, and for baseline (patients 
whose disease has progressed on treatment with imatinib at a dose of 400 mg/day), will be 
identified from relevant sources (NHS cost data, NHS tariff), the review of economic evaluations 
and advice from experts. Data on resource use can generally be classified into different groups: 
for example, resource use in the treatment strategy of the escalated doses of imatinib, secondary 
care resource use related to secondary level of care or services other than the interventions, 
for example side effect management and other associated treatments, laboratory and other 
examinations, and resource use for other health care. Data/information on unit costs will be 
obtained from NHS national reference costs and from studies that will be identified as described 
in the section entitled Economic evaluation. Additional focused searching for relevant cost data 
will also be conducted.
A cost–utility analysis will be conducted, with outcomes estimated in terms of QALYs for 
patients, where the European Quality of Life-5 Dimensions (EQ-5D) health-state profile can 
be used from the information expected to be available from the review of economic evaluation 
studies on such treatments. Each health state of the state transition model will require a utility 
estimated using the best available data [EQ-5D, Eastern Cooperative Oncology Group (ECOG) 
category mapped to QALY]. These data will be identified from the systematic review, additional 
focused searches and routine data sources. Where necessary we may need to make assumptions 
in order to use utility values derived from different patient populations.
Time horizon for the model
The model will look at the costs and consequences directly attributable to the events occurring 
for patients with GIST (whose disease progression takes place despite treatment with imatinib 
at 400 mg per day) and treating them with alternative strategies up to the end of the patient’s 
lifetime. Although the time horizon used will be the patient’s lifetime, it is expected that this is 
unlikely to exceed 6 years (the maximum number of years patients are expected to live after they 
are diagnosed with unresectable and/or metastatic GISTs).
Analysis methods
The results of the model will be presented in terms of a cost–consequence analysis and cost–
utility analysis. The cost–consequence analysis will examine the costs and effects on natural © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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and clinical measures. The likely consequences that are expected to be included in the analysis 
would include OS and PFS. In the cost–utility analysis, results will be presented in terms of an 
incremental cost per QALY, incremental cost per OS (life-years gained) and incremental cost per 
months/year of PFS.
Where appropriate, costs and outcomes will be discounted at 3.5% for both the cost–consequence 
and cost–utility analyses.27 The economic evaluation will consider the different subgroups 
noted earlier.
Both deterministic and probabilistic sensitivity analysis will be conducted for the uncertainty 
surrounding parameters, and a net benefit framework will be used to compare the different 
treatment strategies.
Handling the company submission(s)
Information from the manufacturer will be considered if submitted in accordance with the 
3 December 2009 deadline set by NICE. Following receipt of the submission, members of the 
Aberdeen TAR team will critically appraise sections of the report according to each member’s 
own area of expertise. Studies reported in the manufacturer’s submission that meet the inclusion 
criteria for the review will be data extracted and quality assessed in accordance with the 
procedures outlined in this protocol, and included in the data analysis.
Any economic evaluations included in the company submission, provided they comply with 
NICE’s guidance on presentation, will be assessed for clinical validity, reasonableness of 
assumptions and appropriateness of the data used in the economic model, again using the 
methods outlined in this protocol. Strengths and weaknesses in terms of methodology adopted, 
reporting of results and conclusions will be described. The default position of the TAR team 
is that further modelling work will be necessary and if the TAR team judge that the existing 
economic evidence is not robust then further work will be undertaken, either by adapting what 
already exists or developing de novo modelling (as described in Economic modelling, above). The 
conclusions derived from the company submission may then be compared with those provided 
by the review of the other existing evidence and any model we develop so that differences in 
results can be highlighted. If the model we may develop differs substantively from that submitted 
by any company, we shall justify any assumptions made.
Any ‘CiC’ data taken from a company submission will be reported in accordance with 
NICE guidelines.
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Appendix 8  
Characteristics of included studies
Study ID Participants
Intervention(s) 
and comparators Outcomes summary
B2222 Blanke 200838,39
Time period: July 2000 
to May 2006
Countries involved: 2 
(Finland, USA)
No. of institutions 
involved: 4
n receiving intervention(s): 43
n receiving comparator(s): 0
Baseline characteristics: not stated
Escalated dose 
intervention(s): 
imatinib at 
600 mg/day
Comparator(s): 
NA
n (%) showing response or SD: 11/43 (25.6%)
S0033 Blanke 
200841,68,77
Time period: December 
2000 to (CiC information 
has been removed)
Countries involved: 2 
(Canada, USA)
No. of institutions 
involved: 148
n receiving intervention(s): 118
n receiving comparator(s): 0
Baseline characteristics: not stated
Escalated dose 
intervention(s): 
imatinib at 
800 mg/day
Comparator(s): 
NA
n (%) showing response or SD: 36/117 (30.8%)
Median OS: 19 months (95% CI 13 to 23 
months)
n (%) still alive at data cut-off point: 42/118 
(35.6%)
Median PFS: 5 months (2–10 months)
n (%) still progression free at data cut-off 
point: 19/118 (16.1%)
Park 200979
Time period: June 2001 
to June 2006
Countries involved: 1 
(Republic of Korea)
No. of institutions 
involved: 1
n receiving intervention: 24
n receiving comparator(s): 0
Baseline characteristics:
Age:
Median, years (range): 52 (31–73)
Sex:
n (%) male: 18 (75.0%)
n (%) female: 6 (25.0%)
ECOG performance status:
0: 4 (16.7%)
1: 18 (75.0%)
2: 2 (8.3%)
Primary tumour site:
Stomach: 5 (20.8%)
Small bowel: 15 (62.5%)
Colon or rectum: 3 (12.5%)
Omentum: 1 (4.2%)
n receiving previous treatment of:
Surgery: 20 (83.3%)
Conventional chemotherapy: 3 (12.5%)
Radiofrequency ablation: 1 (4.2%)
Transarterial chemoembolization: 1 (4.2%)
Site(s) of metastases at time of dose 
escalation:
Liver: 20 (83.3%)
Peritoneum: 15 (62.5%)
Retroperitoneum: 5 (20.8%)
Escalated dose 
intervention(s): 
imatinib at 
600 mg/day; 
imatinib at 
800 mg/day
Comparator(s): 
NA
n (%) showing response or SD: at 600 mg/day 
– 5/12 (41.6%); at 800 mg/day – 4/12 (33.3%)
Median time to progression: at 600 mg/day – 
1.7 months (range 0.7–24.9 months).140 Appendix 8
Study ID Participants
Intervention(s) 
and comparators Outcomes summary
n (%) with prior response to standard-dose 
imatinib of:
PR: 9 (37.5%)
SD: 8 (33.3%)
PD: 7 (29.2%)
n (%) whose time to progression (TTP) with 
standard-dose imatinib was:
≤ 6 months: 8 (33.3%)
> 6 months: 16 (66.7%)
n (%) given initial escalated dose of imatinib 
at:
600 mg/day: 12 (50.0%)
800 mg/day: 12 (50.0%)
Seddon 200880–86
Time period: not stated 
to December 2007
Countries involved: 33 
(not stated)
No. of institutions 
involved: 96
n receiving intervention: 0
n receiving comparator(s): 351
Baseline characteristics: not stated
Escalated dose 
intervention(s): 
NA
Comparator(s): 
sunitinib at 50 mg/
day in a 6-week 
cycle of 4 weeks 
on treatment/2 
weeks off 
treatment
Median OS: 90 weeks (95% CI 73 to 106 weeks)
n (%) still alive at data cut-off point: 193/351 
(55.0%)
Zalcberg 200544
Time period: (CiC 
information has been 
removed) to April 2004
Countries involved: 13: 
(Australia, Belgium, 
Denmark, France, 
Germany, Italy, the 
Netherlands, New 
Zealand, Poland, 
Singapore, Spain, 
Switzerland, UK)
No. of institutions 
involved: 56
n receiving intervention: 133
n receiving comparator(s): 0
Baseline characteristics:
Age:
Median, years (range): 59 (20–85)
Sex:
n (%) male: 87 (65%)
n (%) female: 46 (36%)
ECOG performance status:
0: 63 (47%)
1: 49 (37%)
2: 12 (9%)
3: 9 (7%)
n (%) whose primary tumour site was:
GI: 109 (82%)
Gastric: 34 (26%)
Small bowel: 35 (26%)
Duodenum: 20 (15%)
Other GI: 20 (15%)
Other abdominal 20 (15%)
Retroperitoneal: 4 (3%)
n (%) with time since primary diagnosis of:
< 12 months: 70 (53%)
12–24 months: 29 (22%)
> 24 months: 34 (26%)
Escalated dose 
intervention(s): 
imatinib at 
800 mg/day
Comparator(s): 
NA
n (%) showing response or SD: 39/133 (29.3%)
‘Response to cross-over … occurred significantly 
more often in wild-type cases (83%) compared 
with KIT exon 11 mutants (7%) (p = 0.0012, 
Fisher’s exact test), and in KIT exon 9 mutants 
(57%) compared to KIT exon 11 mutants 
(p = 0.0017, Fisher’s exact test)’
Median PFS: 81 days
n (%) still progression free at data cut-off 
point: 24/133 (18.8%)
Median duration of response: 153 days (range 
37–574 days)
n (%) of patients requiring at least one dose 
reduction: 12/77 (15.6%)
n (%) of patients requiring at least one dose 
delay: 18/77 (23.4%)
n (%) with adverse events:
Oedema: 99/124 (79.8%)
Skin rash: 45/124 (36.3%)
Fatigue: 102/124 (82.3%)
Dyspnoea: 30/124 (24.2%)
Infection: 20/124 (16.1%)
Nausea: 82/124 (66.1%)
Leucopenia: 56/121 (46.3%)
Neutropenia: 49/121 (40.5%)
Thrombocytopenia: 7/121 (5.8%)
Anaemia: 119/121 (98.3%)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Study ID Participants
Intervention(s) 
and comparators Outcomes summary
n (%) with site(s) of active disease at study 
entry in:
Site of primary tumour: 50 (38%)
Liver: 96 (72%)
Lung: 16 (12%)
Ascites: 12 (9%)
Pleura: 4 (3%)
Bone: 3 (2%)
Skin: 3 (2%)
n (%) receiving previous treatment of:
Surgery: 116 (87%)
Radiotherapy: 6 (5%)
Chemotherapy: 51 (38%)
n (%) with adverse event reporting decreased 
severity after crossover:
Oedema: 25/99 (25.3%)
Skin rash: 23/45 (51.1%)
Fatigue: 21/102 (20.6%)
Dyspnoea: 8/30 (26.7%)
Infection: 9/20 (45.0%)
Nausea: 38/82 (46.3%)
Leucopenia: 25/56 (44.6%)
Neutropenia: 30/49 (61.2%)
Thrombocytopenia: 4/7 (57.1%)
Anaemia: 15/119 (12.6%)
n (%) with adverse event reporting increased 
severity after crossover:
Oedema: 33/99 (33.3%)
Skin rash: 19/45 (42.2%)
Fatigue: 47/102 (46.1%)
Dyspnoea: 14/30 (46.7%)
Infection: 9/20 (45.0%)
Nausea: 26/82 (31.7%)
Leucopenia: 16.56 (28.6%)
Neutropenia: 13/49 (26.5%)
Thrombocytopenia: 2/7 (28.6%)
Anaemia: 51/119 (42.9%)
n (%) with adverse event achieving increased 
severity to grade 3- to grade-4 level:
Oedema: 7/99 (7.1%)
Skin rash: 2/45 (4.4%)
Fatigue: 10/102 (9.8%)
Dyspnoea: 1/30 (3.3%)
Infection: 1/20 (5.0%)
Nausea: 3/82 (3.7%)
Leucopenia: 0/56 (0.0%)
Neutropenia: 0/49 (0.0%)
Thrombocytopenia: 0/7 (0.0%)
Anaemia: 17/119 (14.3%)
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Appendix 9  
Quality assessment of the individual 
full-text studies
TABLE 24  Quality assessment of the non-randomised studies (comparative studies and case series)
Quality criteria
Study ID
Blanke 
200839 
(B2222)
Blanke 
200841 
(S0033) Park 200979
Zalcberg 
200544
Q1: Were participants a representative sample selected from a relevant patient 
population? 
? ? ? ?
Q2: Were the inclusion/exclusion criteria of participants clearly described? + + + +
Q3: Were participants entering the study at a similar point in their disease 
progression?
+ + + ?
Q4: Was selection of patients consecutive? – – – –
Q5: Was data collection undertaken prospectively? + + + +
Q6: Were the groups comparable on demographic characteristics and clinical 
features?
N/A N/A N/A N/A
Q7: Was the intervention (and comparison) clearly defined? + + + +
Q8: Was the intervention undertaken by someone experienced at performing the 
procedure?
? ? ? ?
Q9: Were the staff, place and facilities where the patients were treated appropriate 
for performing the procedure? (e.g. access to back-up facilities)
? ? ? ?
Q10: Were all the important outcomes considered? – – – –
Q11: Were objective (valid and reliable) outcome measure(s) used? + + + +
Q12: Was the assessment of main outcomes blind? – – – –
Q13: Was follow-up long enough to detect important effects on outcomes of 
interest?
+ + ? +
Q14: Was information provided on non-respondents, dropouts? – + ? ?
Q15: Were participants lost to follow-up likely to introduce bias? (e.g. high dropout 
rate; differential dropout; no description of those lost)
+ ? ? ?
Q16: Was length of follow-up similar between comparison groups? N/A N/A N/A N/A
Q17: Were important prognostic factors identified? ? ? + –
Q18: Were the analyses adjusted for confounding factors? ? ? – –
+, yes; –, no; ?, unclear; N/A, not applicable (items specific to comparative studies).
TABLE 25  Quality assessment at trial entry if study itself is randomised
Quality criteria
Study ID
Blanke 
2008 
(B2222)39
Blanke 
2008
(S0033)81 Park 200979
Zalcberg 
200544
Was the allocation sequence adequately generated?  ? + N/A +
Was allocation adequately concealed? ? ? N/A –
+, yes; –, no; ?, unclear; N/A, not applicable (items specific to comparative studies).© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 10  
Search strategies for review of 
economic analysis studies, cost-
effectiveness analysis
MEDLINE (2000 – October, week 4 2009), EMBASE (2000–9, 
week 44), MEDLINE In-Process (3 November 2009)
Ovid Multifile Search URL: https://shibboleth.ovid.com/
1.  Gastrointestinal Stromal Tumors/use mesz
2.  Gastrointestinal Stromal Tumor/use emez
3.  gastrointestinal neoplasms/use mesz
4.  exp digestive system tumor/use emez
5.  gist.tw.
6.  ((gastro$or gastric) adj3 stromal).tw.
7.  (3 or 4) and (kit or cd117 or cd 117).tw.
8.  (3 or 4) and (stromal or connective or mesenchymal).tw.
9.  or/1-2,5-8
10.  exp “costs and cost analysis”/
11.  exp economic evaluation/use emez
12.  economics/
13.  exp economics,hospital/
14.  exp economics,medical/
15.  economics,pharmaceutical/
16.  exp budgets/
17.  exp models, economic/
18.  exp decision theory/
19.  ec.fs. use mesz
20.  monte carlo method/
21.  markov chains/
22.  exp technology assessment, biomedical/
23.  cost$.ti.
24.  (cost$adj2 (effective$or utilit$or benefit$or minimis$))
25.  economics model$.tw.
26.  (economics$or pharmacoeconomic$or pharmo-economic$).ti.
27.  (price$or pricing$).tw.
28.  (financial or finance or finances or financed).tw.
29.  (value adj2 (money or monetary)).tw.
30.  markov$.tw.
31.  monte carlo.tw.
32.  (decision$adj2 (tree? or analy$or model$)).tw.
33.  or/10-32
34.  9 and 33
35.  limit 34 to yr=“2000 -Current”
36.  quality of life/146 Appendix 10
37.  quality adjusted life year/
38.  “Value of Life”/use mesz
39.  health status indicators/use mesz
40.  health status/use emez
41.  sickness impact profile/use mesz
42.  disability evaluation/use mesz
43.  disability/use emez
44.  activities of daily living/use mesz
45.  exp daily life activity/use emez
46.  cost utility analysis/use emez
47.  rating scale/
48.  questionnaires/
49.  (quality adj1 life).tw.
50.  quality adjusted life.tw.
51.  disability adjusted life.tw.
52.  (qaly? or qald? or qale? or qtime? or daly?).tw.
53.  (euroqol or euro qol or eq5d or eq 5d).tw.
54.  (hql or hqol or h qol or hrqol or hr qol).tw.
55.  (hye or hyes).tw.
56.  health$year$equivalent$.tw.
57.  (hui or hui1 or hui2 or hui3).tw.
58.  (health adj3 (utilit$or disutili$)).tw.
59.  (health adj3 (state or status)).tw.
60.  (sf36 or sf 36 or short form 36 or shortform 36).tw.
61.  (sf6 or sf 6 or short form 6 or shortform 6).tw.
62.  (sf12 or sf 12 or short form 12 or shortform 12).tw.
63.  (sf16 or sf 16 or short form 16 or shortform 16).tw.
64.  (sf20 or sf 20 or short form 20 or shortform 20).tw.
65.  willingness to pay.tw.
66.  standard gamble.tw.
67.  trade off.tw.
68.  conjoint analys?s.tw.
69.  discrete choice.tw.
70.  or/36-69
71.  9 and 70
72.  limit 71 to yr=“2000 -Current”
73.  35 or 72
Science Citation Index (2000, 3 November 2009)
Web of Knowledge URL: http://wok.mimas.ac.uk/
# 1 TS=gist
# 2 TS=((gastric or gastro*) SAME stromal)
# 3 TS=((gastric or gastro*) SAME (kit or cd117 or cd 117))
# 4 TS=((gastric or gastro*) SAME mesenchymal)
# 5 #1 or #2 or #3 or #4
# 6 #5 and TS=economic*
# 7 #5 and TS=cost*
# 8 #5 and TS=(price* or pricing)
# 9 #5 and TS=(financial or finance*)
# 10 #5 and TS=(decision* SAME (tree* OR analy* or model*))© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
147   Health Technology Assessment 2011; Vol. 15: No. 25 DOI: 10.3310/hta15250
# 11 #5 and TS=markov*
# 12 #5 and TS=monte carlo
# 13 #5 and TS=conjoint analys*
# 14 #5 and TS=discrete choice*
# 15 #5 and TS=standard gamble
# 16 #5 and TS=trade off
# 17 #5 and TS=willingness to pay
# 18 #5 and TS=(health SAME (indicator* or status or utilit*))
# 19 #5 and TS=quality of life
# 20 #5 and TS=quality adjusted life
# 21 #5 and TS=disability adjusted life
# 22 #5 and TS=(qaly* or qald* or qale* or qtime* or daly*)
# 23 #5 and TS=(euroqol* or euro qol* or eq5d or eq 5d)
# 24 #5 and TS=(hql or hqol or h qol or hrqol or hr qol)
# 25 #5 and TS=(hye or hyes)
# 26 #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR 
#14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
#27 #26 CPCI-S Timespan=2000–2009
Health Management Information Consortium (September 2009)
Ovid Multifile Search URL: http://gateway.ovid.com/athens
1.  gist.tw.
2.  ((gastro$or gastric$) adj3 stromal).tw.
3.  gastrointestinal cancer/94
4.  3 and (kit or CD117 or cd 117).tw.
5.  3 and (stromal or connective or mesenchymal).tw.
6.  or/1-2,4-5
NHS Economic Evaluation Database (October 2009), HTA 
Database (October 2009)
NHS Centre for Reviews and Dissemination URL: http://nhscrd.york.ac.uk/
welcome.htm
# 1 MeSH Gastrointestinal Stromal Tumors EXPLODE 1 2 3
# 2 gist
# 3 (gastric OR gastro*) AND (kit OR cd117 OR cd AND 117)
# 4 (gastric OR gastro*) AND (stromal OR connective OR mesenchymal)
# 5 #1 or #2 or #3 or #4
IDEAS (October 2009)
RePEC URL: http://ideas.repec.org/
Gist or gastrointestinal stromal
Conference proceedings
International Society for Pharamoeconomics and Outcomes 
Research
9th Annual European Congress, Copenhagen, October 2006148 Appendix 10
10th Annual European Congress, Dublin, October 2007
11th Annual European Congress, Athens, November 2008
12th Annual European Congress, Paris, October 2009
11th Annual International Meeting, Philadelphia, May 2006
12th Annual International Meeting, Arlington, May 2007
13th Annual International Meeting, Toronto, May 2008
14th Annual International Meeting, Orlando, May 2009
Websites consulted (accessed October 2009)
Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
URL: www.augis.org/
Department of Health
URL: www.dh.gov.uk/en/index.htm
GIST Support International
URL: www.gistsupport.org/
Glivec
URL: www.glivec.com/index.jsp
Medicines and Healthcare products Regulatory Agency (MHRA)
URL: www.mhra.gov.uk/
National Cancer Institute
URL: www.cancer.gov/
National Comprehensive Cancer Network
URL: www.nccn.org/index.asp
National Institute for Health and Clinical Excellence
URL: www.nice.org.uk/nice-web/Cat.asp?c=20
NHS Evidence
URL: www.library.nhs.uk/Default.aspx
NHS Knowledge Network Scotland
URL: www.knowledge.scot.nhs.uk/home.aspx
Novaritis UK
URL: www.novartis.co.uk/
Pfizer UK
URL: www.pfizer.co.uk/Pages/Home.aspx
Scottish Sarcoma Network
URL: www.ssn.scot.nhs.uk/© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 11  
Summary of the included economic 
analysis and economic evaluation 
studies
Study identification Author and year Chabot 200895
Intervention studied/
comparators
BSC vs sunitinib for imatinib-resistant or -intolerant patients
Hypothesis/question Examine the challenges to undertake cost-effectiveness study in oncology using 
crossover trial, and presented the submission to the CDR of a cost-effectiveness 
evaluation of sunitinib vs BSC for treatment of GIST in patients who are imatinib 
resistant or intolerant
Key features of the study Type of study Descriptive, and a full economic evaluation (cost-effectiveness analysis) 
Target population/sample 
population 
Patients who failed or are intolerant to imatinib
Context/settings Canada, hypothetical population at provincial level
Date to which the data of the 
study relate
2005
Source of effectiveness data Clinical effectiveness from Phase III clinical trials (NCT00075218)52
Health outcome – QALY-based utility measured by EQ-5D questionnaire 
administered on clinical trial patients
Modelling Markov modelling
Link between effectiveness and 
costs data
Costs in the model include costs of sunitinib acquisition, and health-care resource 
use for BSC, cost of routine follow-up for patients receiving sunitinib, cost of 
adverse events, and end-life costs. Information on health-care resource use 
and corresponding unit costs were derived from published literature, medical 
oncologist and Canadian Government Schedule
Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Cohort population in the model
Study design Modelling for cost–utility analysis 
Effectiveness analysis The following trial end points were used for the valuation of the outcomes 
(effectiveness):
(a)  PFS, defined as the time from randomisation to the point when the tumour 
progressed or death was due to GIST
(b)  OS
(c)  utility, measured by the EQ-5D
(d)  treatment-related adverse events150 Appendix 11
Effectiveness measures and 
results/outcome measures
Sunitinib compared with BSC for the patients who failed or did not respond to 
imatinib and found sunitinib more effective than BSC – in terms of OS, PFS, LYG, 
LYS and QALY
Primary end points/outcome and 
secondary end points/outcome
Mean survival sunitinib group,1.6 years; mean progression-free health state, 0.5 
years; and 1.1 years with PD
Patients in BSC group spent on average 0.2 years in the progression-free health 
state and 0.7 years with PD; and had mean survival of 0.9 years
Sunitinib treatment resulted in 0.7 LYG, and 0.4 QALYs compared with BSC
Statistical precision of these 
outcomes
Utilities associated with sunitinib:
No progression during 4 weeks’ sunitinib: 0.712 ± 0.2
Next 2 weeks’ utility improvement: 0.081 ± 0.02
No progression BSC: 0.781 ± 0.2
Progression: 0.577 + 0.3
Clinical recommendations and 
conclusion
The initial CDR recommendation based on the economic evaluation was ‘not to 
reimburse’ sunitinib in Canada. This was reversed owing to the fact that patients 
who are resistant to imatinib have no other treatment options. Based on review of 
the quality, safety and efficacy data, Health Canada concluded that sunitinib had 
favourable risk–benefit profile for the treatment of GIST after failure or intolerance 
of imatinib treatment
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
QALY based on EQ-5D from UK study55
Direct costs and its components Cost per 6-week cycle
Prospective or retrospective 
(depend on study design)
Whether values were imputed 
in for certain cases
How hospital stay was 
defined, and whether any 
classifications were used 
or not
Costing of complications or 
side effects
Estimations of unit costs and 
source/methods
Sunitinib treatment standard dose: C$6947.99
Sunitinib treatment reduced dose for adverse event management: C$5210.99
Sunitinib treatment medical follow-up: cycle 1 C$2275.13, cycle 2 726.47, cycle 
3+ 1072.11
Terminal phase – end-of-life cost C$3752. Cost of serious adverse event with 
sunitinib $42.84
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support for 
the patient
Not considered
Currency, year prices C$, at 2005 prices
Statistical analysis/cost  Mean and standard deviation of the progression and progression-free time
Sensitivity analysis Univariate sensitivity analysis was conducted by varying the most influential model 
parameters, namely utility of progression and no progression, OS (HR), PFS, PET 
at initiation of sunitinib treatment, the cost of palliative care and the cost of PET. 
The model assumed the cost of acquisition of sunitinib is certain and did not vary 
this in sensitivity analysis. The sensitivity analysis suggests that results of the 
economic evaluation were most sensitive to health-state utility value and rate of 
OS and PFS© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Results/major findings Benefits results from the 
economic evaluation
Mean QALYs:
Sunitinib 0.97
BSC 0.54
ICER ($/LYS) 49,826
ICUR ($/QALYs) 79,884
These (ICER, ICUR lies between an estimated thresholds boundary of $26,433–
132,166)
Costs results used in the 
economic evaluation
Mean costs in C$
Cost of treatment, costs to 
health sector (cost to NHS)
Major determinants of costs, 
the principle costs drivers
Sunitinib $46,125
BSC $11,632
Synthesis of costs and benefits Cost-effectiveness of sunitinib vs BSC
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
ICER ($/LYS) 49,826
ICUR ($/QALYs) 79,884 
Sensitivity analysis – sensitivity uncertainty in the OS advantage for sunitinib? As 
patients were allowed to cross over
Author conclusion/
recommendations
Sunitinib cost-effective
The decision of approval for sunitinib from Health Canada was based on the 
recognition of sunitinib’s clinical benefits for the imatinib-intolerant group. The 
paper suggests reliance on cost-effectiveness methodology is unsatisfactory
Guidance is needed on how better to reconcile the best available clinical trial data 
with the cost-effectiveness requirements and the objectives of prompt access to 
oncology medicine
CDR, Canadian Drug Review; ICUR, incremental cost–utility ratio.
Study identification Author and year Contreras-Hermandez 200896
Intervention studied/
comparators
Sunitinib 50 mg/day, imatinib 800 mg/day and BSC
Hypothesis/question Examine the cost-effectiveness to compare the alternatives (imatinib 800 mg/day, 
sunitinib 50 mg/day) as second line of treatment for those who failed or became 
intolerant with imatinib 400 mg/day. The study examined whether it is worth it for 
the Mexican insurance system to reimburse for sunitinib or higher dose of imatinib
Key features of the study Type of study Model-based (Markov) full economic evaluation (cost-effectiveness analysis)
Target population/sample 
population 
Twenty-one advanced GIST patients who were treated at Hospital de Oncología 
IMSS, Mexico. Treatment examined over 5 years
Context/settings Mexico, 21 advanced GIST patients who were treated at Hospital de Oncología IMSS
Dates to which the data of the 
study relate
January 2005 to 31 December 2007
Source of effectiveness data Clinical trial and published literature
Motzer et al. 2006104 – sunitinib Phase III study and study by Demetri et al. 200652 
mainly from survival data and 21 advanced GIST patients who were treated at 
Hospital de Oncología IMSS
Modelling Markov model. Model utilised the effectiveness data from Motzer et al. 2006104 
(review of sunitinib treatment) – sunitinib Phase III study and study by Demetri et al. 
200652
Link between effectiveness 
and costs data
All costs used in the model (except for the cost of sunitinib) were based on 
the information from IMSS pricing and reimbursement procedures. For cost of 
sunitinib, as it was not available in the Mexican market at the time of the analysis, 
the cost information was provided by Pfizer Laboratories. Costs included cost of 
mean number of visits to the oncologist, laboratory examinations, and radiology 
procedures, and cost of mean length of stay152 Appendix 11
Information on the 
clinical evidence and 
effectiveness, main 
outcome of the study
Sample patients/study 
sample/patient groups
Twenty-one advanced GIST patients who were treated at Hospital de Oncología IMSS 
and hypothetical cohort of 1000 patients for modelling exercise
Study design Observation study based on 21 patients and Markov modelling with a follow-up 
period of 5 years
Effectiveness analysis PFMs, PFS, LYG
Effectiveness measures and 
results/outcome measures
Primary end points/outcome 
and secondary end points/
outcome
Statistical precision of these 
outcomes
PFMs 5.64 and 1.4 LYG (95% CI 1.3 to 1.6) for sunitinib
Imatinib – PFM = 5.28 and 1.31 LYG (95% CI 1.1 to 1.4)
BSC – PFM = 2.52 and 1.08 LYG (95% CI 1.0 to 1.3)
Clinical recommendations and 
conclusion
Sunitinib as second line of treatment for those who failed with 400 mg
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
PFMs
LYGs
Direct costs and its 
components
Direct costs estimated from treatment follow-up, health systems perspective
Imatinib higher dose: expected costs per patient US$35,225 (SD US$1253)
Sunitinib: expected costs per patient US$17,805 (SD US$694.83)
BSC: expected cost per patient US$2071.86 (SD US$472.88)
Using IMSS data, the estimated annual cost per patient for medical consultation, 
hospitalisation, laboratory examination and radiology procedures was $2424.32, 
$2657.57, $566.99 and $2392.67, respectively
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support 
for the patient
Not taken into consideration
Currency, year prices US$, at 2006 prices 
Statistical analysis/cost 
(whether parametric or non-
parametric bootstrap used 
to generate the CIs around 
each difference in costs and 
differences in total costs
Standard deviation of the mean costs, and mean life-years saved, and CI of the 
mean life-years saved
Sensitivity analysis: one way 
or two way
Monte Carlo second order sensitivity analysis, probabilistic sensitivity analysis 
conducted
Results from the sensitivity analysis were used to develop the acceptability curve
Results/major findings Benefits results from the 
economic evaluation
Sunitinib resulted in mean PFMs of 5.64, and 1.4 LYG
For imatinib, PFM = 5.28, and 1.31 LYG
For BSC, PFM = 2.52, and 1.08 LYG
Incrementally, sunitinib yielded 0.32 LYG when compared with BSC
ICER: sunitinib vs BSC
$15,734.23 per patient treated with sunitinib and $56,612.55 per year of PFS and 
$46,108.89 per LYG 
Costs results used in the 
economic evaluation
Imatinib higher dose: expected cost per patient US$35,225 (SD US$1253)
Sunitinib: expected cost per patient US$17,805 (SD US$694.83)
BSC: expected cost per patient – US$2071.86 (SD US$472.88)
Using IMSS data, the estimated annual cost per patient for medical consultation, 
hospitalisation, laboratory examination and radiology procedures was $2424.32, 
$2657.57, $566.99 and $2392.67, respectively
Author conclusion/
recommendations
Reimbursing sunitinib over high dose of imatinib would deliver cost savings to the 
IMSS and greater survival benefits
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Study identification Author and year Mabasa 200898
Intervention studied/
comparators
Imatinib vs no imatinib (BSC) in GISTs
Hypothesis/question Examine the cost-effectiveness of imatinib 
Key features of the study Type of study Full economic evaluation (cost-effectiveness analysis)
Target population/sample 
population
Patients in British Columbia, BCCA patients with advanced GIST who received 
imatinib or historical treatment
Context/settings BCCA-registered patients with advanced GIST, British Columbia, Canada
Dates to which the data of the 
study relate
1996–2001 for non-imatinib cases
2002–5 imatinib cases.
Follow-up periods:
60 months and 44 months, respectively
Source of effectiveness data Data derived from medical records of the patients
Modelling No modelling, patient-level data used for CEA
Link between effectiveness and 
costs data
All costs used were based on the information on the BCCA patients followed and 
included on an intention-to-treat basis. The mean and median duration of follow-
up for the imatinib group were significantly longer than for the historical group
Costs of treatment include cost of drugs, cost per cycle of 1 month, cost of labour 
and supply (not clearly specified what it includes) and cost of counselling 
Costing was based on BCCA registry:
  ■ ICER imatinib vs no imatinib per median LYG (incremental cost per LYG)
  ■ ICER imatinib vs no imatinib per progression survival
Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
46 imatinib group
47 no imatinib (historical) group
Study design Retrospective follow up case–control study based on medical records
Effectiveness analysis Kaplan–Meier estimates of OS and imatinib and historical groups
Effectiveness measures and 
results/outcome measures
Primary end points/outcome 
and secondary end points/
outcome
Statistical precision of these 
outcomes
Median OS (months)
Imatinib 66.7
No imatinib 7.7
Median PFS (months)
Imatinib 45.3
No imatinib 5.6
OS at 1 year
Imatinib 95.4%
No imatinib 32.6%
PFS at 1 year
Imatinib 81.4%
No imatinib 17.4%
Clinical recommendations and 
conclusion
Patient receiving imatinib had significantly longer median OS and median PFS, and 
higher 1-year OS and 1-year PFS than the historical group154 Appendix 11
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
OS, PFS and life-year gained
Direct costs and its components Details provided in methods section on actual cost of drugs, labour and supply, but 
no results given
Prospective or retrospective 
(depend on study design)
Whether values were imputed 
in for certain cases
How hospital stay was 
defined, and whether any 
classifications were used 
or not
Mean costs per patient: $79,829 imatinib; $1743 no imatinib
Costs of surgery or radiotherapy not included (though similar in both arms)
Costing of complications or 
side effects
Estimations of unit costs and 
source/methods
Did not include the cost of side effects, cost of health-care visits, or supportive 
care
Cost of drugs presumably include cost of side effects treatment
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support for 
the patient
Not included 
Currency, year prices C$, 2006 prices
Sensitivity analysis Conducted univariate sensitivity analysis to examine the impact of upper and lower 
values of the cost of the drugs, the cost of treatment, the utilities of successful 
treatment and PD, the time horizon, and the annual rate of discount. They used 
imatinib at a 600 mg/day dose to examine the impact of results variation as an 
alternative scenario for the sensitivity analysis
Results/major findings Benefits results from the 
economic evaluation
Mean OS from imatinib 66.7 months, and historical control group 7.7 months
Mean PFS – 45.3 months vs 5.6 months
Costs results used in the 
economic evaluation
Cost of treatment, costs to health sector (cost to NHS)
Major determinants of costs, the principle costs drivers 
Synthesis of costs and benefits Conducted the sensitivity analysis
Author conclusion/
recommendations
Imatinib cost-effective in treatment of GIST with an ICER of $15,882
BCCA, British Columbia Cancer Agency.
Study identification  Author and year Paz-Ares 200899
Intervention studied/
comparators
Sunitinib (50 mg/day) with BSC and BSC alone
Hypothesis/question Assess cost-effectiveness of sunitinib vs BSC as second line of treatment
Key features of the study Type of study Full economic evaluation (cost-effectiveness analysis)
Target population/sample 
population
Hypothetical cohort of Spanish population with GIST after progression with 
imatinib. Perspective – Spanish national health system
Context/settings Patients with advanced unresectable GIST, intolerant to or with diseases 
progressing during treatment with imatinib 
Dates to which the data of the 
study relate
Used Demetri et al. 2006 study52
Source of effectiveness data Used Demetri et al. 2006 study52
Expert panel, three pathology experts, three health economists
Modelling Markov model
Link between effectiveness and 
costs data
Data reported by expert panel on number of visits to oncology clinic, laboratory 
tests, CT scans, nurse visits, visits to palliative units and analgesic drugs. QoL 
obtained from EQ-5D scores of A6181004 (Demetri study population)© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Hypothetical cohort of patients with advanced unresectable GIST, intolerant to 
or with disease progressing during treatment with imatinib (same as Demetri 
study??)
Study design Decision model analysis, based on the trial52
Effectiveness analysis LYG, QALY
Progression-free life-years
Total mean cost per patient
Cost per QALY gained
ICER
Effectiveness measures and 
results/outcome measures
Primary end points/outcome 
and secondary end points/
outcome
Statistical precision of these 
outcomes
OS, LYG
PFS
Incidence and treatment of adverse effects 
Clinical recommendations and 
conclusion
According to oncology thresholds for oncology patients, sunitinib is considered 
better 
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
QoL obtained from EQ-5D scores
Direct costs and its components Total mean costs/patient
€23,259 in sunitinib group (including costs of adverse events) as against €1622 
for BSC
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support for 
the patient
Not included
Currency, year prices €, 2007 prices 
Statistical analysis/cost 
(whether parametric or non-
parametric boot strap used 
to generate the CIs around 
each difference in costs and 
differences in total costs 
Deterministic 
Sensitivity analysis Univariate sensitivity analysis156 Appendix 11
Results/major findings  Benefits results from the 
economic evaluation
Patients benefits in LYG: 1.59 (for sunitinib + BSC) vs 0.88 (BSC)
Progression-free life-years: 0.50 (sunitinib) vs 0.24 (BSC)
QALY 1 vs 0.55
Costs results used in the 
economic evaluation
Total mean costs/patients:
€23,259 vs €1622
Synthesis of cost and benefits Treatment with sunitinib vs BSC resulted in patients’ benefits of 0.26 progression-
free life-years, 0.71 LYG and 0.45 QALYs gained with the cost difference of 
€21,637/per patient between both treatments
ICER of sunitinib vs BSC:
i.  per LYG €30,242
ii.  per month of PFS €4090
iii. per QALY gained €49,090
Univariate sensitivity analysis
The most important variables:
OS HR
Cost of sunitinib
Utility value during active treatment and after progression
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
Yes, considered the uncertainty surrounding estimates of effects
Considering ± 25% variation on the OS, the parameter most influencing the model 
results, the ICER/QALY gained would oscillate between €39,201 and €62,806
Author conclusion/
recommendations
Sunitinib can be considered cost-effective vs BSC with acceptable cost per LYG 
and QALY gained
Notes the limitation in using an extrapolated survival curve
Study identification  Author and year Huse 200797
Intervention studied/
comparators
Imatinib in the treatment of advanced GIST
Hypothesis/question Estimated the cost-effectiveness of imatinib mesylate in treatment of unresectable 
GIST using trials data elsewhere and using them in US context
Key features of the study Type of study Cost-effectiveness modelling for decision analysis
Target population/sample 
population 
Advanced GIST patients
Context/settings USA, imatinib mesylate treatment vs no treatment of advanced hypothetical GIST 
population in USA
Dates to which the data of the 
study relates to
Mostly trial data used: Demetri et al. 200238 trial data and Blanke trial39,103,117 data 
and Phase II clinical trial data
Source of effectiveness data Demetri et al. 200238 trial data and Blanke trial39,103,117 data
Modelling  Decision modelling
Link between effectiveness and 
costs data
Imatinib cost: Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson Health 
Care; 2005, and Physicians’ Desk Reference 2005. Montvale, NJ: Thomson PDR; 
2005
Cost of medical management for pancreatic cancer was used in absence of data 
for GIST management
Cost data for diseases specific
For palliative care – as GIST-specific palliative care data not available, information 
on palliative care for pancreatic cancer was used© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Hypothetical cohort population with advanced GIST 
Study design Decision model
Effectiveness analysis QALY 
Effectiveness measures and 
results/outcome measures
Used from UK study (Wilson et al.55)
Primary end points/outcome 
and secondary end points/
outcome
Statistical precision of these 
outcomes
Utilities
0.875 for PD (lower bound 0.75 to 1.00 upper)
0.935 for successful treatment (0.4 to 1.00)
Clinical recommendations and 
conclusion
Imatinib is cost-effective in advanced GIST patients
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
QALY, OS, cost, cost per LYG and cost per QALY gained
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support 
for the patient
Not included 
Currency, year prices US$, 2005 prices
Sensitivity analysis One-way sensitivity analysis 
Results/major findings  Benefits results from the 
economic evaluation
Effectiveness QALYs – 4.15 for imatinib, 2.23 for untreated
Difference (treated – untreated) 1.92
The net discounted cost of achieving the survival benefit of 2.2 QALY (PV of 1.9 
QALY) is US$74,369 per imatinib-treated patient
CER – US$38,723
Costs results used in the 
economic evaluation
Cost of treatment, costs to 
health sector (cost to NHS)
Major determinants of costs, 
the principle costs drivers
Imatinib treatment US$416,255
Untreated US$341,886
Weekly cost of imatinib: $US685 (685 to 1028)
Weekly costs of care successfully treated patients: US$359 (226 to 492)
Weekly cost of care for PD: US$2575 (1700 to 3450)
Utilities of successful treatment and PD: 0.935, 0.875, respectively
Time horizon (years): 10, 20 in sensitivity analysis
Major cost drivers – cost of drugs
Synthesis of cost and benefits
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
The cost-effectiveness ratio was most sensitive to variation in the cost estimates 
and time horizon for the analysis
CER ratios were estimated for the upper and lower bound of the parameters
Author conclusion/
recommendations
Over 10 years’ time horizon, imatinib treatment increases mean quality-adjusted 
survival from 2.4 to 4.6 QALYs, this gain of 2.2 QALYs (undiscounted) with PV of 
1.92 QALYs. Net undiscounted cost of achieving this survival benefit is US$74,369 
per imatinib-treated patient, yielding a cost-effectiveness ratio of US$38,723 per 
QALY
PV, present value.158 Appendix 11
Study identification  Author and year Teich 2009100
Intervention studied/
comparators
Sunitinib vs imatinib 800 mg/day, and BSC for those who failed with imatinib 
400 mg/day
Hypothesis/question What is the cost-effectiveness of sunitinib vs imatinib in second-line treatment for 
GIST in Brazil
Key features of the study Type of study Model analysis
Target population/sample 
population 
Cohort population failed with imatinib 400 mg/day
Dates to which the data of the 
study relate
Not specified, 2005 prices used
Modelling  Markov model
Link between effectiveness 
and costs data
Cost per LYGs, cost per progression-free life-years
ICER
Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Cohort population number 1000
Study design Modelling
Effectiveness analysis In comparison with BSC sunitinib increases life-years and progression-free life-
years by 0.3 and 0.26 years, respectively
With incremental costs of R$86,756 (US$61,968, PPP 2005)
In comparison with imatinib, sunitinib was more effective and cost-effective with 
increased life-year of 0.02 and progression-free LYG of 0.47, and less costly over 
6 years 
Results/major findings Author conclusion/
recommendations
Sunitinib is cost-effective when compared with imatinib 800 mg/day and BSC 
Study identification  Author and year Wilson 200555
Intervention studied/
comparators
Cost-effectiveness of imatinib in the treatment of unresectable and/or metastatic 
KIT-positive GIST relative to current standard practice
Hypothesis/question Assess the clinical effectiveness and cost-effectiveness of imatinib in the treatment 
of unresectable and/or metastatic KIT-positive GIST relative to current standard 
practice
Key features of the study Type of study Systematic review of clinical effectiveness and economic evaluation
Target population/sample 
population 
Hypothetical cohort population with unresectable GIST in UK
Context/settings UK NHS perspective
Dates to which the data of the 
study relates to
2004?
Source of effectiveness data Trials
Novartis model from clinical trial
Modelling  Markov modelling
Reporting results from two modelling works
1. Novartis model
2. Birmingham model
Link between effectiveness and 
costs data
ICER, cost per QALY © Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Trial patients – 147 patients with malignant unresectable and/or metastatic GISTs 
with median follow-up 25 months
Modelled for 10 years
Study design Open-label multicentre trial compared two imatinib doses: 400 or 600 mg/day
Effectiveness analysis The survival rate was 88% after 1 year and 78% after 2 years
Clinical recommendations and 
conclusion
The survival rate was 88% after 1 year and 78% after 2 years
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
QALYs from ECOG performance of the trial patients
Direct costs and its 
components
Prospective or retrospective 
(depend on study design)
Prospective as trial data
Whether values were imputed 
in for certain cases
How hospital stay was defined, 
and whether any classifications 
were used or not
Values were not imputed as patients’ data were used from trials
Costing of complications or 
side effects
Costs of side effects were available from patients’ data
Estimations of unit costs and 
source/methods
From Novartis model
Drug cost of imatinib £20,000
Costs of outpatient visits £440 per year
Cost of CT scan £656 for imatinib patients and £82 for patients with PD
Cost of GP visits £40 per year
Cost of management of adverse events £159 per year (range £127.20–190.80)
Costs discounted at 6% (sensitivity – 3% and 6%)
QALY discounted at 1.5% (sensitivity – 1.5–3%)
Birmingham model developed for this report
4 weeks
Cost of adverse event £12.23
Cost of imatinib 400 mg £1453.54
Cost of imatinib 600 mg £1874.49
Costs of no treatment (BSC) £43.23
Cost of terminal disease (death) £2730
Discounted rate for cost 0.0046154
Discounted rate for QALY 0.0011538
Other costs for imatinib-treated patients £87.38
Utility for imatinib 0.935
Utility for progressive state 0.875
Using incidence rate used by Novartis (15 per million population) and assuming 
10–30% of all GIST patients expected to have metastatic and/or unresectable 
disease, the number of patients treated with metastatic and/or unresectable 
disease would be between 80 and 240, and the budgetary impact on the NHS 
is estimated at between £2.4M and £11.8M per year. The costs to the NHS per 
patient at £20,400 per year
Indirect costs and its 
components
Not included
Currency, year prices £, 2004 prices160 Appendix 11
Results/major findings Benefits results from the 
economic evaluation
The cost per QALY ranged from £51,515 to £98,889 after 2 years and from 
£27,331 to £44,236 after 5 years and from £21,404 to £33,976 after 10 years
Results from Birmingham model
ICER changes depending whether Weibull or exponential distribution is used
Weibull ICER – £26,427
Exponential ICER £21,707
Costs results used in the 
economic evaluation
Cost of treatment, costs to 
health sector (cost to NHS)
Major determinants of costs, 
the principle costs drivers
From Novartis model
Drug cost of imatinib £20,000
Costs of outpatient visits £440 per year
Cost of CT scan £656 for imatinib patients and £82 for patients with PD
Cost of GP visits £40 per year
Cost of management of adverse events £159 per year (range £127.20–190.80)
Weekly cost of imatinib (pooled trial data) £420.38 (£420.38–370.38; 400 mg per 
day start dose)
Other costs per imatinib-treated patients £1136 (£1786–570)
Others costs per PD patients £562 (£1498–233) 
Utilities:
Imatinib treated 0.935 (0.900–0.935)
Progressive 0.875 (0.875)
Birmingham model developed for this report
4 weeks
Cost of adverse event £12.23
Cost of imatinib 400 mg £1453.54
Cost of imatinib 600 mg £1874.49
Costs of no treatment (BSC) £43.23
Cost of terminal disease (death) £2730
Discounted rate for cost 0.0046154
Discounted rate for QALY 0.0011538
Other costs for imatinib-treated patients £87.38
Utility for imatinib 0.935
Utility for progressive state 0.875
Synthesis of cost and benefits
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
Yes costs, discount rate, cost for acquisition of drugs
Author conclusion/
recommendations
The Novartis model suggested that the costs per QALY gained ranged from 
£51,515 to £98,889 after 2 years, from £27,331 to £44,236 after 5 years 
and from £21,404 to £33,976 after 10 years. This range of estimates may 
still not reflect the uncertainty, as the estimates after 2 years are mainly based 
on mathematical extrapolation beyond observed data. The results from the 
Birmingham model confirm the findings of the Novartis model
Because there were no directly controlled trials the results for the model cannot be 
very conclusive owing to the uncertainties© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Study identification Author and year Reddy 200754
Intervention studied/
comparators
NA
Hypothesis/question NA
Key features of the study Type of study Systematic review to identify, summarise and evaluate published studies and 
abstracts describing the epidemiological, HRQoL and economic impact of GIST
2000–6
34 publications
29 provided data on epidemiology
One provided cost data
Three reported HRQoL
One reported cost and HRQoL
Target population/sample 
population 
NA
Context/settings NA
Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
Performance stated was assessed using ECOG scale performance take from 
Demetri et al. study52 
Results/major findings Costs results used in the 
economic evaluation
Cost of treatment, costs to 
health sector (cost to NHS)
Major determinants of costs, 
the principle costs drivers
The acquisition costs of imatinib were estimated at $18 per 100-mg tablet in the 
USA and €23 in France
Annual cost $32,850 in the USA and €41,975 in France (assuming 50% of 
patients each received 400 or 600 mg/day)
UK study
Annual drug cost £20,000
Outpatient visits including laboratory tests £440
GP visits £40 per year
CT scans £656 for imatinib patients and £82 for patients with PD
Management of adverse events: £159 (range £127–191)
Another study (model base Wilson et al.55)
Annual costs of imatinib were £18,896 and £24,368 for patients on 400 and 
600 mg daily, respectively
Synthesis of cost and benefits
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
Total costs with imatinib over 2 years £30,295 and for 10 years £47,521
BSC – £1949 at 2 years and £4047 at 10 years
Cost QALY gained £85,224 after 2 years and £29,789 after 10 years
Total costs were £31,160 at 2 years compared with £56,146 at 10 years with 
imatinib vs £1998 and £4230 at 2 and 10 years, respectively, with BSC
The cost per QALY gain varied from £45,533 to £70,206 at 2 years and from 
£21,708 to £25,859 at 10 years162 Appendix 11
Study identification Author and year Hopkins 2008101
Intervention studied/
comparators
Sunitinib and imatinib, and placebo (different studies reviewed)
Hypothesis/question Review the new developments in therapeutic cancer drugs
Key features of the study Type of study Review
Target population/sample 
population
GIST patients, patients with diseases resistant to imatinib 800 mg/day or intolerant 
of imatinib
Sample not applicable
Context/settings Settings of the clinical trials for sunitinib
Three trials
Phase III, 56 sites, Europe, America, Asia and Australia
Dates to which the data of the 
study relate
2003, 2004, 2005 and 2009 
Source of effectiveness data Reviewed from all the studies mentioned
Modelling  Not applicable
Link between effectiveness and 
costs data
Not relevant
Information on the 
clinical evidence and 
effectiveness – main 
outcome of the study
Sample patients/study sample/
patient groups
Maki118 2005 – 97
Demetri 200652 – 207 and 105 (placebo)
George119 2007 – 60
Clinical recommendations and 
conclusion
Initial results for use of sunitinib are promising; however, too early to draw 
conclusion
Important to consider the secondary resistance in GIST
Mutational status should be determined before treatment in order to decide the 
initial dosage of kinase inhibitor
 Economic analysis Measures of health outcome/
benefits used in the economic 
analysis
Referred to SMC study120
Direct costs and its 
components
Prospective or retrospective 
(depend on study design)
Whether values were imputed 
in for certain cases
How hospital stay was defined, 
and whether any classifications 
were used or not
Costing of complications or 
side effects
Estimations of unit costs and 
source/methods
Not relevant – did not use or refer to studies with costing of the intervention
Refer to SMC study120
Drug costs for one 6-week cycle of sunitinib 50 mg – £3304 for the 4–2 regimen 
– 4-cycle costing over £1300
Indirect costs and its 
components
Cost of productivity, cost of 
volunteer care and support for 
the patient
Not considered
Currency, year prices Drug costs at 2006 prices
Statistical analysis/cost 
Sensitivity analysis© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Results/major findings Benefits results from the 
economic evaluation
Costs results used in the 
economic evaluation
Drugs costs – UK NHS
Cost of treatment, costs to 
health sector (cost to NHS)
Major determinants of costs, 
the principle costs drivers
The total costs were not reported for the study reviewed. The costs are not from 
study reviewed
Synthesis of cost and benefits: There was not a complete economic evaluation either referred or modelled in this 
study
So synthesising not relevant
Any attempt to consider 
the uncertainty surrounding 
estimates of effects
No
Author conclusion/
recommendations
No recommendation from economic evaluation
SMC, Scottish Medicines Consortium.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
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Appendix 12  
Model structure
Progressive disease
Pathway 1
Best supportive
care
M
  Markov
information
Term: _stage=
lengthof_run Death
  Markov information
Initial cost:0.5 x (cNott+othCostBSC)
Incremental cost: cNott+othCostBSC/(1+DR)^_stage)
Final cost: 0.5 x (cNott+othCostBSC/((1+DR)^_stage))
Initial effect: 0.5 x ((1/12  x uProg)/((1+DR)^_stage))
Incremental effect: (1/12  x uProg)/((1+DR)^_stage)
Final effect: 0.5 x ((1/12 x uProg)/((1+DR)^_stage))
Progressive
disease
Death
die due to GIST
#
1
deathBSC
#
survive
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0166 Appendix 12
Pathway 2
Imatinib 600
to 800 to
sunitinib
M
PD with initial treatment imatinib 600
PD at imatinib 800
CR/Stable imatinib 800
CR/Stable with imatinib 600
PD with sunitinib
0
0
0
0
0
0
0
  Markov
information
Term: _stage=
lengthof_run
  Markov information
Initial cost: 0.5 x (cImat600+OthCostIm)
Incremental cost: 1 x (cImat600+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x ((cImat600+OthCostIm)/(1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x uImat600/(1+DR)^_stage)
Incremental effect: (1/12) x uImat600/(1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uImat600/(1+DR)^_stage)
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat600+OthCostIm)/((1+DR)^_stage)
Final cost: 0.5 x (1 x (cImat600+OthCostIm)/((1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x (uImat600/((1+DR)^_stage))
Incremental effect: (1/12) x uImat600/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uImat600/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/((1+DR)^_stage))
Final cost: 0.5 x (cNott+othCostBSC/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12)+(uProg/((1+DR)^_stage))
Incremental effect: (1/12) x uProg/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uProg)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat800+OthCostIm)/((1+DR)^_stage)
Final cost: 0.5 x (cImat800+OthCostIm)/((1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x uImat800/((1+DR)^_stage))
Incremental effect: (1/12) x uImat800/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uImat800/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat800+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x ((cImat800+OthCostIm)/(1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat800)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (OthCostSun/((1+DR)^_stage)) 
Initial effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (cSunbxOthCostSun)/((1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
CR/Stable with sunitinib
PD no treatment/BSC
Death
no response
CR/Stable imatinib 600
CR/Stable imatinib 600
CR/Stable with imatinib 800
CR/Stable with imatinib 800
CR/Stable with sunitinib
CR/Stable with sunitinib
PD at imatinib 800
PD with sunitinib
PD with sunitinib
PD no treatment/BSC
PD no treatment/BSC
PD no treatment/BSC
PD at imatinib 800
response
nonrespIm600
Death
Death
Death
Death
Death
Death
Death
dth600
die due to GIST
#
#
no response
response
nonrespIm600
#
no response
response
nonrespIm800
#
no response
response
nonrespIm800
#
no response
response
nonrespImSun
#
no response
response
nonrespSun
#
survive
1
dth600
die due to GIST
#
survive
dth800
die due to GIST
#
survive
dth800
die due to GIST
#
survive
dthsun
die due to GIST
#
survive
dthsun
die due to GIST
#
survive
deathBSC
die due to GIST
#
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Pathway 3
Imatinib 600
to sunitinib
M
CR/Stable with imatinib 600
PD with sunitinib
PD with initial treatment imatinib 600
CR/Stable with sunitinib
1
0
0
0
0
0
  Markov
information
Term: 
  Markov information
Initial cost: 0.5 x (cImat600+OthCostIm)
Incremental cost: 1 x (cImat600+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x ((cImat600+OthCostIm)/(1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x uImat600/((1+DR)^_stage))
Incremental effect: (1/12) x uImat600/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uImat600/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat600+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (cImat600+OthCostIm)/(1+DR)^_stage
Initial effect: 0.5 x (((1/12) x uImat600)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat600)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat600)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (cSunb+OthCostSun)/((1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (cSunb+OthCostSun)/((1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x uSun/((1+DR)^_stage))
Incremental effect: (1/12) x uSun/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uSun/((1+DR)^_stage))
PD no treatment/BSC
Death
CR/Stable with imatinib 600
CR/Stable with imatinib 600
CR/Stable with sunitinib
CR/Stable with sunitinib
PD with sunitinib
PD with sunitinib
PD no treatment/BSC
PD no treatment/BSC
PD no treatment/BSC
Death
Death
Death
Death
Death
no response
response
nonrespIm600
#
no response
response
nonrespIm600
#
no response
response
nonrespSun
#
no response
response
nonrespSun
#
dth600
die due to GIST
#
survive
dth600
die due to GIST
#
survive
dthsun
die due to GIST
#
survive
dthsun
die due to GIST
#
survive
deathBSC
die due to GIST
#
survive
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/((1+DR)^_stage))
Final cost: 0.5 x (cNott+othCostBSC/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12) x uProg/(1+DR)^_stage)
Incremental effect: (1/12) x uProg/(1+DR)^_stage
Final effect: 0.5 x ((1/12) x uProg/(1+DR)^_stage)168 Appendix 12
Pathway 4
Imatinib 600 mg
M
PD with initial treatment imatinib 600
CR/Stable with imatinib 600
1
0
0
0
  Markov
information
Term: _stage=
lengthof_run 
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat600+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (cImat600+OthCostIm)/(1+DR)^_stage 
Initial effect: 0.5 x ((1/12) x (uImat600/(1+DR)^_stage))
Incremental effect: (1/12) x (uImat600/(1+DR)^_stage)
Final effect: 0.5 x ((1/12) x (uImat600/(1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/((1+DR)^_stage))
Final cost: 0.5 x (cNott+OthCostBSC/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12) x (uProg)/(1+DR)^_stage)
Incremental effect: (1/12) x (uProg)/(1+DR)^_stage
Final effect: 0.5 x ((1/12) x (uProg)/(1+DR)^_stage)  
  Markov information
Initial cost: 0.5 x (cImat600+OthCostIm)
Incremental cost: 1 x (cImat600+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (1 x (cImat600+OthCostIm)/(1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x (uImat600/(1+DR)^_stage))
Incremental effect: (1/12) x (uImat600/(1+DR)^_stage)
Final effect: 0.5 x ((1/12) x (uImat600/(1+DR)^_stage))
PD no treatment/BSC
Death
CR/Stable with imatinib 600
CR/Stable with imatinib 600
PD no treatment/BSC
PD no treatment/BSC
PD no treatment/BSC
Death
Death
Death
no response
response
nonrespIm600
#
no response
response
nonrespIm600
#
dth600
die due to GIST
#
survive
dth600
die due to GIST
#
survive
deathBSC
die due to GIST
#
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Pathway 5
Imatinib 800
to sunitinib
M
CR/Stable with imatinib 800
PD with sunitinib
PD with initial treatment imatinib 800
CR/Stable with sunitinib
1
0
0
0
0
0
  Markov
information
Term: 
  Markov information
Initial cost: 0.5 x (cImat800+OthCostIm)
Incremental cost: 1 x (cImat800+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (1 x (cImat800+OthCostIm)/(1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat800)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat800+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (cImat800+OthCostIm)/(1+DR)^_stage
Initial effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat800)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/((1+DR)^_stage))
Final cost: 0.5 x (cNott+othCostBSC/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12)+(uProg/(1+DR)^_stage))
Incremental effect: (1/12) x (uProg/(1+DR)^_stage)
Final effect: 0.5 x ((1/12) x (uProg/(1+DR)^_stage))
  Markov information
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Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (cSunb+OthCostSun)/((1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (cSunb+OthCostSun)/((1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x uSun)
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
PD no treatment/BSC
Death
CR/Stable with imatinib 800
CR/Stable with imatinib 800
CR/Stable with sunitinib
CR/Stable with sunitinib
PD with sunitinib
PD with sunitinib
PD no treatment/BSC
PD no treatment/BSC
PD no treatment/BSC
Death
Death
Death
Death
Death
no response
response
nonrespIm800
#
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response
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#
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response
nonrespSun
#
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#
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#
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#
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Pathway 6
Imatinib 600 mg
M
PD with initial treatment imatinib 800
CR/Stable imatinib 800
1
0
0
0
  Markov
information
Term: _stage=
lengthof_run 
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cImat800+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (cImat800+OthCostIm)/((1+DR)^_stage) 
Initial effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat800)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/((1+DR)^_stage))
Final cost: 0.5 x (cNott+othCostBSC/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12) x uProg/((1+DR)^_stage))
Incremental effect: (1/12) x uProg/((1+DR)^_stage)
Final effect: 0.5 x ((1/12) x uProg/((1+DR)^_stage))  
  Markov information
Initial cost: 0.5 x (cImat800+OthCostIm)
Incremental cost: 1 x (cImat800+OthCostIm)/(1+DR)^_stage
Final cost: 0.5 x (cImat800+OthCostIm)/(1+DR)^_stage 
Initial effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
Incremental effect: ((1/12) x uImat800)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uImat800)/((1+DR)^_stage))
PD no treatment/BSC
Death
CR/Stable with imatinib 800
CR/Stable with imatinib 800
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Death
Death
Death
no response
response
nonrespIm800
#
no response
response
nonrespIm800
#
dth800
die due to GIST
#
survive
dth800
die due to GIST
#
survive
deathBSC
die due to GIST
#
survive
Pathway 7
Sunitinib
M
PD with initial treatment sunitinib
CR/Stable with sunitinib
1
0
0
0
  Markov
information
Term: _stage=
lengthof_run 
  Markov information
Initial cost: 0
Incremental cost: 0
Final cost: 0
Initial effect: 0
Incremental effect: 0
Final effect: 0
  Markov information
Initial cost: 0
Incremental cost: 1 x (cSunb+OthCostSun)/((1+DR)^_stage)
Final cost: 0.5 x (1 x (cSunb+OthCostSun)/((1+DR)^_stage)) 
Initial effect: 0.5 x ((1/12) x uSun/(1+DR)^_stage)
Incremental effect: (1/12) x uSun/(1+DR)^_stage
Final effect: 0.5 x ((1/12) x uSun/(1+DR)^_stage)
  Markov information
Initial cost: 0
Incremental cost: 1 x (cNott+othCostBSC/(1+DR)^_stage)
Final cost: 0.5 x (cNott+othCostBSC/(1+DR)^_stage) 
Initial effect: 0.5 x ((1/12) x (uProg/(1+DR)^_stage))
Incremental effect: (1/12) x (uProg/(1+DR)^_stage)
Final effect: 0.5 x ((1/12) x (uProg/(1+DR)^_stage))  
  Markov information
Initial cost: 0.5 x (cSunb+OthCostSun)
Incremental cost: 1 x ((cSunb+OthCostSun)/((1+DR))_stage)
Final cost: 0.5 x ((cSunb+OthCostSun)/((1+DR))_stage) 
Initial effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
Incremental effect: ((1/12) x uSun)/((1+DR)^_stage)
Final effect: 0.5 x (((1/12) x uSun)/((1+DR)^_stage))
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Death
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Appendix 13  
Alternative best supportive care 
survival estimates
Source Year
Definition of population for which survival 
outcome is given
No. in 
sample
Follow-up 
time Median OS
Percentage 
surviving
Conlon18 1995 Those not having a complete resection 38 5 years 0
Dematteo19 2000 Metastatic (including 28/94 who had 
complete resection)
94 14 months 19 months
de Mestier121/
Dematteo19
2005/2000 Those not having a complete resection 86 14 months 12 months < 30 at 1 year
Demetri52 2006 Receiving placebo after median prior imatinib 
dose of 800 mg
105 7.2 months 62.5
Nilsson26 2005 Those with overtly malignant GISTs 29 1.4 years 5/29
Von Mehren122 2006 Those who had metastic GIST or recurrence 
after primary resection
6–18 months
Plaat123 2000 Those with malignant GIST (18/26 had 
metastatic disease)
26 28 months
2 years 58.5
5 years 13.0
Pidhorecky124 2000 Those undergoing palliative surgical 
procedure/biopsy
11 5 years 15 months 10
Those with unresectable metastatic GIST 40 months
Comandone125 2005 Metastatic GIST 6 months
Pierie107 2001 Those with incomplete resection (41% had 
metastatic disease)
69 3 years 13
5 years 9
Duffaud126 2003 Those with unresectable disease 10–20 months
Cohen127 2002 Those with metastatic or recurrent disease 12–19 months
Totman128/Van 
Oosterom40
2001 Those with unresectable or metastatic 
sarcoma (including GIST)
53 weeks
Katz129 2008 Those who could not undergo complete 
resection
9–12 months
Trent130 2003 Those with advanced/metastatic GIST treated 
with temozolomide, of which none responded
17 2 years 26.4 months 62a
Le Cesne131/
Verweij42
2009/2004 Those presenting with incurable advanced 
disease
2 years 10.25 monthsa 25
McGrath106 1987 Those with partial resection 21 5 years 9 months 10
Those with distant metastases 28 5 years 10 months 0
Dougherty112 1991 Presenting with unresectable disease 15 2.167 years 12 months 3/15
2.75 years 2/15
4.167 years 1/15
Artinyan113 2008 Those with metastatic GIST 140 3 years 12 months 24
3 years 11 
months
21
a  Data estimated from Kaplan–Meier curve within paper.© Queen’s Printer and Controller of HMSO 2011. This work was produced by Hislop et al. under the terms of a commissioning contract issued by the 
Secretary of State for Health.
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Feedback
The HTA programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish your 
comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.